primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Fournier's gangrene,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Anxiety,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Cholecystitis acute,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Cholecystitis infective,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Perirectal abscess,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Abscess limb,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Renal tubular necrosis,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Genital abscess,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Renal failure,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Urinary tract infection,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Chronic kidney disease,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Anal abscess,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Necrotising soft tissue infection,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Perineal abscess,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
170382587,17038258,34,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Sepsis,,2023,Q1,7,F,20180112.0,20230124.0,20191115,20230202,EXP,,US-AstraZeneca-2019SF60246,ASTRAZENECA,,21911.0,DY,,F,Y,,,20230202,,LW,US,,2023,Q1,Elderly
172004023,17200402,63,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Renal failure,,2023,Q1,3,F,20130529.0,20230314.0,20191226,20230322,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230322,,LW,US,,2023,Q1,Elderly
172004023,17200402,63,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hyperparathyroidism secondary,,2023,Q1,3,F,20130529.0,20230314.0,20191226,20230322,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230322,,LW,US,,2023,Q1,Elderly
172004023,17200402,63,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Rebound acid hypersecretion,,2023,Q1,3,F,20130529.0,20230314.0,20191226,20230322,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230322,,LW,US,,2023,Q1,Elderly
172004023,17200402,63,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Chronic kidney disease,,2023,Q1,3,F,20130529.0,20230314.0,20191226,20230322,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230322,,LW,US,,2023,Q1,Elderly
172004023,17200402,63,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Nephropathy,,2023,Q1,3,F,20130529.0,20230314.0,20191226,20230322,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230322,,LW,US,,2023,Q1,Elderly
177475324,17747532,28,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2023,Q1,Decreased activity,,2023,Q1,4,F,,20230109.0,20200505,20230202,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20230202,,CN,CA,CA,2023,Q1,Elderly
177475324,17747532,28,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2023,Q1,Frequent bowel movements,,2023,Q1,4,F,,20230109.0,20200505,20230202,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20230202,,CN,CA,CA,2023,Q1,Elderly
177475324,17747532,28,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2023,Q1,Colitis ulcerative,,2023,Q1,4,F,,20230109.0,20200505,20230202,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20230202,,CN,CA,CA,2023,Q1,Elderly
177475324,17747532,28,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2023,Q1,Rectal haemorrhage,,2023,Q1,4,F,,20230109.0,20200505,20230202,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20230202,,CN,CA,CA,2023,Q1,Elderly
177475324,17747532,28,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2023,Q1,Colitis,,2023,Q1,4,F,,20230109.0,20200505,20230202,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20230202,,CN,CA,CA,2023,Q1,Elderly
196289835,19628983,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.75,MG,Injection,/WK,2023,Q1,Diarrhoea,,2023,Q1,5,F,20210714.0,20230104.0,20210728,20230109,EXP,,ES-ROCHE-2876051,ROCHE,,60.0,YR,,F,Y,82.9,KG,20230109,,MD,ES,,2023,Q1,Adult
199170483,19917048,22,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Death,,2023,Q1,3,F,20210921.0,20230312.0,20211005,20230315,EXP,,IL-ABBVIE-21K-082-4106653-00,ABBVIE,,84.0,YR,,M,Y,72.0,KG,20230315,,MD,IL,IL,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Extradural abscess,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Intervertebral discitis,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Escherichia urinary tract infection,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Anti-neutrophil cytoplasmic antibody positive vasculitis,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Escherichia bacteraemia,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Infection reactivation,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Urosepsis,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Pulmonary renal syndrome,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Neutropenic sepsis,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199236502,19923650,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Injection,/WK,2023,Q1,Varicella zoster virus infection,,2023,Q1,2,F,,20230221.0,20211006,20230301,EXP,,AU-MYLANLABS-2021M1069277,MYLAN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology 2021;26 (Suppl. 2):35.",69.0,YR,,F,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
199395212,19939521,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Infection,,2023,Q1,2,F,,20230203.0,20211011,20230209,EXP,,AU-PFIZER INC-202101291899,PFIZER,"Jeyaruban, A.. A CASE OF HYDRALAZINE INDUCED VASCULITIS, WITH PULMONARY-RENAL SYNDROME.. Nephrology. 2021;26(SUPPL 2):35",69.0,YR,,F,Y,,,20230209,,HP,AU,AU,2023,Q1,Elderly
199395212,19939521,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Escherichia bacteraemia,,2023,Q1,2,F,,20230203.0,20211011,20230209,EXP,,AU-PFIZER INC-202101291899,PFIZER,"Jeyaruban, A.. A CASE OF HYDRALAZINE INDUCED VASCULITIS, WITH PULMONARY-RENAL SYNDROME.. Nephrology. 2021;26(SUPPL 2):35",69.0,YR,,F,Y,,,20230209,,HP,AU,AU,2023,Q1,Elderly
199395212,19939521,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Varicella zoster viraemia,,2023,Q1,2,F,,20230203.0,20211011,20230209,EXP,,AU-PFIZER INC-202101291899,PFIZER,"Jeyaruban, A.. A CASE OF HYDRALAZINE INDUCED VASCULITIS, WITH PULMONARY-RENAL SYNDROME.. Nephrology. 2021;26(SUPPL 2):35",69.0,YR,,F,Y,,,20230209,,HP,AU,AU,2023,Q1,Elderly
199395212,19939521,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Urosepsis,,2023,Q1,2,F,,20230203.0,20211011,20230209,EXP,,AU-PFIZER INC-202101291899,PFIZER,"Jeyaruban, A.. A CASE OF HYDRALAZINE INDUCED VASCULITIS, WITH PULMONARY-RENAL SYNDROME.. Nephrology. 2021;26(SUPPL 2):35",69.0,YR,,F,Y,,,20230209,,HP,AU,AU,2023,Q1,Elderly
199395212,19939521,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Off label use,,2023,Q1,2,F,,20230203.0,20211011,20230209,EXP,,AU-PFIZER INC-202101291899,PFIZER,"Jeyaruban, A.. A CASE OF HYDRALAZINE INDUCED VASCULITIS, WITH PULMONARY-RENAL SYNDROME.. Nephrology. 2021;26(SUPPL 2):35",69.0,YR,,F,Y,,,20230209,,HP,AU,AU,2023,Q1,Elderly
199395212,19939521,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Neutropenic sepsis,,2023,Q1,2,F,,20230203.0,20211011,20230209,EXP,,AU-PFIZER INC-202101291899,PFIZER,"Jeyaruban, A.. A CASE OF HYDRALAZINE INDUCED VASCULITIS, WITH PULMONARY-RENAL SYNDROME.. Nephrology. 2021;26(SUPPL 2):35",69.0,YR,,F,Y,,,20230209,,HP,AU,AU,2023,Q1,Elderly
199395212,19939521,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Intervertebral discitis,,2023,Q1,2,F,,20230203.0,20211011,20230209,EXP,,AU-PFIZER INC-202101291899,PFIZER,"Jeyaruban, A.. A CASE OF HYDRALAZINE INDUCED VASCULITIS, WITH PULMONARY-RENAL SYNDROME.. Nephrology. 2021;26(SUPPL 2):35",69.0,YR,,F,Y,,,20230209,,HP,AU,AU,2023,Q1,Elderly
199455763,19945576,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, per week",,,,,,,,1.5,MG,,,2023,Q1,Intervertebral discitis,,2023,Q1,3,F,,20230221.0,20211012,20230306,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-19274,LUPIN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology. 2021;26(2):35",69.0,YR,,F,Y,,,20230306,,HP,AU,AU,2023,Q1,Elderly
199455763,19945576,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, per week",,,,,,,,1.5,MG,,,2023,Q1,Escherichia urinary tract infection,,2023,Q1,3,F,,20230221.0,20211012,20230306,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-19274,LUPIN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology. 2021;26(2):35",69.0,YR,,F,Y,,,20230306,,HP,AU,AU,2023,Q1,Elderly
199455763,19945576,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, per week",,,,,,,,1.5,MG,,,2023,Q1,Infection reactivation,,2023,Q1,3,F,,20230221.0,20211012,20230306,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-19274,LUPIN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology. 2021;26(2):35",69.0,YR,,F,Y,,,20230306,,HP,AU,AU,2023,Q1,Elderly
199455763,19945576,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, per week",,,,,,,,1.5,MG,,,2023,Q1,Varicella zoster virus infection,,2023,Q1,3,F,,20230221.0,20211012,20230306,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-19274,LUPIN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology. 2021;26(2):35",69.0,YR,,F,Y,,,20230306,,HP,AU,AU,2023,Q1,Elderly
199455763,19945576,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, per week",,,,,,,,1.5,MG,,,2023,Q1,Neutropenic sepsis,,2023,Q1,3,F,,20230221.0,20211012,20230306,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-19274,LUPIN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology. 2021;26(2):35",69.0,YR,,F,Y,,,20230306,,HP,AU,AU,2023,Q1,Elderly
199455763,19945576,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, per week",,,,,,,,1.5,MG,,,2023,Q1,Escherichia bacteraemia,,2023,Q1,3,F,,20230221.0,20211012,20230306,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-19274,LUPIN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology. 2021;26(2):35",69.0,YR,,F,Y,,,20230306,,HP,AU,AU,2023,Q1,Elderly
199455763,19945576,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, per week",,,,,,,,1.5,MG,,,2023,Q1,Urosepsis,,2023,Q1,3,F,,20230221.0,20211012,20230306,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-19274,LUPIN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology. 2021;26(2):35",69.0,YR,,F,Y,,,20230306,,HP,AU,AU,2023,Q1,Elderly
199455763,19945576,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, per week",,,,,,,,1.5,MG,,,2023,Q1,Extradural abscess,,2023,Q1,3,F,,20230221.0,20211012,20230306,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-19274,LUPIN,"Jeyaruban A, Downie E, Ismail AK, Nandakoban H. A case of hydralazine induced vasculitis, with pulmonary-renal syndrome. Nephrology. 2021;26(2):35",69.0,YR,,F,Y,,,20230306,,HP,AU,AU,2023,Q1,Elderly
204739766,20473976,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q1,COVID-19,,2023,Q1,6,F,20220120.0,20230316.0,20220215,20230317,EXP,,PT-ROCHE-3025733,ROCHE,,49.0,YR,,F,Y,,,20230317,,MD,PT,,2023,Q1,Adult
204739766,20473976,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q1,Blood immunoglobulin G decreased,,2023,Q1,6,F,20220120.0,20230316.0,20220215,20230317,EXP,,PT-ROCHE-3025733,ROCHE,,49.0,YR,,F,Y,,,20230317,,MD,PT,,2023,Q1,Adult
207945727,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Pulmonary oedema,,2023,Q1,7,F,20220310.0,20230222.0,20220506,20230303,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
207945727,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,C-reactive protein increased,,2023,Q1,7,F,20220310.0,20230222.0,20220506,20230303,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
207945727,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Metabolic acidosis,,2023,Q1,7,F,20220310.0,20230222.0,20220506,20230303,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
207945727,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Hyperglycaemia,,2023,Q1,7,F,20220310.0,20230222.0,20220506,20230303,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
207945727,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Dyspnoea,,2023,Q1,7,F,20220310.0,20230222.0,20220506,20230303,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
207945727,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Headache,,2023,Q1,7,F,20220310.0,20230222.0,20220506,20230303,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
207945727,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Hypotension,,2023,Q1,7,F,20220310.0,20230222.0,20220506,20230303,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
209536012,20953601,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,2,F,20220310.0,20230221.0,20220613,20230228,EXP,,CA-AstraZeneca-2022A216119,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20230228,,HP,CA,,2023,Q1,Adult
209536012,20953601,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,20220310.0,20230221.0,20220613,20230228,EXP,,CA-AstraZeneca-2022A216119,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20230228,,HP,CA,,2023,Q1,Adult
209536012,20953601,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,2,F,20220310.0,20230221.0,20220613,20230228,EXP,,CA-AstraZeneca-2022A216119,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20230228,,HP,CA,,2023,Q1,Adult
209817074,20981707,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,4,F,20220310.0,20230301.0,20220620,20230313,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20230313,,HP,CA,CA,2023,Q1,Adult
209817074,20981707,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,4,F,20220310.0,20230301.0,20220620,20230313,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20230313,,HP,CA,CA,2023,Q1,Adult
209817074,20981707,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,4,F,20220310.0,20230301.0,20220620,20230313,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20230313,,HP,CA,CA,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Fatigue,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,COVID-19,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Blood testosterone increased,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Clostridium difficile infection,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Myalgia,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Arthralgia,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Headache,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Gastric ulcer,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Disease complication,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Nausea,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Immune system disorder,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
210966672,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Cold sweat,,2023,Q1,2,F,20220531.0,20230217.0,20220718,20230224,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20230224,,CN,US,US,2023,Q1,Adult
212184779,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Cytokine release syndrome,,2023,Q1,9,F,20220729.0,20230224.0,20220816,20230302,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,US,2023,Q1,Elderly
212184779,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Pyrexia,,2023,Q1,9,F,20220729.0,20230224.0,20220816,20230302,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,US,2023,Q1,Elderly
212184779,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Stomatitis,,2023,Q1,9,F,20220729.0,20230224.0,20220816,20230302,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,US,2023,Q1,Elderly
212184779,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Neutropenia,,2023,Q1,9,F,20220729.0,20230224.0,20220816,20230302,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,US,2023,Q1,Elderly
212184779,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,9,F,20220729.0,20230224.0,20220816,20230302,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,US,2023,Q1,Elderly
212184779,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Blood lactic acid increased,,2023,Q1,9,F,20220729.0,20230224.0,20220816,20230302,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,US,2023,Q1,Elderly
212184779,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Cardiac failure,,2023,Q1,9,F,20220729.0,20230224.0,20220816,20230302,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,US,2023,Q1,Elderly
212184779,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Tachycardia,,2023,Q1,9,F,20220729.0,20230224.0,20220816,20230302,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,US,2023,Q1,Elderly
212208312,21220831,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,,20230221.0,20220817,20230224,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20230224,,MD,CA,,2023,Q1,Adult
212208312,21220831,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,2,F,,20230221.0,20220817,20230224,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20230224,,MD,CA,,2023,Q1,Adult
212208312,21220831,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,2,F,,20230221.0,20220817,20230224,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20230224,,MD,CA,,2023,Q1,Adult
212208312,21220831,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,2,F,,20230221.0,20220817,20230224,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20230224,,MD,CA,,2023,Q1,Adult
212261092,21226109,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,2,F,,20230222.0,20220818,20230303,EXP,,CA-BAUSCH-BL-2022-020411,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
212261092,21226109,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,2,F,,20230222.0,20220818,20230303,EXP,,CA-BAUSCH-BL-2022-020411,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
212261092,21226109,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,2,F,,20230222.0,20220818,20230303,EXP,,CA-BAUSCH-BL-2022-020411,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
212261092,21226109,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,,20230222.0,20220818,20230303,EXP,,CA-BAUSCH-BL-2022-020411,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230303,,HP,CA,CA,2023,Q1,Adult
212341683,21234168,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Chronic kidney disease,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212341683,21234168,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Nephrogenic anaemia,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212341683,21234168,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Renal failure,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212341683,21234168,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212341683,21234168,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Rebound acid hypersecretion,,2023,Q1,3,F,20131014.0,20230223.0,20220819,20230321,EXP,,US-AstraZeneca-2022A287268,ASTRAZENECA,,24466.0,DY,,M,Y,82.6,KG,20230321,,LW,US,,2023,Q1,Elderly
212402492,21240249,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,2,F,,20230227.0,20220822,20230309,EXP,,CA-BAUSCH-BL-2022-020590,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
212402492,21240249,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,2,F,,20230227.0,20220822,20230309,EXP,,CA-BAUSCH-BL-2022-020590,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
212402492,21240249,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,,20230227.0,20220822,20230309,EXP,,CA-BAUSCH-BL-2022-020590,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
212402492,21240249,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,2,F,,20230227.0,20220822,20230309,EXP,,CA-BAUSCH-BL-2022-020590,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
212634337,21263433,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,1.0,MG,Unknown,,2023,Q1,Confusional state,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,1.0,MG,Unknown,,2023,Q1,Insomnia,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,1.0,MG,Unknown,,2023,Q1,Tachycardia,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,1.0,MG,Unknown,,2023,Q1,Restlessness,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,1.0,MG,Unknown,,2023,Q1,Agitation,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,1.0,MG,Unknown,,2023,Q1,Drug interaction,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,5.0,MG,Unknown,,2023,Q1,Confusional state,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,5.0,MG,Unknown,,2023,Q1,Insomnia,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,5.0,MG,Unknown,,2023,Q1,Tachycardia,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,5.0,MG,Unknown,,2023,Q1,Restlessness,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,5.0,MG,Unknown,,2023,Q1,Agitation,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212634337,21263433,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,,,,,,5.0,MG,Unknown,,2023,Q1,Drug interaction,,2023,Q1,7,F,,20230310.0,20220829,20230316,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230316,,MD,ES,ES,2023,Q1,Adult
212846074,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,Injection,,2023,Q1,Hypotension,,2023,Q1,4,F,,20230215.0,20220902,20230227,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230227,,HP,CA,CA,2023,Q1,Adult
212846074,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,Injection,,2023,Q1,Hyperglycaemia,,2023,Q1,4,F,,20230215.0,20220902,20230227,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230227,,HP,CA,CA,2023,Q1,Adult
212846074,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,Injection,,2023,Q1,Pulmonary oedema,,2023,Q1,4,F,,20230215.0,20220902,20230227,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230227,,HP,CA,CA,2023,Q1,Adult
212846074,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,Injection,,2023,Q1,C-reactive protein increased,,2023,Q1,4,F,,20230215.0,20220902,20230227,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230227,,HP,CA,CA,2023,Q1,Adult
212846074,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,Injection,,2023,Q1,Metabolic acidosis,,2023,Q1,4,F,,20230215.0,20220902,20230227,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230227,,HP,CA,CA,2023,Q1,Adult
212846074,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,Injection,,2023,Q1,Dyspnoea,,2023,Q1,4,F,,20230215.0,20220902,20230227,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230227,,HP,CA,CA,2023,Q1,Adult
212846074,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,Injection,,2023,Q1,Headache,,2023,Q1,4,F,,20230215.0,20220902,20230227,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230227,,HP,CA,CA,2023,Q1,Adult
213885504,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,4,F,,20230221.0,20220928,20230224,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
213885504,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,4,F,,20230221.0,20220928,20230224,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
213885504,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,4,F,,20230221.0,20220928,20230224,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
213885504,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Dyspnoea,,2023,Q1,4,F,,20230221.0,20220928,20230224,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
213885504,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Headache,,2023,Q1,4,F,,20230221.0,20220928,20230224,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
213885504,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,C-reactive protein increased,,2023,Q1,4,F,,20230221.0,20220928,20230224,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
213885504,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,4,F,,20230221.0,20220928,20230224,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
214069892,21406989,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once weekly",,,,,,,,0.75,MG,Formulation unknown,/WK,2023,Q1,Immunosuppressant drug level increased,,2023,Q1,2,F,,20230116.0,20221004,20230125,EXP,,JP-ASTELLAS-2022JP011329,ASTELLAS,Hirai T. Evidence of study on drug interactions delivered from the clinical site. The Japanese society of hospital pharmacists Tokai block/The Pharmaceutical Soci. 2022;62,60.0,YR,,M,Y,61.9,KG,20230125,,,COUNTRY NOT SPECIFIED,JP,2023,Q1,Adult
214069892,21406989,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once weekly",,,,,,,,0.75,MG,Formulation unknown,/WK,2023,Q1,COVID-19 pneumonia,,2023,Q1,2,F,,20230116.0,20221004,20230125,EXP,,JP-ASTELLAS-2022JP011329,ASTELLAS,Hirai T. Evidence of study on drug interactions delivered from the clinical site. The Japanese society of hospital pharmacists Tokai block/The Pharmaceutical Soci. 2022;62,60.0,YR,,M,Y,61.9,KG,20230125,,,COUNTRY NOT SPECIFIED,JP,2023,Q1,Adult
214069892,21406989,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once weekly",,,,,,,,0.75,MG,Formulation unknown,/WK,2023,Q1,Pneumonia bacterial,,2023,Q1,2,F,,20230116.0,20221004,20230125,EXP,,JP-ASTELLAS-2022JP011329,ASTELLAS,Hirai T. Evidence of study on drug interactions delivered from the clinical site. The Japanese society of hospital pharmacists Tokai block/The Pharmaceutical Soci. 2022;62,60.0,YR,,M,Y,61.9,KG,20230125,,,COUNTRY NOT SPECIFIED,JP,2023,Q1,Adult
214069892,21406989,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once weekly",,,,,,,,0.75,MG,Formulation unknown,/WK,2023,Q1,Drug interaction,,2023,Q1,2,F,,20230116.0,20221004,20230125,EXP,,JP-ASTELLAS-2022JP011329,ASTELLAS,Hirai T. Evidence of study on drug interactions delivered from the clinical site. The Japanese society of hospital pharmacists Tokai block/The Pharmaceutical Soci. 2022;62,60.0,YR,,M,Y,61.9,KG,20230125,,,COUNTRY NOT SPECIFIED,JP,2023,Q1,Adult
214109142,21410914,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,2,F,,20230131.0,20221005,20230201,EXP,,CA-BAUSCH-BL-2022-022960,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230201,,HP,CA,CA,2023,Q1,Adult
214109142,21410914,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,2,F,,20230131.0,20221005,20230201,EXP,,CA-BAUSCH-BL-2022-022960,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230201,,HP,CA,CA,2023,Q1,Adult
214109142,21410914,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,2,F,,20230131.0,20221005,20230201,EXP,,CA-BAUSCH-BL-2022-022960,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230201,,HP,CA,CA,2023,Q1,Adult
214128664,21412866,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,4,F,,20230227.0,20221005,20230309,EXP,,CA-BAUSCH-BL-2022-022962,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
214128664,21412866,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Headache,,2023,Q1,4,F,,20230227.0,20221005,20230309,EXP,,CA-BAUSCH-BL-2022-022962,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
214128664,21412866,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,4,F,,20230227.0,20221005,20230309,EXP,,CA-BAUSCH-BL-2022-022962,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
214128664,21412866,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,4,F,,20230227.0,20221005,20230309,EXP,,CA-BAUSCH-BL-2022-022962,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
214128664,21412866,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,4,F,,20230227.0,20221005,20230309,EXP,,CA-BAUSCH-BL-2022-022962,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230309,,HP,CA,CA,2023,Q1,Adult
214369324,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,4,F,20220729.0,20230224.0,20221010,20230301,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20230301,,MD,US,US,2023,Q1,Elderly
214369324,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Stomatitis,,2023,Q1,4,F,20220729.0,20230224.0,20221010,20230301,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20230301,,MD,US,US,2023,Q1,Elderly
214369324,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Cytokine release syndrome,,2023,Q1,4,F,20220729.0,20230224.0,20221010,20230301,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20230301,,MD,US,US,2023,Q1,Elderly
214369324,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Neutropenia,,2023,Q1,4,F,20220729.0,20230224.0,20221010,20230301,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20230301,,MD,US,US,2023,Q1,Elderly
215236145,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Dyspnoea,,2023,Q1,5,F,,20230228.0,20221029,20230310,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,90.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
215236145,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Hyperglycaemia,,2023,Q1,5,F,,20230228.0,20221029,20230310,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,90.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
215236145,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Hypotension,,2023,Q1,5,F,,20230228.0,20221029,20230310,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,90.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
215236145,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,C-reactive protein increased,,2023,Q1,5,F,,20230228.0,20221029,20230310,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,90.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
215236145,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Headache,,2023,Q1,5,F,,20230228.0,20221029,20230310,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,90.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
215236145,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Pulmonary oedema,,2023,Q1,5,F,,20230228.0,20221029,20230310,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,90.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
215236145,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q1,Metabolic acidosis,,2023,Q1,5,F,,20230228.0,20221029,20230310,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,90.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
215651954,21565195,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Extravasation,,2023,Q1,4,F,20220923.0,20221229.0,20221108,20230102,EXP,,DE-ROCHE-3206980,ROCHE,,60.0,YR,,F,Y,86.0,KG,20230102,,MD,DE,,2023,Q1,Adult
215651954,21565195,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,General physical health deterioration,,2023,Q1,4,F,20220923.0,20221229.0,20221108,20230102,EXP,,DE-ROCHE-3206980,ROCHE,,60.0,YR,,F,Y,86.0,KG,20230102,,MD,DE,,2023,Q1,Adult
216044104,21604410,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW (every 7 days)",,,U,,,,,1.5,MG,,/WK,2023,Q1,Confusional state,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW (every 7 days)",,,U,,,,,1.5,MG,,/WK,2023,Q1,Antipsychotic drug level increased,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW (every 7 days)",,,U,,,,,1.5,MG,,/WK,2023,Q1,Insomnia,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW (every 7 days)",,,U,,,,,1.5,MG,,/WK,2023,Q1,Restlessness,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW (every 7 days)",,,U,,,,,1.5,MG,,/WK,2023,Q1,Agitation,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW (every 7 days)",,,U,,,,,1.5,MG,,/WK,2023,Q1,Tachycardia,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW (every 7 days)",,,U,,,,,1.5,MG,,/WK,2023,Q1,Drug interaction,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW (every 7 days)",,,U,,,,,1.5,MG,,/WK,2023,Q1,Nervousness,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q1,Confusional state,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q1,Antipsychotic drug level increased,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q1,Insomnia,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q1,Restlessness,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q1,Agitation,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q1,Tachycardia,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216044104,21604410,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q1,Nervousness,,2023,Q1,4,F,,20221227.0,20221116,20230102,EXP,,NVSC2022ES254405,NOVARTIS,"Blundell DB, Naranjo OC. Servicio de dispensacion: interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230102,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW",,,,,,,,1.0,MG,,/WK,2023,Q1,Agitation,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW",,,,,,,,1.0,MG,,/WK,2023,Q1,Insomnia,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW",,,,,,,,1.0,MG,,/WK,2023,Q1,Drug interaction,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW",,,,,,,,1.0,MG,,/WK,2023,Q1,Confusional state,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW",,,,,,,,1.0,MG,,/WK,2023,Q1,Nervousness,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW",,,,,,,,1.0,MG,,/WK,2023,Q1,Restlessness,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW",,,,,,,,1.0,MG,,/WK,2023,Q1,Tachycardia,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW",,,,,,,,1.0,MG,,/WK,2023,Q1,Drug level increased,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW",,,,,,,,5.0,MG,,/WK,2023,Q1,Agitation,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW",,,,,,,,5.0,MG,,/WK,2023,Q1,Insomnia,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW",,,,,,,,5.0,MG,,/WK,2023,Q1,Drug interaction,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW",,,,,,,,5.0,MG,,/WK,2023,Q1,Confusional state,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW",,,,,,,,5.0,MG,,/WK,2023,Q1,Nervousness,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW",,,,,,,,5.0,MG,,/WK,2023,Q1,Restlessness,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW",,,,,,,,5.0,MG,,/WK,2023,Q1,Tachycardia,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW",,,,,,,,5.0,MG,,/WK,2023,Q1,Drug level increased,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q1,Agitation,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q1,Insomnia,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q1,Drug interaction,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q1,Confusional state,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q1,Nervousness,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q1,Restlessness,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q1,Tachycardia,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216105394,21610539,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q1,Drug level increased,,2023,Q1,4,F,,20230119.0,20221117,20230120,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. REVISTA TRIMESTRAL DE FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20230120,,HP,ES,ES,2023,Q1,Adult
216179223,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Vascular stenosis,,2023,Q1,3,F,20210901.0,20230119.0,20221119,20230127,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230127,,MD,JP,JP,2023,Q1,Elderly
216179223,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Off label use,,2023,Q1,3,F,20210901.0,20230119.0,20221119,20230127,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230127,,MD,JP,JP,2023,Q1,Elderly
216179223,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Renal impairment,,2023,Q1,3,F,20210901.0,20230119.0,20221119,20230127,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230127,,MD,JP,JP,2023,Q1,Elderly
216179223,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Blood glucose abnormal,,2023,Q1,3,F,20210901.0,20230119.0,20221119,20230127,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230127,,MD,JP,JP,2023,Q1,Elderly
218114183,21811418,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,3,F,,20230109.0,20230103,20230113,EXP,,US-PFIZER INC-PV202200133695,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230113,,PH,US,US,2023,Q1,Elderly
218114183,21811418,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Chronic kidney disease,,2023,Q1,3,F,,20230109.0,20230103,20230113,EXP,,US-PFIZER INC-PV202200133695,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230113,,PH,US,US,2023,Q1,Elderly
218114183,21811418,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,3,F,,20230109.0,20230103,20230113,EXP,,US-PFIZER INC-PV202200133695,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230113,,PH,US,US,2023,Q1,Elderly
218139372,21813937,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Skin reaction,,2023,Q1,2,F,20220901.0,20230202.0,20230104,20230317,PER,,US-ABBVIE-4220045,ABBVIE,,63.0,YR,,F,Y,,,20230317,,CN,US,US,2023,Q1,Adult
218245481,21824548,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,/WK,2023,Q1,Diarrhoea,,2023,Q1,1,I,20221227.0,20221229.0,20230105,20230105,EXP,GB-MHRA-TPP977717C579002YC1672154914831,GB-LABORATORIOS LICONSA S.A.-2212GB05732,INSUD PHARMA,,65.0,YR,,F,Y,95.0,KG,20230105,,MD,GB,GB,2023,Q1,Elderly
218245481,21824548,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,/WK,2023,Q1,Malaise,,2023,Q1,1,I,20221227.0,20221229.0,20230105,20230105,EXP,GB-MHRA-TPP977717C579002YC1672154914831,GB-LABORATORIOS LICONSA S.A.-2212GB05732,INSUD PHARMA,,65.0,YR,,F,Y,95.0,KG,20230105,,MD,GB,GB,2023,Q1,Elderly
218441442,21844144,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,2,F,,20230109.0,20230110,20230113,EXP,,US-BAUSCH-BL-2023-000298,BAUSCH AND LOMB,"Rauser M, McGrane I. A CYP3A4 Drug-Drug Interaction Between  Nirmatrelvir/Ritonavir and Nifedipine  Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;00(0):1-2. doi:10.1177/10600280221143131",79.0,YR,,F,Y,,,20230113,,HP,US,US,2023,Q1,Elderly
218441442,21844144,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,2,F,,20230109.0,20230110,20230113,EXP,,US-BAUSCH-BL-2023-000298,BAUSCH AND LOMB,"Rauser M, McGrane I. A CYP3A4 Drug-Drug Interaction Between  Nirmatrelvir/Ritonavir and Nifedipine  Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;00(0):1-2. doi:10.1177/10600280221143131",79.0,YR,,F,Y,,,20230113,,HP,US,US,2023,Q1,Elderly
218441442,21844144,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,2,F,,20230109.0,20230110,20230113,EXP,,US-BAUSCH-BL-2023-000298,BAUSCH AND LOMB,"Rauser M, McGrane I. A CYP3A4 Drug-Drug Interaction Between  Nirmatrelvir/Ritonavir and Nifedipine  Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;00(0):1-2. doi:10.1177/10600280221143131",79.0,YR,,F,Y,,,20230113,,HP,US,US,2023,Q1,Elderly
218486883,21848688,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2023,Q1,Hypoglycaemia,,2023,Q1,3,F,20181017.0,20230317.0,20230111,20230329,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202301000692,ELI LILLY AND CO,,23.0,YR,,M,Y,117.0,KG,20230329,,CN,DE,DE,2023,Q1,Youth
218486883,21848688,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2023,Q1,Metabolic acidosis,,2023,Q1,3,F,20181017.0,20230317.0,20230111,20230329,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202301000692,ELI LILLY AND CO,,23.0,YR,,M,Y,117.0,KG,20230329,,CN,DE,DE,2023,Q1,Youth
218486883,21848688,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2023,Q1,Ketoacidosis,,2023,Q1,3,F,20181017.0,20230317.0,20230111,20230329,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202301000692,ELI LILLY AND CO,,23.0,YR,,M,Y,117.0,KG,20230329,,CN,DE,DE,2023,Q1,Youth
218486883,21848688,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2023,Q1,Lactic acidosis,,2023,Q1,3,F,20181017.0,20230317.0,20230111,20230329,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202301000692,ELI LILLY AND CO,,23.0,YR,,M,Y,117.0,KG,20230329,,CN,DE,DE,2023,Q1,Youth
218555303,21855530,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,Unknown,,,,,,/WK,2023,Q1,Metabolic acidosis,,2023,Q1,3,F,20181017.0,20230116.0,20230112,20230120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212375",BOEHRINGER INGELHEIM,,23.0,YR,A,M,Y,117.0,KG,20230120,,MD,DE,DE,2023,Q1,Youth
218555303,21855530,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,Unknown,,,,,,/WK,2023,Q1,Hypoglycaemia,,2023,Q1,3,F,20181017.0,20230116.0,20230112,20230120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212375",BOEHRINGER INGELHEIM,,23.0,YR,A,M,Y,117.0,KG,20230120,,MD,DE,DE,2023,Q1,Youth
218555303,21855530,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,Unknown,,,,,,/WK,2023,Q1,Lactic acidosis,,2023,Q1,3,F,20181017.0,20230116.0,20230112,20230120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212375",BOEHRINGER INGELHEIM,,23.0,YR,A,M,Y,117.0,KG,20230120,,MD,DE,DE,2023,Q1,Youth
218555303,21855530,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,Unknown,,,,,,/WK,2023,Q1,Ketoacidosis,,2023,Q1,3,F,20181017.0,20230116.0,20230112,20230120,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-212375",BOEHRINGER INGELHEIM,,23.0,YR,A,M,Y,117.0,KG,20230120,,MD,DE,DE,2023,Q1,Youth
218671501,21867150,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,UNK,,,,,,,2023,Q1,Bundle branch block left,,2023,Q1,1,I,,20230102.0,20230116,20230116,EXP,US-MLMSERVICE-20230103-4014779-1,US-CIPLA LTD.-2023US00129,CIPLA,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;00 (0):1 to 2",79.0,YR,,F,Y,,,20230116,,HP,US,US,2023,Q1,Elderly
218671501,21867150,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,UNK,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230102.0,20230116,20230116,EXP,US-MLMSERVICE-20230103-4014779-1,US-CIPLA LTD.-2023US00129,CIPLA,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;00 (0):1 to 2",79.0,YR,,F,Y,,,20230116,,HP,US,US,2023,Q1,Elderly
218671501,21867150,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,UNK,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230102.0,20230116,20230116,EXP,US-MLMSERVICE-20230103-4014779-1,US-CIPLA LTD.-2023US00129,CIPLA,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;00 (0):1 to 2",79.0,YR,,F,Y,,,20230116,,HP,US,US,2023,Q1,Elderly
218671501,21867150,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,UNK,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,1,I,,20230102.0,20230116,20230116,EXP,US-MLMSERVICE-20230103-4014779-1,US-CIPLA LTD.-2023US00129,CIPLA,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;00 (0):1 to 2",79.0,YR,,F,Y,,,20230116,,HP,US,US,2023,Q1,Elderly
218745531,21874553,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Necrotising fasciitis,,2023,Q1,1,I,20230106.0,20230110.0,20230117,20230117,EXP,,GB-AstraZeneca-2023A006649,ASTRAZENECA,,68.0,YR,,F,Y,,,20230113,,MD,GB,,2023,Q1,Elderly
218845261,21884526,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,0.75 milligram,,,,,,,,0.75,MG,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230111.0,20230119,20230119,EXP,,JP-JNJFOC-20230136642,JOHNSON AND JOHNSON,Tatsujo M and Yagi I. 61 A case of prolonged effect up to 14 days after discontinuation of SGLT2 inhibitor. The 683rd Kanto Regional Meeting of the Japanese Society of Internal Medicine. 2022.12. 10,55.0,YR,A,F,Y,,,20230119,,MD,JP,JP,2023,Q1,Adult
218845261,21884526,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,0.75 milligram,,,,,,,,0.75,MG,,,2023,Q1,Epiglottitis,,2023,Q1,1,I,,20230111.0,20230119,20230119,EXP,,JP-JNJFOC-20230136642,JOHNSON AND JOHNSON,Tatsujo M and Yagi I. 61 A case of prolonged effect up to 14 days after discontinuation of SGLT2 inhibitor. The 683rd Kanto Regional Meeting of the Japanese Society of Internal Medicine. 2022.12. 10,55.0,YR,A,F,Y,,,20230119,,MD,JP,JP,2023,Q1,Adult
218880931,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q1,Nephropathy toxic,,2023,Q1,1,I,,20230117.0,20230120,20230120,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",8.0,DEC,,M,Y,,,20230120,,HP,AU,AU,2023,Q1,Child
218911971,21891197,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, qw",,,U,U,,,,,,Injection,/WK,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230116.0,20230120,20230120,EXP,AU-MLMSERVICE-20220707-3662195-1,AU-MYLANLABS-2023M1007044,MYLAN,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ-Case-Rep 2022;15:No. 6.",8.0,DEC,,M,Y,,,20230120,,MD,AU,AU,2023,Q1,Child
218912691,21891269,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Oliguria,,2023,Q1,1,I,,20230110.0,20230120,20230120,EXP,,US-ALVOGEN-2023089021,ALVOGEN,"Madison SR and Ian RM. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;1-2. doi:10.1177/10600280221143131",79.0,YR,,F,Y,,,20230120,,HP,US,US,2023,Q1,Elderly
218912691,21891269,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Oedema,,2023,Q1,1,I,,20230110.0,20230120,20230120,EXP,,US-ALVOGEN-2023089021,ALVOGEN,"Madison SR and Ian RM. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;1-2. doi:10.1177/10600280221143131",79.0,YR,,F,Y,,,20230120,,HP,US,US,2023,Q1,Elderly
218912691,21891269,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230110.0,20230120,20230120,EXP,,US-ALVOGEN-2023089021,ALVOGEN,"Madison SR and Ian RM. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;1-2. doi:10.1177/10600280221143131",79.0,YR,,F,Y,,,20230120,,HP,US,US,2023,Q1,Elderly
218912691,21891269,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230110.0,20230120,20230120,EXP,,US-ALVOGEN-2023089021,ALVOGEN,"Madison SR and Ian RM. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;1-2. doi:10.1177/10600280221143131",79.0,YR,,F,Y,,,20230120,,HP,US,US,2023,Q1,Elderly
218915291,21891529,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, q weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Adrenal insufficiency,,2023,Q1,1,I,20230104.0,20230113.0,20230120,20230120,EXP,IT-MINISAL02-904535,IT-EXELIXIS-CABO-23059731,EXELIXIS,,70.0,YR,,M,Y,,,20230120,,MD,IT,IT,2023,Q1,Elderly
218915291,21891529,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, q weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Hypothyroidism,,2023,Q1,1,I,20230104.0,20230113.0,20230120,20230120,EXP,IT-MINISAL02-904535,IT-EXELIXIS-CABO-23059731,EXELIXIS,,70.0,YR,,M,Y,,,20230120,,MD,IT,IT,2023,Q1,Elderly
218915291,21891529,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, q weekly",,,,,,,,1.5,MG,,/WK,2023,Q1,Cardiac failure,,2023,Q1,1,I,20230104.0,20230113.0,20230120,20230120,EXP,IT-MINISAL02-904535,IT-EXELIXIS-CABO-23059731,EXELIXIS,,70.0,YR,,M,Y,,,20230120,,MD,IT,IT,2023,Q1,Elderly
218926781,21892678,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"unknown?Pen, Disposable",,,U,,Unknown,,,,,,,2023,Q1,Fungal infection,,2023,Q1,1,I,,20221228.0,20230120,20230120,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-213980",BOEHRINGER INGELHEIM,,67.0,YR,E,F,Y,,,20230120,,CN,US,US,2023,Q1,Elderly
218943001,21894300,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,1,I,,20230109.0,20230121,20230121,EXP,,US-AUROBINDO-AUR-APL-2023-001506,AUROBINDO,"Rauser MS, McGrane IR.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report.. The Annals of pharmacotherapy. 2022;106002802211431",79.0,YR,,F,Y,,,20230121,,PH,US,US,2023,Q1,Elderly
218943001,21894300,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230109.0,20230121,20230121,EXP,,US-AUROBINDO-AUR-APL-2023-001506,AUROBINDO,"Rauser MS, McGrane IR.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report.. The Annals of pharmacotherapy. 2022;106002802211431",79.0,YR,,F,Y,,,20230121,,PH,US,US,2023,Q1,Elderly
218943001,21894300,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230109.0,20230121,20230121,EXP,,US-AUROBINDO-AUR-APL-2023-001506,AUROBINDO,"Rauser MS, McGrane IR.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report.. The Annals of pharmacotherapy. 2022;106002802211431",79.0,YR,,F,Y,,,20230121,,PH,US,US,2023,Q1,Elderly
218943001,21894300,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q1,Bundle branch block left,,2023,Q1,1,I,,20230109.0,20230121,20230121,EXP,,US-AUROBINDO-AUR-APL-2023-001506,AUROBINDO,"Rauser MS, McGrane IR.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report.. The Annals of pharmacotherapy. 2022;106002802211431",79.0,YR,,F,Y,,,20230121,,PH,US,US,2023,Q1,Elderly
219098472,21909847,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,U,,,,125469.0,,,,/WK,2023,Q1,Ketoacidosis,,2023,Q1,2,F,20181017.0,20230317.0,20230125,20230329,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202301006396,ELI LILLY AND CO,,23.0,YR,,M,Y,117.0,KG,20230329,,CN,DE,DE,2023,Q1,Youth
219098472,21909847,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,U,,,,125469.0,,,,/WK,2023,Q1,Lactic acidosis,,2023,Q1,2,F,20181017.0,20230317.0,20230125,20230329,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202301006396,ELI LILLY AND CO,,23.0,YR,,M,Y,117.0,KG,20230329,,CN,DE,DE,2023,Q1,Youth
219098472,21909847,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,U,,,,125469.0,,,,/WK,2023,Q1,Hypoglycaemia,,2023,Q1,2,F,20181017.0,20230317.0,20230125,20230329,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202301006396,ELI LILLY AND CO,,23.0,YR,,M,Y,117.0,KG,20230329,,CN,DE,DE,2023,Q1,Youth
219098472,21909847,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,U,,,,125469.0,,,,/WK,2023,Q1,Metabolic acidosis,,2023,Q1,2,F,20181017.0,20230317.0,20230125,20230329,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202301006396,ELI LILLY AND CO,,23.0,YR,,M,Y,117.0,KG,20230329,,CN,DE,DE,2023,Q1,Youth
219118871,21911887,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,1,I,,20230123.0,20230125,20230125,EXP,,CA-BAUSCH-BL-2023-001286,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230125,,HP,CA,CA,2023,Q1,Adult
219118871,21911887,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230123.0,20230125,20230125,EXP,,CA-BAUSCH-BL-2023-001286,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230125,,HP,CA,CA,2023,Q1,Adult
219118871,21911887,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230123.0,20230125,20230125,EXP,,CA-BAUSCH-BL-2023-001286,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20230125,,HP,CA,CA,2023,Q1,Adult
219165531,21916553,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Diabetic ketosis,,2023,Q1,1,I,20230116.0,20230122.0,20230126,20230126,EXP,,GB-MYLANLABS-2023M1008234,MYLAN,,63.0,YR,,F,Y,,,20230126,,HP,GB,GB,2023,Q1,Adult
219244691,21924469,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Diabetic ketosis,,2023,Q1,1,I,20230116.0,20230122.0,20230130,20230130,EXP,,GB-EMD Serono-E2B_90090528,EMD SERONO INC,,63.0,YR,A,F,Y,,,20230130,,HP,GB,,2023,Q1,Adult
219251381,21925138,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,Injection,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230116.0,20230130,20230130,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-375833,RANBAXY,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ Case Rep. 2022;15(6):e249552",8.0,DEC,,M,Y,,,20230130,,HP,AU,AU,2023,Q1,Child
219272171,21927217,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20230104.0,,20230129,20230129,DIR,646408,,FDA-CTU,,54.0,YR,,M,N,98.0,KG,20230129,N,PH,US,,2023,Q1,Adult
219272171,21927217,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20230104.0,,20230129,20230129,DIR,646408,,FDA-CTU,,54.0,YR,,M,N,98.0,KG,20230129,N,PH,US,,2023,Q1,Adult
219318971,21931897,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,20221102.0,20230123.0,20230131,20230131,EXP,FR-AFSSAPS-RE2023000050,FR-Accord-298551,ACCORD,,81.0,YR,E,M,Y,108.0,KG,20230131,,PH,FR,FR,2023,Q1,Elderly
219337301,21933730,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,unk,,,,,,,2023,Q1,Diabetic ketosis,,2023,Q1,1,I,20230116.0,20230122.0,20230201,20230201,EXP,,GB-AUROBINDO-AUR-APL-2023-003673,AUROBINDO,,63.0,YR,,F,Y,,,20230201,,HP,GB,GB,2023,Q1,Adult
219370421,21937042,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Diabetic ketosis,,2023,Q1,1,I,20230116.0,20230122.0,20230201,20230201,EXP,,GB-TEVA-2023-GB-2849451,TEVA,,63.0,YR,A,F,Y,,,20230201,,HP,GB,GB,2023,Q1,Adult
219436272,21943627,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,Solution for injection,,2023,Q1,Cardiac failure,,2023,Q1,2,F,,20230126.0,20230202,20230331,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-012703,BRISTOL MYERS SQUIBB,,61.0,YR,A,M,Y,,,20230331,,CN,US,US,2023,Q1,Adult
219479551,21947955,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, QW (weekly (1/W))",,,U,,,,,,,Solution for injection,/WK,2023,Q1,Lactic acidosis,,2023,Q1,1,I,20180101.0,20230127.0,20230203,20230203,EXP,,NVSC2023DE019168,NOVARTIS,,23.0,YR,,M,Y,117.0,KG,20230203,,MD,DE,DE,2023,Q1,Youth
219479551,21947955,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, QW (weekly (1/W))",,,U,,,,,,,Solution for injection,/WK,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,20180101.0,20230127.0,20230203,20230203,EXP,,NVSC2023DE019168,NOVARTIS,,23.0,YR,,M,Y,117.0,KG,20230203,,MD,DE,DE,2023,Q1,Youth
219479551,21947955,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, QW (weekly (1/W))",,,U,,,,,,,Solution for injection,/WK,2023,Q1,Ketoacidosis,,2023,Q1,1,I,20180101.0,20230127.0,20230203,20230203,EXP,,NVSC2023DE019168,NOVARTIS,,23.0,YR,,M,Y,117.0,KG,20230203,,MD,DE,DE,2023,Q1,Youth
219479551,21947955,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, QW (weekly (1/W))",,,U,,,,,,,Solution for injection,/WK,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,20180101.0,20230127.0,20230203,20230203,EXP,,NVSC2023DE019168,NOVARTIS,,23.0,YR,,M,Y,117.0,KG,20230203,,MD,DE,DE,2023,Q1,Youth
219482941,21948294,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Weekly",,,,,,,,1.5,MG,,,2023,Q1,Treatment noncompliance,,2023,Q1,1,I,,20230120.0,20230203,20230203,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-375947,RANBAXY,"Burlina S, Dalfra MG, Caprino R, Lapolla A. A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus. Acta Diabetol. 2023;60(1):137-138",38.0,YR,,F,Y,,,20230203,,HP,IT,IT,2023,Q1,Adult
219482941,21948294,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Weekly",,,,,,,,1.5,MG,,,2023,Q1,Exposure during pregnancy,,2023,Q1,1,I,,20230120.0,20230203,20230203,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-375947,RANBAXY,"Burlina S, Dalfra MG, Caprino R, Lapolla A. A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus. Acta Diabetol. 2023;60(1):137-138",38.0,YR,,F,Y,,,20230203,,HP,IT,IT,2023,Q1,Adult
219492891,21949289,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Diabetic ketosis,,2023,Q1,1,I,20230116.0,20230122.0,20230203,20230203,EXP,,GB-MICRO LABS LIMITED-ML2023-00461,MICRO LABS,,63.0,YR,A,F,Y,,,20230203,,HP,GB,,2023,Q1,Adult
219501962,21950196,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,sol 4.5mg/0.5 sub,,,U,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,2,F,20230118.0,20230222.0,20230203,20230309,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-016391,BRISTOL MYERS SQUIBB,,55.0,YR,A,M,Y,,,20230309,,HP,US,US,2023,Q1,Adult
219501962,21950196,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,sol 4.5mg/0.5 sub,,,U,,,,,,,,,2023,Q1,Platelet count decreased,,2023,Q1,2,F,20230118.0,20230222.0,20230203,20230309,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-016391,BRISTOL MYERS SQUIBB,,55.0,YR,A,M,Y,,,20230309,,HP,US,US,2023,Q1,Adult
219501962,21950196,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,sol 4.5mg/0.5 sub,,,U,,,,,,,,,2023,Q1,Hypercoagulation,,2023,Q1,2,F,20230118.0,20230222.0,20230203,20230309,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-016391,BRISTOL MYERS SQUIBB,,55.0,YR,A,M,Y,,,20230309,,HP,US,US,2023,Q1,Adult
219531201,21953120,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,U,,,,,,,Solution for injection,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,20180101.0,20230125.0,20230204,20230204,EXP,,DE-AUROBINDO-AUR-APL-2023-004278,AUROBINDO,,23.0,YR,,M,Y,117.0,KG,20230204,,MD,DE,DE,2023,Q1,Youth
219531201,21953120,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,U,,,,,,,Solution for injection,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,20180101.0,20230125.0,20230204,20230204,EXP,,DE-AUROBINDO-AUR-APL-2023-004278,AUROBINDO,,23.0,YR,,M,Y,117.0,KG,20230204,,MD,DE,DE,2023,Q1,Youth
219531201,21953120,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,U,,,,,,,Solution for injection,,2023,Q1,Ketoacidosis,,2023,Q1,1,I,20180101.0,20230125.0,20230204,20230204,EXP,,DE-AUROBINDO-AUR-APL-2023-004278,AUROBINDO,,23.0,YR,,M,Y,117.0,KG,20230204,,MD,DE,DE,2023,Q1,Youth
219531201,21953120,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,U,,,,,,,Solution for injection,,2023,Q1,Lactic acidosis,,2023,Q1,1,I,20180101.0,20230125.0,20230204,20230204,EXP,,DE-AUROBINDO-AUR-APL-2023-004278,AUROBINDO,,23.0,YR,,M,Y,117.0,KG,20230204,,MD,DE,DE,2023,Q1,Youth
219539411,21953941,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, unknown",,,U,,LYVI31C,,125469.0,0.75,MG,Solution for injection in pre-filled pen,,2023,Q1,Underdose,,2023,Q1,1,I,20230121.0,20230121.0,20230204,20230204,PER,,US-ELI_LILLY_AND_COMPANY-US202301012787,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20230204,,CN,US,US,2023,Q1,Adult
219773031,21977303,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,CA-TEVA-2023-CA-2852047,TEVA,,64.0,YR,A,M,Y,90.0,KG,20230210,,HP,CA,CA,2023,Q1,Adult
219773031,21977303,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,CA-TEVA-2023-CA-2852047,TEVA,,64.0,YR,A,M,Y,90.0,KG,20230210,,HP,CA,CA,2023,Q1,Adult
219773031,21977303,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230131.0,20230210,20230210,EXP,,CA-TEVA-2023-CA-2852047,TEVA,,64.0,YR,A,M,Y,90.0,KG,20230210,,HP,CA,CA,2023,Q1,Adult
219792771,21979277,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Accidental overdose,,2023,Q1,1,I,,20230203.0,20230210,20230210,EXP,,AU-PERRIGO-21AU033511,PERRIGO,,46.0,YR,,F,Y,78.5,KG,20230210,,HP,AU,AU,2023,Q1,Adult
219792771,21979277,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hypotension,,2023,Q1,1,I,,20230203.0,20230210,20230210,EXP,,AU-PERRIGO-21AU033511,PERRIGO,,46.0,YR,,F,Y,78.5,KG,20230210,,HP,AU,AU,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Product dose omission issue,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Sleep disorder,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Somnolence,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Malaise,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Blood glucose decreased,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,COVID-19,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hypothyroidism,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Bacterial infection,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Condition aggravated,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Blood sodium decreased,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Fatigue,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Pain in extremity,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Blood glucose increased,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Myalgia,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Rotator cuff syndrome,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Arthralgia,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Nasal congestion,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219850161,21985016,25,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Vomiting,,2023,Q1,1,I,20220101.0,20230130.0,20230213,20230213,EXP,,US-Accord-299263,ACCORD,,52.0,YR,A,M,Y,129.3,KG,20230213,,CN,US,US,2023,Q1,Adult
219947971,21994797,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230209.0,20230215,20230215,EXP,,US-MYLANLABS-2023M1016420,MYLAN,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann-Pharmacother 2022;:1-2.",79.0,YR,,F,Y,,,20230215,,PH,US,US,2023,Q1,Elderly
219947971,21994797,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,1,I,,20230209.0,20230215,20230215,EXP,,US-MYLANLABS-2023M1016420,MYLAN,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann-Pharmacother 2022;:1-2.",79.0,YR,,F,Y,,,20230215,,PH,US,US,2023,Q1,Elderly
219947971,21994797,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Condition aggravated,,2023,Q1,1,I,,20230209.0,20230215,20230215,EXP,,US-MYLANLABS-2023M1016420,MYLAN,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann-Pharmacother 2022;:1-2.",79.0,YR,,F,Y,,,20230215,,PH,US,US,2023,Q1,Elderly
219947971,21994797,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Intentional product misuse,,2023,Q1,1,I,,20230209.0,20230215,20230215,EXP,,US-MYLANLABS-2023M1016420,MYLAN,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann-Pharmacother 2022;:1-2.",79.0,YR,,F,Y,,,20230215,,PH,US,US,2023,Q1,Elderly
219947971,21994797,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230209.0,20230215,20230215,EXP,,US-MYLANLABS-2023M1016420,MYLAN,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann-Pharmacother 2022;:1-2.",79.0,YR,,F,Y,,,20230215,,PH,US,US,2023,Q1,Elderly
219949272,21994927,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, QW",,,U,,,,,7.5,MG,,/WK,2023,Q1,Colitis ulcerative,,2023,Q1,2,F,,20230207.0,20230215,20230216,EXP,,NVSC2023CA028435,NOVARTIS,,73.0,YR,,F,Y,,,20230216,,HP,CA,CA,2023,Q1,Elderly
219949272,21994927,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, QW",,,U,,,,,7.5,MG,,/WK,2023,Q1,Rectal haemorrhage,,2023,Q1,2,F,,20230207.0,20230215,20230216,EXP,,NVSC2023CA028435,NOVARTIS,,73.0,YR,,F,Y,,,20230216,,HP,CA,CA,2023,Q1,Elderly
219949272,21994927,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, QW",,,U,,,,,7.5,MG,,/WK,2023,Q1,Decreased activity,,2023,Q1,2,F,,20230207.0,20230215,20230216,EXP,,NVSC2023CA028435,NOVARTIS,,73.0,YR,,F,Y,,,20230216,,HP,CA,CA,2023,Q1,Elderly
219949272,21994927,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, QW",,,U,,,,,7.5,MG,,/WK,2023,Q1,Colitis,,2023,Q1,2,F,,20230207.0,20230215,20230216,EXP,,NVSC2023CA028435,NOVARTIS,,73.0,YR,,F,Y,,,20230216,,HP,CA,CA,2023,Q1,Elderly
219949272,21994927,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, QW",,,U,,,,,7.5,MG,,/WK,2023,Q1,Frequent bowel movements,,2023,Q1,2,F,,20230207.0,20230215,20230216,EXP,,NVSC2023CA028435,NOVARTIS,,73.0,YR,,F,Y,,,20230216,,HP,CA,CA,2023,Q1,Elderly
219949821,21994982,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,U,U,,,,,,Solution for injection,/WK,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,20180101.0,20230209.0,20230215,20230215,EXP,,DE-MYLANLABS-2023M1015624,MYLAN,,23.0,YR,,M,Y,117.0,KG,20230215,,MD,DE,DE,2023,Q1,Youth
219949821,21994982,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,U,U,,,,,,Solution for injection,/WK,2023,Q1,Ketoacidosis,,2023,Q1,1,I,20180101.0,20230209.0,20230215,20230215,EXP,,DE-MYLANLABS-2023M1015624,MYLAN,,23.0,YR,,M,Y,117.0,KG,20230215,,MD,DE,DE,2023,Q1,Youth
219949821,21994982,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,U,U,,,,,,Solution for injection,/WK,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,20180101.0,20230209.0,20230215,20230215,EXP,,DE-MYLANLABS-2023M1015624,MYLAN,,23.0,YR,,M,Y,117.0,KG,20230215,,MD,DE,DE,2023,Q1,Youth
219949821,21994982,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,U,U,,,,,,Solution for injection,/WK,2023,Q1,Lactic acidosis,,2023,Q1,1,I,20180101.0,20230209.0,20230215,20230215,EXP,,DE-MYLANLABS-2023M1015624,MYLAN,,23.0,YR,,M,Y,117.0,KG,20230215,,MD,DE,DE,2023,Q1,Youth
219976122,21997612,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Diarrhoea,,2023,Q1,2,F,20220729.0,20230224.0,20230216,20230302,EXP,,US-ROCHE-3169587,ROCHE,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,,2023,Q1,Elderly
219976122,21997612,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Stomatitis,,2023,Q1,2,F,20220729.0,20230224.0,20230216,20230302,EXP,,US-ROCHE-3169587,ROCHE,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,,2023,Q1,Elderly
219976122,21997612,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Cytokine release syndrome,,2023,Q1,2,F,20220729.0,20230224.0,20230216,20230302,EXP,,US-ROCHE-3169587,ROCHE,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,,2023,Q1,Elderly
219976122,21997612,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Neutropenia,,2023,Q1,2,F,20220729.0,20230224.0,20230216,20230302,EXP,,US-ROCHE-3169587,ROCHE,,72.0,YR,,M,Y,70.4,KG,20230302,,MD,US,,2023,Q1,Elderly
220004231,22000423,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,20230201.0,,20230215,20230215,DIR,648754,,FDA-CTU,,66.0,YR,,F,N,86.5,KG,20230215,N,PH,US,,2023,Q1,Elderly
220102262,22010226,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Meningitis,,2023,Q1,2,F,20230214.0,20230224.0,20230220,20230228,EXP,,IL-ROCHE-3287833,ROCHE,,67.0,YR,,M,Y,,,20230228,,MD,IL,,2023,Q1,Elderly
220112082,22011208,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",4.929,MG,U,,,,125469.0,1.5,MG,,/WK,2023,Q1,Pulmonary embolism,,2023,Q1,2,F,20221224.0,20230219.0,20230220,20230302,EXP,GB-MHRA-ADR 27655583,GB-ELI_LILLY_AND_COMPANY-GB202302003557,ELI LILLY AND CO,,76.0,YR,,M,Y,80.0,KG,20230302,,CN,GB,GB,2023,Q1,Elderly
220112082,22011208,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",4.929,MG,U,,,,125469.0,1.5,MG,,/WK,2023,Q1,Chronic kidney disease,,2023,Q1,2,F,20221224.0,20230219.0,20230220,20230302,EXP,GB-MHRA-ADR 27655583,GB-ELI_LILLY_AND_COMPANY-GB202302003557,ELI LILLY AND CO,,76.0,YR,,M,Y,80.0,KG,20230302,,CN,GB,GB,2023,Q1,Elderly
220187461,22018746,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230209.0,20230222,20230222,EXP,,US-RISINGPHARMA-US-2023RISSPO00030,RISING PHARMACEUTICALS,,79.0,YR,E,F,Y,,,20230222,,HP,US,US,2023,Q1,Elderly
220187461,22018746,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Condition aggravated,,2023,Q1,1,I,,20230209.0,20230222,20230222,EXP,,US-RISINGPHARMA-US-2023RISSPO00030,RISING PHARMACEUTICALS,,79.0,YR,E,F,Y,,,20230222,,HP,US,US,2023,Q1,Elderly
220187461,22018746,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230209.0,20230222,20230222,EXP,,US-RISINGPHARMA-US-2023RISSPO00030,RISING PHARMACEUTICALS,,79.0,YR,E,F,Y,,,20230222,,HP,US,US,2023,Q1,Elderly
220187461,22018746,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,1,I,,20230209.0,20230222,20230222,EXP,,US-RISINGPHARMA-US-2023RISSPO00030,RISING PHARMACEUTICALS,,79.0,YR,E,F,Y,,,20230222,,HP,US,US,2023,Q1,Elderly
220198271,22019827,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,,,,,,1.5,MG,,/WK,2023,Q1,Red blood cell count decreased,,2023,Q1,1,I,20230203.0,20230217.0,20230222,20230222,EXP,,GB-MYLANLABS-2023M1013288,MYLAN,,50.0,YR,,M,Y,100.0,KG,20230222,,MD,GB,GB,2023,Q1,Adult
220198271,22019827,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,,,,,,1.5,MG,,/WK,2023,Q1,Full blood count abnormal,,2023,Q1,1,I,20230203.0,20230217.0,20230222,20230222,EXP,,GB-MYLANLABS-2023M1013288,MYLAN,,50.0,YR,,M,Y,100.0,KG,20230222,,MD,GB,GB,2023,Q1,Adult
220198271,22019827,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,,,,,,1.5,MG,,/WK,2023,Q1,Rectal haemorrhage,,2023,Q1,1,I,20230203.0,20230217.0,20230222,20230222,EXP,,GB-MYLANLABS-2023M1013288,MYLAN,,50.0,YR,,M,Y,100.0,KG,20230222,,MD,GB,GB,2023,Q1,Adult
220198271,22019827,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,,,,,,1.5,MG,,/WK,2023,Q1,Haematocrit decreased,,2023,Q1,1,I,20230203.0,20230217.0,20230222,20230222,EXP,,GB-MYLANLABS-2023M1013288,MYLAN,,50.0,YR,,M,Y,100.0,KG,20230222,,MD,GB,GB,2023,Q1,Adult
220237141,22023714,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003742,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230223,,HP,CA,CA,2023,Q1,Adult
220237141,22023714,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003742,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230223,,HP,CA,CA,2023,Q1,Adult
220237141,22023714,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003742,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230223,,HP,CA,CA,2023,Q1,Adult
220237511,22023751,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003751,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230223,,HP,CA,CA,2023,Q1,Adult
220237511,22023751,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003751,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230223,,HP,CA,CA,2023,Q1,Adult
220237511,22023751,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,1,I,,20230215.0,20230223,20230223,EXP,,CA-APOTEX-2023AP003751,APOTEX,,64.0,YR,,M,Y,89.0,KG,20230223,,HP,CA,CA,2023,Q1,Adult
220285884,22028588,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,ML,Injection,,2023,Q1,Troponin increased,,2023,Q1,4,F,20230131.0,20230322.0,20230223,20230327,EXP,,GR-ROCHE-3277676,ROCHE,,78.0,YR,,M,Y,105.0,KG,20230327,,MD,GR,,2023,Q1,Elderly
220285884,22028588,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,ML,Injection,,2023,Q1,Blood creatine phosphokinase increased,,2023,Q1,4,F,20230131.0,20230322.0,20230223,20230327,EXP,,GR-ROCHE-3277676,ROCHE,,78.0,YR,,M,Y,105.0,KG,20230327,,MD,GR,,2023,Q1,Elderly
220310341,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Anaemia,,2023,Q1,1,I,20220209.0,20230215.0,20230223,20230223,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230223,,MD,US,US,2023,Q1,Adult
220310341,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Gastrointestinal haemorrhage,,2023,Q1,1,I,20220209.0,20230215.0,20230223,20230223,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230223,,MD,US,US,2023,Q1,Adult
220310341,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Sepsis,,2023,Q1,1,I,20220209.0,20230215.0,20230223,20230223,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230223,,MD,US,US,2023,Q1,Adult
220310341,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Pneumonia,,2023,Q1,1,I,20220209.0,20230215.0,20230223,20230223,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230223,,MD,US,US,2023,Q1,Adult
220310341,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q1,Septic shock,,2023,Q1,1,I,20220209.0,20230215.0,20230223,20230223,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230223,,MD,US,US,2023,Q1,Adult
220312571,22031257,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Oliguria,,2023,Q1,1,I,,20230209.0,20230223,20230223,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-370949,RANBAXY,"Ian R McGrane. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann Pharmacother. 2022;Dec 22:10600280221143131",79.0,YR,,F,Y,,,20230224,,HP,US,US,2023,Q1,Elderly
220312571,22031257,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230209.0,20230223,20230223,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-370949,RANBAXY,"Ian R McGrane. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann Pharmacother. 2022;Dec 22:10600280221143131",79.0,YR,,F,Y,,,20230224,,HP,US,US,2023,Q1,Elderly
220312571,22031257,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230209.0,20230223,20230223,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-370949,RANBAXY,"Ian R McGrane. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann Pharmacother. 2022;Dec 22:10600280221143131",79.0,YR,,F,Y,,,20230224,,HP,US,US,2023,Q1,Elderly
220312571,22031257,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,1,I,,20230209.0,20230223,20230223,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-370949,RANBAXY,"Ian R McGrane. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann Pharmacother. 2022;Dec 22:10600280221143131",79.0,YR,,F,Y,,,20230224,,HP,US,US,2023,Q1,Elderly
220312571,22031257,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q1,Oedema,,2023,Q1,1,I,,20230209.0,20230223,20230223,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-370949,RANBAXY,"Ian R McGrane. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Ann Pharmacother. 2022;Dec 22:10600280221143131",79.0,YR,,F,Y,,,20230224,,HP,US,US,2023,Q1,Elderly
220327501,22032750,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,1,I,,20230221.0,20230224,20230224,EXP,,CA-AstraZeneca-2023A046216,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
220327501,22032750,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230221.0,20230224,20230224,EXP,,CA-AstraZeneca-2023A046216,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
220327501,22032750,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230221.0,20230224,20230224,EXP,,CA-AstraZeneca-2023A046216,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230224,,MD,CA,,2023,Q1,Adult
220425583,22042558,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q1,Pulmonary oedema,,2023,Q1,3,F,,20230308.0,20230228,20230310,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
220425583,22042558,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q1,Hypotension,,2023,Q1,3,F,,20230308.0,20230228,20230310,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
220425583,22042558,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q1,Metabolic acidosis,,2023,Q1,3,F,,20230308.0,20230228,20230310,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
220425583,22042558,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q1,Headache,,2023,Q1,3,F,,20230308.0,20230228,20230310,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
220425583,22042558,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q1,Hyperglycaemia,,2023,Q1,3,F,,20230308.0,20230228,20230310,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
220425583,22042558,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q1,Dyspnoea,,2023,Q1,3,F,,20230308.0,20230228,20230310,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
220425583,22042558,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q1,C-reactive protein increased,,2023,Q1,3,F,,20230308.0,20230228,20230310,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230310,,HP,CA,CA,2023,Q1,Adult
220479772,22047977,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Colitis,,2023,Q1,2,F,20230116.0,20230227.0,20230301,20230302,EXP,,GB-ABBVIE-4253665,ABBVIE,,75.0,YR,,M,Y,50.0,KG,20230302,,CN,GB,GB,2023,Q1,Elderly
220482702,22048270,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,2,F,,20230306.0,20230301,20230316,EXP,,US-TEVA-2023-US-2859564,TEVA,,79.0,YR,E,F,Y,,,20230316,,PH,US,US,2023,Q1,Elderly
220482702,22048270,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,2,F,,20230306.0,20230301,20230316,EXP,,US-TEVA-2023-US-2859564,TEVA,,79.0,YR,E,F,Y,,,20230316,,PH,US,US,2023,Q1,Elderly
220482702,22048270,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2023,Q1,Off label use,,2023,Q1,2,F,,20230306.0,20230301,20230316,EXP,,US-TEVA-2023-US-2859564,TEVA,,79.0,YR,E,F,Y,,,20230316,,PH,US,US,2023,Q1,Elderly
220482702,22048270,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2023,Q1,Drug interaction,,2023,Q1,2,F,,20230306.0,20230301,20230316,EXP,,US-TEVA-2023-US-2859564,TEVA,,79.0,YR,E,F,Y,,,20230316,,PH,US,US,2023,Q1,Elderly
220482702,22048270,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2023,Q1,Intentional product misuse,,2023,Q1,2,F,,20230306.0,20230301,20230316,EXP,,US-TEVA-2023-US-2859564,TEVA,,79.0,YR,E,F,Y,,,20230316,,PH,US,US,2023,Q1,Elderly
220510031,22051003,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,,2023,Q1,Hypertransaminasaemia,,2023,Q1,1,I,20210801.0,20230218.0,20230301,20230301,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202302010544,ELI LILLY AND CO,"Komala M.G.,Renthawa J..A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist..Clinical Diabetes 2022;40(4):508-510.DOI:https://doi.org/10. 2337/cd21-0142",78.0,YR,,M,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
220510031,22051003,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,,2023,Q1,Tubulointerstitial nephritis,,2023,Q1,1,I,20210801.0,20230218.0,20230301,20230301,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202302010544,ELI LILLY AND CO,"Komala M.G.,Renthawa J..A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist..Clinical Diabetes 2022;40(4):508-510.DOI:https://doi.org/10. 2337/cd21-0142",78.0,YR,,M,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
220510031,22051003,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,20210801.0,20230218.0,20230301,20230301,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202302010544,ELI LILLY AND CO,"Komala M.G.,Renthawa J..A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist..Clinical Diabetes 2022;40(4):508-510.DOI:https://doi.org/10. 2337/cd21-0142",78.0,YR,,M,Y,,,20230301,,HP,AU,AU,2023,Q1,Elderly
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Headache,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Blood testosterone increased,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Arthralgia,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Cold sweat,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Disease complication,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Myalgia,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Clostridium difficile infection,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Fatigue,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,COVID-19,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Gastric ulcer,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220518991,22051899,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNK,,,,,,,2023,Q1,Immune system disorder,,2023,Q1,1,I,20220101.0,20230217.0,20230302,20230302,EXP,,US-ALVOGEN-2022088112,ALVOGEN,,38.0,YR,,F,Y,,,20230302,,CN,US,US,2023,Q1,Adult
220598281,22059828,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, OW",,,,,LYVF89F,,,1.5,MG,Injection,/WK,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,20230208.0,20230223.0,20230303,20230303,EXP,,CN-BAYER-2023A023239,BAYER,,48.0,YR,A,F,Y,70.0,KG,20230303,,HP,CN,CN,2023,Q1,Adult
220598281,22059828,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, OW",,,,,LYVF89F,,,1.5,MG,Injection,/WK,2023,Q1,Abdominal distension,,2023,Q1,1,I,20230208.0,20230223.0,20230303,20230303,EXP,,CN-BAYER-2023A023239,BAYER,,48.0,YR,A,F,Y,70.0,KG,20230303,,HP,CN,CN,2023,Q1,Adult
220615791,22061579,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,Unknown,,,,,,,2023,Q1,Acute kidney injury,,2023,Q1,1,I,,20230221.0,20230304,20230304,EXP,,US-LEADINGPHARMA-US-2023LEALIT00065,LEADING PHARMA,"Rauser MS.A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report.Annals of Pharmacotherapy.JAN-2022; 1-2",79.0,YR,E,F,Y,,,20230304,,HP,US,US,2023,Q1,Elderly
220615791,22061579,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,Unknown,,,,,,,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230221.0,20230304,20230304,EXP,,US-LEADINGPHARMA-US-2023LEALIT00065,LEADING PHARMA,"Rauser MS.A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report.Annals of Pharmacotherapy.JAN-2022; 1-2",79.0,YR,E,F,Y,,,20230304,,HP,US,US,2023,Q1,Elderly
220615791,22061579,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,Unknown,,,,,,,2023,Q1,Cardiac failure congestive,,2023,Q1,1,I,,20230221.0,20230304,20230304,EXP,,US-LEADINGPHARMA-US-2023LEALIT00065,LEADING PHARMA,"Rauser MS.A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report.Annals of Pharmacotherapy.JAN-2022; 1-2",79.0,YR,E,F,Y,,,20230304,,HP,US,US,2023,Q1,Elderly
220671521,22067152,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Skin ulcer,,2023,Q1,1,I,20180201.0,20230228.0,20230307,20230307,EXP,,JP-EMD Serono-9377836,EMD SERONO INC,,74.0,YR,E,M,Y,82.0,KG,20230307,,HP,JP,,2023,Q1,Elderly
220671521,22067152,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,20180201.0,20230228.0,20230307,20230307,EXP,,JP-EMD Serono-9377836,EMD SERONO INC,,74.0,YR,E,M,Y,82.0,KG,20230307,,HP,JP,,2023,Q1,Elderly
220757051,22075705,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 (unit unspecified),,,U,,,,,,,,,2023,Q1,Type 1 diabetes mellitus,,2023,Q1,1,I,,20230226.0,20230308,20230308,EXP,,GR-BAUSCH-BL-2023-003484,BAUSCH AND LOMB,,62.0,YR,,F,Y,62.0,KG,20230308,,HP,GR,GR,2023,Q1,Adult
220757051,22075705,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 (unit unspecified),,,U,,,,,,,,,2023,Q1,Weight decreased,,2023,Q1,1,I,,20230226.0,20230308,20230308,EXP,,GR-BAUSCH-BL-2023-003484,BAUSCH AND LOMB,,62.0,YR,,F,Y,62.0,KG,20230308,,HP,GR,GR,2023,Q1,Adult
220757051,22075705,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 (unit unspecified),,,U,,,,,,,,,2023,Q1,Hypoglycaemia,,2023,Q1,1,I,,20230226.0,20230308,20230308,EXP,,GR-BAUSCH-BL-2023-003484,BAUSCH AND LOMB,,62.0,YR,,F,Y,62.0,KG,20230308,,HP,GR,GR,2023,Q1,Adult
220757051,22075705,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 (unit unspecified),,,U,,,,,,,,,2023,Q1,Diabetes mellitus inadequate control,,2023,Q1,1,I,,20230226.0,20230308,20230308,EXP,,GR-BAUSCH-BL-2023-003484,BAUSCH AND LOMB,,62.0,YR,,F,Y,62.0,KG,20230308,,HP,GR,GR,2023,Q1,Adult
220771521,22077152,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, 1 dose per 1W",,,,,UNK,,,0.75,MG,,/WK,2023,Q1,Drug interaction,,2023,Q1,1,I,,20230226.0,20230309,20230309,EXP,,US-AVET LIFESCIENCES LTD-2023-AVET-000063,EMCURE,"Jessop JP, Russell J, DeJesus A, Bardolia C, Hanna A, Turgeon J, Michaud V, Amin NS.. Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case Report. American Journal of Case Reports. 2023;24:e938850",70.0,YR,,F,Y,,,20230309,,HP,US,US,2023,Q1,Elderly
220771521,22077152,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, 1 dose per 1W",,,,,UNK,,,0.75,MG,,/WK,2023,Q1,Drug ineffective,,2023,Q1,1,I,,20230226.0,20230309,20230309,EXP,,US-AVET LIFESCIENCES LTD-2023-AVET-000063,EMCURE,"Jessop JP, Russell J, DeJesus A, Bardolia C, Hanna A, Turgeon J, Michaud V, Amin NS.. Pharmacogenetic Testing in a 70-Year-Old Woman with Polypharmacy and Multiple Comorbidities: A Case Report. American Journal of Case Reports. 2023;24:e938850",70.0,YR,,F,Y,,,20230309,,HP,US,US,2023,Q1,Elderly
220947812,22094781,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q1,Swelling face,,2023,Q1,2,F,20230225.0,20230303.0,20230314,20230315,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202303003159,ELI LILLY AND CO,,36.0,YR,,F,Y,82.0,KG,20230315,,CN,CN,CN,2023,Q1,Adult
220947812,22094781,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q1,Erythema,,2023,Q1,2,F,20230225.0,20230303.0,20230314,20230315,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202303003159,ELI LILLY AND CO,,36.0,YR,,F,Y,82.0,KG,20230315,,CN,CN,CN,2023,Q1,Adult
220947812,22094781,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q1,Pruritus,,2023,Q1,2,F,20230225.0,20230303.0,20230314,20230315,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202303003159,ELI LILLY AND CO,,36.0,YR,,F,Y,82.0,KG,20230315,,CN,CN,CN,2023,Q1,Adult
221137351,22113735,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,,/WK,2023,Q1,Anti-neutrophil cytoplasmic antibody positive vasculitis,,2023,Q1,1,I,,20230309.0,20230320,20230320,EXP,,AU-SCIEGENP-2023SCLIT00154,SCIEGEN,"Jeyaruban A, et al..Hydralazine induced vasculitis with pulmonary-renal syndrome-A case report.SN Comprehensive Clinical Medicine.2023;5 (1):70",7.0,DEC,,F,Y,,,20230320,,HP,AU,AU,2023,Q1,Child
221484421,22148442,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Angioedema,,2023,Q1,1,I,,20230318.0,20230328,20230328,PER,,US-BAYER-2023A037614,BAYER,,79.0,YR,E,M,Y,,,20230328,,HP,US,US,2023,Q1,Elderly
221484421,22148442,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Anaphylactic reaction,,2023,Q1,1,I,,20230318.0,20230328,20230328,PER,,US-BAYER-2023A037614,BAYER,,79.0,YR,E,M,Y,,,20230328,,HP,US,US,2023,Q1,Elderly
221503971,22150397,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Injection,/WK,2023,Q1,Gastroenteritis,,2023,Q1,1,I,,20230320.0,20230329,20230329,EXP,,JP-EMD Serono-9392272,EMD SERONO INC,,4.0,DEC,A,,Y,88.0,KG,20230329,,HP,JP,,2023,Q1,Child
221503971,22150397,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Injection,/WK,2023,Q1,Euglycaemic diabetic ketoacidosis,,2023,Q1,1,I,,20230320.0,20230329,20230329,EXP,,JP-EMD Serono-9392272,EMD SERONO INC,,4.0,DEC,A,,Y,88.0,KG,20230329,,HP,JP,,2023,Q1,Child
221591071,22159107,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Nausea,,2023,Q1,1,I,20230130.0,20230323.0,20230331,20230331,EXP,,JP-EMD Serono-9392650,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230331,,MD,JP,,2023,Q1,Elderly
221591071,22159107,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Glycosylated haemoglobin increased,,2023,Q1,1,I,20230130.0,20230323.0,20230331,20230331,EXP,,JP-EMD Serono-9392650,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230331,,MD,JP,,2023,Q1,Elderly
221591071,22159107,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Orthopaedic procedure,,2023,Q1,1,I,20230130.0,20230323.0,20230331,20230331,EXP,,JP-EMD Serono-9392650,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230331,,MD,JP,,2023,Q1,Elderly
221611411,22161141,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230321.0,20230331,20230331,EXP,,CA-TEVA-2023-CA-2870955,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230331,,HP,CA,CA,2023,Q1,Adult
221611411,22161141,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,1,I,,20230321.0,20230331,20230331,EXP,,CA-TEVA-2023-CA-2870955,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230331,,HP,CA,CA,2023,Q1,Adult
221611411,22161141,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230321.0,20230331,20230331,EXP,,CA-TEVA-2023-CA-2870955,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230331,,HP,CA,CA,2023,Q1,Adult
221611911,22161191,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Hyperglycaemia,,2023,Q1,1,I,,20230321.0,20230331,20230331,EXP,,CA-TEVA-2023-CA-2870962,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230331,,HP,CA,CA,2023,Q1,Adult
221611911,22161191,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Pulmonary oedema,,2023,Q1,1,I,,20230321.0,20230331,20230331,EXP,,CA-TEVA-2023-CA-2870962,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230331,,HP,CA,CA,2023,Q1,Adult
221611911,22161191,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q1,Metabolic acidosis,,2023,Q1,1,I,,20230321.0,20230331,20230331,EXP,,CA-TEVA-2023-CA-2870962,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230331,,HP,CA,CA,2023,Q1,Adult
172004024,17200402,62,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Hyperparathyroidism secondary,,2023,Q2,4,F,20130529.0,20230427.0,20191226,20230502,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230502,,LW,US,,2023,Q2,Elderly
172004024,17200402,62,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Rebound acid hypersecretion,,2023,Q2,4,F,20130529.0,20230427.0,20191226,20230502,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230502,,LW,US,,2023,Q2,Elderly
172004024,17200402,62,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Nephropathy,,2023,Q2,4,F,20130529.0,20230427.0,20191226,20230502,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230502,,LW,US,,2023,Q2,Elderly
172004024,17200402,62,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Renal failure,,2023,Q2,4,F,20130529.0,20230427.0,20191226,20230502,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230502,,LW,US,,2023,Q2,Elderly
172004024,17200402,62,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Chronic kidney disease,,2023,Q2,4,F,20130529.0,20230427.0,20191226,20230502,EXP,,US-AstraZeneca-2019SE09805,ASTRAZENECA,,21669.0,DY,,F,Y,109.8,KG,20230502,,LW,US,,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Fall,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Gastrointestinal haemorrhage,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Cardiac disorder,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Ocular hyperaemia,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Cough,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Haemarthrosis,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Myocardial infarction,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Haemoglobin decreased,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Weight decreased,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Eye haemorrhage,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Fluid retention,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Dyspnoea,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Melaena,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Coronary artery disease,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Asthenia,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Gait disturbance,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Atrial fibrillation,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Chest wall haematoma,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Pulmonary congestion,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Pulmonary oedema,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,General physical health deterioration,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Hypercalcaemia,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Localised oedema,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Lacrimation increased,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Blood pressure increased,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Oedema peripheral,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Inflammation,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
1856126122,18561261,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Pneumonia,,2023,Q2,22,F,20200510.0,20230524.0,20201130,20230601,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20230601,,HP,DE,DE,2023,Q2,Elderly
191270152,19127015,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2023,Q2,Weight increased,,2023,Q2,2,F,,20230427.0,20210412,20230428,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-034211,BRISTOL MYERS SQUIBB,,69.0,YR,E,F,Y,59.42,KG,20230428,,CN,US,US,2023,Q2,Elderly
191270152,19127015,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2023,Q2,Off label use,,2023,Q2,2,F,,20230427.0,20210412,20230428,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-034211,BRISTOL MYERS SQUIBB,,69.0,YR,E,F,Y,59.42,KG,20230428,,CN,US,US,2023,Q2,Elderly
203540142,20354014,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20211224.0,20230517.0,20220120,20230522,EXP,,DE-ROCHE-2994105,ROCHE,,63.0,YR,,M,Y,,,20230522,,MD,DE,,2023,Q2,Adult
204739767,20473976,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q2,COVID-19,,2023,Q2,7,F,20220120.0,20230525.0,20220215,20230526,EXP,,PT-ROCHE-3025733,ROCHE,,49.0,YR,,F,Y,,,20230526,,MD,PT,,2023,Q2,Adult
204739767,20473976,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q2,Blood immunoglobulin G decreased,,2023,Q2,7,F,20220120.0,20230525.0,20220215,20230526,EXP,,PT-ROCHE-3025733,ROCHE,,49.0,YR,,F,Y,,,20230526,,MD,PT,,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Confusional state,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Drug interaction,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Drug level increased,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Agitation,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Insomnia,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Restlessness,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Nervousness,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Antipsychotic drug level increased,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Tachycardia,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,24,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,U,U,,,,1.5,MG,,/WK,2023,Q2,Extra dose administered,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Confusional state,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Drug interaction,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Drug level increased,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Agitation,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Insomnia,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Restlessness,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Nervousness,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Antipsychotic drug level increased,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Tachycardia,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 milligram, qw (5 milligram/ 7 d",,,U,U,,,,5.0,MG,,/WK,2023,Q2,Extra dose administered,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Confusional state,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Drug interaction,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Drug level increased,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Agitation,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Insomnia,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Restlessness,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Nervousness,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Antipsychotic drug level increased,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Tachycardia,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
2108816613,21088166,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2023,Q2,Extra dose administered,,2023,Q2,13,F,,20230412.0,20220715,20230414,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
212030842,21203084,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2023,Q2,Thrombosis,,2023,Q2,2,F,20220421.0,20230411.0,20220811,20230419,EXP,FR-AFSSAPS-AM20221866,FR-SA-2022SA328392,SANOFI AVENTIS,,75.0,YR,E,F,Y,73.0,KG,20230419,,MD,FR,FR,2023,Q2,Elderly
212030842,21203084,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2023,Q2,Heparin-induced thrombocytopenia,,2023,Q2,2,F,20220421.0,20230411.0,20220811,20230419,EXP,FR-AFSSAPS-AM20221866,FR-SA-2022SA328392,SANOFI AVENTIS,,75.0,YR,E,F,Y,73.0,KG,20230419,,MD,FR,FR,2023,Q2,Elderly
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Nervousness,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Drug level increased,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Confusional state,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Condition aggravated,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Insomnia,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Tachycardia,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Drug interaction,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Restlessness,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Insomnia,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Nervousness,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Tachycardia,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Confusional state,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Drug interaction,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Agitation,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,Unknown,,2023,Q2,Nervousness,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Nervousness,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Drug level increased,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Confusional state,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Condition aggravated,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Insomnia,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Tachycardia,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Drug interaction,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Restlessness,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Insomnia,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Nervousness,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Tachycardia,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Confusional state,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Drug interaction,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Agitation,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121361710,21213617,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Nervousness,,2023,Q2,10,F,,20230410.0,20220816,20230419,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20230419,,MD,ES,ES,2023,Q2,Adult
2121847711,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Cytokine release syndrome,,2023,Q2,11,F,20220729.0,20230512.0,20220816,20230517,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230517,,MD,US,US,2023,Q2,Elderly
2121847711,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Blood lactic acid increased,,2023,Q2,11,F,20220729.0,20230512.0,20220816,20230517,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230517,,MD,US,US,2023,Q2,Elderly
2121847711,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Tachycardia,,2023,Q2,11,F,20220729.0,20230512.0,20220816,20230517,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230517,,MD,US,US,2023,Q2,Elderly
2121847711,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Cardiac failure,,2023,Q2,11,F,20220729.0,20230512.0,20220816,20230517,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230517,,MD,US,US,2023,Q2,Elderly
2121847711,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Stomatitis,,2023,Q2,11,F,20220729.0,20230512.0,20220816,20230517,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230517,,MD,US,US,2023,Q2,Elderly
2121847711,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Pyrexia,,2023,Q2,11,F,20220729.0,20230512.0,20220816,20230517,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230517,,MD,US,US,2023,Q2,Elderly
2121847711,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,11,F,20220729.0,20230512.0,20220816,20230517,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230517,,MD,US,US,2023,Q2,Elderly
2121847711,21218477,40,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Neutropenia,,2023,Q2,11,F,20220729.0,20230512.0,20220816,20230517,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230517,,MD,US,US,2023,Q2,Elderly
212208314,21220831,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Hyperglycaemia,,2023,Q2,4,F,20220310.0,20230510.0,20220817,20230517,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20230517,,MD,CA,,2023,Q2,Adult
212208314,21220831,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,4,F,20220310.0,20230510.0,20220817,20230517,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20230517,,MD,CA,,2023,Q2,Adult
212208314,21220831,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,4,F,20220310.0,20230510.0,20220817,20230517,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20230517,,MD,CA,,2023,Q2,Adult
212208314,21220831,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Pulmonary oedema,,2023,Q2,4,F,20220310.0,20230510.0,20220817,20230517,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20230517,,MD,CA,,2023,Q2,Adult
212346317,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q2,Hyperglycaemia,,2023,Q2,7,F,,20230417.0,20220820,20230427,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230427,,HP,CA,CA,2023,Q2,Adult
212346317,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,7,F,,20230417.0,20220820,20230427,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230427,,HP,CA,CA,2023,Q2,Adult
212346317,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q2,Pulmonary oedema,,2023,Q2,7,F,,20230417.0,20220820,20230427,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230427,,HP,CA,CA,2023,Q2,Adult
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Product dose omission issue,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Body temperature decreased,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Onychalgia,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Blood glucose increased,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Scab,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Dyspnoea,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Blood potassium decreased,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Balance disorder,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Arthritis,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Nasopharyngitis,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Visual impairment,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Cough,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Skin discolouration,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Seasonal allergy,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Back pain,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Pulmonary oedema,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Pain in extremity,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Oropharyngeal discomfort,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Depressed mood,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
212521117,21252111,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q2,Pneumonia,,2023,Q2,7,F,20230201.0,20230614.0,20220825,20230622,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20230622,,HP,US,US,2023,Q2,Elderly
2134907021,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q2,Rhegmatogenous retinal detachment,,2023,Q2,21,F,20220912.0,20230331.0,20220919,20230405,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20230405,,MD,US,,2023,Q2,Adult
2134907021,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q2,Vitreous haemorrhage,,2023,Q2,21,F,20220912.0,20230331.0,20220919,20230405,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20230405,,MD,US,,2023,Q2,Adult
2134907021,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q2,Cataract,,2023,Q2,21,F,20220912.0,20230331.0,20220919,20230405,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20230405,,MD,US,,2023,Q2,Adult
214369326,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Stomatitis,,2023,Q2,6,F,20220729.0,20230512.0,20221010,20230518,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20230518,,MD,US,US,2023,Q2,Elderly
214369326,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Neutropenia,,2023,Q2,6,F,20220729.0,20230512.0,20221010,20230518,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20230518,,MD,US,US,2023,Q2,Elderly
214369326,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Diarrhoea,,2023,Q2,6,F,20220729.0,20230512.0,20221010,20230518,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20230518,,MD,US,US,2023,Q2,Elderly
214369326,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Cytokine release syndrome,,2023,Q2,6,F,20220729.0,20230512.0,20221010,20230518,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20230518,,MD,US,US,2023,Q2,Elderly
215517872,21551787,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Disease progression,,2023,Q2,2,F,20220705.0,20230411.0,20221104,20230414,EXP,,IL-ABBVIE-4186828,ABBVIE,,78.0,YR,,M,Y,98.0,KG,20230414,,MD,IL,IL,2023,Q2,Elderly
215517872,21551787,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Disease recurrence,,2023,Q2,2,F,20220705.0,20230411.0,20221104,20230414,EXP,,IL-ABBVIE-4186828,ABBVIE,,78.0,YR,,M,Y,98.0,KG,20230414,,MD,IL,IL,2023,Q2,Elderly
216179224,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Off label use,,2023,Q2,4,F,20210901.0,20230119.0,20221119,20230531,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230531,,MD,JP,JP,2023,Q2,Elderly
216179224,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Renal impairment,,2023,Q2,4,F,20210901.0,20230119.0,20221119,20230531,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230531,,MD,JP,JP,2023,Q2,Elderly
216179224,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Blood glucose abnormal,,2023,Q2,4,F,20210901.0,20230119.0,20221119,20230531,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230531,,MD,JP,JP,2023,Q2,Elderly
216179224,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q2,Vascular stenosis,,2023,Q2,4,F,20210901.0,20230119.0,20221119,20230531,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20230531,,MD,JP,JP,2023,Q2,Elderly
216250562,21625056,4,C,Dulaglutide (genetical recombination),,2,Unknown,0.75 mg/week,,,,,,,,,,,,2023,Q2,Chronic kidney disease,,2023,Q2,2,F,20211216.0,20230608.0,20221122,20230612,EXP,,JP-ABBVIE-4205624,ABBVIE,,60.0,YR,,M,Y,64.0,KG,20230612,,MD,JP,JP,2023,Q2,Adult
216256774,21625677,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q2,Insomnia,,2023,Q2,4,F,,20230406.0,20221122,20230414,EXP,,ES-AUROBINDO-AUR-APL-2022-048450,AUROBINDO,"Barris Blundell,D.; Carrasco Naranjo,O. Servicio de dispensaci?n: interacci?n entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. Farmac?uticos Comunitarios. 2022;14 (4):38-41",52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
216256774,21625677,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q2,Antipsychotic drug level increased,,2023,Q2,4,F,,20230406.0,20221122,20230414,EXP,,ES-AUROBINDO-AUR-APL-2022-048450,AUROBINDO,"Barris Blundell,D.; Carrasco Naranjo,O. Servicio de dispensaci?n: interacci?n entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. Farmac?uticos Comunitarios. 2022;14 (4):38-41",52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
216256774,21625677,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q2,Confusional state,,2023,Q2,4,F,,20230406.0,20221122,20230414,EXP,,ES-AUROBINDO-AUR-APL-2022-048450,AUROBINDO,"Barris Blundell,D.; Carrasco Naranjo,O. Servicio de dispensaci?n: interacci?n entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. Farmac?uticos Comunitarios. 2022;14 (4):38-41",52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
216256774,21625677,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q2,Agitation,,2023,Q2,4,F,,20230406.0,20221122,20230414,EXP,,ES-AUROBINDO-AUR-APL-2022-048450,AUROBINDO,"Barris Blundell,D.; Carrasco Naranjo,O. Servicio de dispensaci?n: interacci?n entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. Farmac?uticos Comunitarios. 2022;14 (4):38-41",52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
216256774,21625677,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q2,Restlessness,,2023,Q2,4,F,,20230406.0,20221122,20230414,EXP,,ES-AUROBINDO-AUR-APL-2022-048450,AUROBINDO,"Barris Blundell,D.; Carrasco Naranjo,O. Servicio de dispensaci?n: interacci?n entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. Farmac?uticos Comunitarios. 2022;14 (4):38-41",52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
216256774,21625677,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q2,Drug interaction,,2023,Q2,4,F,,20230406.0,20221122,20230414,EXP,,ES-AUROBINDO-AUR-APL-2022-048450,AUROBINDO,"Barris Blundell,D.; Carrasco Naranjo,O. Servicio de dispensaci?n: interacci?n entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. Farmac?uticos Comunitarios. 2022;14 (4):38-41",52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
216256774,21625677,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q2,Tachycardia,,2023,Q2,4,F,,20230406.0,20221122,20230414,EXP,,ES-AUROBINDO-AUR-APL-2022-048450,AUROBINDO,"Barris Blundell,D.; Carrasco Naranjo,O. Servicio de dispensaci?n: interacci?n entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. Farmac?uticos Comunitarios. 2022;14 (4):38-41",52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
216256774,21625677,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q2,Nervousness,,2023,Q2,4,F,,20230406.0,20221122,20230414,EXP,,ES-AUROBINDO-AUR-APL-2022-048450,AUROBINDO,"Barris Blundell,D.; Carrasco Naranjo,O. Servicio de dispensaci?n: interacci?n entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. Farmac?uticos Comunitarios. 2022;14 (4):38-41",52.0,YR,,M,Y,,,20230414,,PH,ES,ES,2023,Q2,Adult
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Abdominal distension,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Cardiac failure congestive,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Contraindicated product administered,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Malaise,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Drug interaction,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Oedema peripheral,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Bradycardia,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Chronic kidney disease,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217229273,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Urine output decreased,,2023,Q2,3,F,,20230531.0,20221213,20230605,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230605,,PH,US,US,2023,Q2,Elderly
217643732,21764373,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Jaundice,,2023,Q2,2,F,,20230524.0,20221222,20230608,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-369650,RANBAXY,,67.0,YR,,M,Y,75.0,KG,20230608,,MD,IT,IT,2023,Q2,Elderly
219218922,21921892,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, qw",,,U,,,,,,,,/WK,2023,Q2,Hypoglycaemia,,2023,Q2,2,F,20181017.0,20230404.0,20230127,20230411,EXP,,DE-009507513-2301DEU008209,MERCK,,23.0,YR,,M,Y,117.0,KG,20230411,,MD,DE,DE,2023,Q2,Youth
219218922,21921892,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, qw",,,U,,,,,,,,/WK,2023,Q2,Lactic acidosis,,2023,Q2,2,F,20181017.0,20230404.0,20230127,20230411,EXP,,DE-009507513-2301DEU008209,MERCK,,23.0,YR,,M,Y,117.0,KG,20230411,,MD,DE,DE,2023,Q2,Youth
219218922,21921892,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, qw",,,U,,,,,,,,/WK,2023,Q2,Metabolic acidosis,,2023,Q2,2,F,20181017.0,20230404.0,20230127,20230411,EXP,,DE-009507513-2301DEU008209,MERCK,,23.0,YR,,M,Y,117.0,KG,20230411,,MD,DE,DE,2023,Q2,Youth
219218922,21921892,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, qw",,,U,,,,,,,,/WK,2023,Q2,Ketoacidosis,,2023,Q2,2,F,20181017.0,20230404.0,20230127,20230411,EXP,,DE-009507513-2301DEU008209,MERCK,,23.0,YR,,M,Y,117.0,KG,20230411,,MD,DE,DE,2023,Q2,Youth
219318972,21931897,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,2,F,20221102.0,20230418.0,20230131,20230427,EXP,FR-AFSSAPS-RE2023000050,FR-Accord-298551,ACCORD,,81.0,YR,E,M,Y,108.0,KG,20230427,,PH,FR,FR,2023,Q2,Elderly
220285885,22028588,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,ML,Injection,,2023,Q2,Troponin increased,,2023,Q2,5,F,20230131.0,20230620.0,20230223,20230623,EXP,,GR-ROCHE-3277676,ROCHE,,78.0,YR,,M,Y,105.0,KG,20230623,,MD,GR,,2023,Q2,Elderly
220285885,22028588,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,ML,Injection,,2023,Q2,Blood creatine phosphokinase increased,,2023,Q2,5,F,20230131.0,20230620.0,20230223,20230623,EXP,,GR-ROCHE-3277676,ROCHE,,78.0,YR,,M,Y,105.0,KG,20230623,,MD,GR,,2023,Q2,Elderly
220310342,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Pneumonia,,2023,Q2,2,F,20220209.0,20230522.0,20230223,20230524,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230524,,MD,US,US,2023,Q2,Adult
220310342,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Anaemia,,2023,Q2,2,F,20220209.0,20230522.0,20230223,20230524,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230524,,MD,US,US,2023,Q2,Adult
220310342,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Septic shock,,2023,Q2,2,F,20220209.0,20230522.0,20230223,20230524,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230524,,MD,US,US,2023,Q2,Adult
220310342,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Gastrointestinal haemorrhage,,2023,Q2,2,F,20220209.0,20230522.0,20230223,20230524,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230524,,MD,US,US,2023,Q2,Adult
220310342,22031034,36,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q2,Sepsis,,2023,Q2,2,F,20220209.0,20230522.0,20230223,20230524,EXP,,US-GILEAD-2022-0569611,GILEAD,,64.0,YR,A,M,Y,78.2,KG,20230524,,MD,US,US,2023,Q2,Adult
220425585,22042558,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Dyspnoea,,2023,Q2,5,F,,20230613.0,20230228,20230615,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230615,,HP,CA,CA,2023,Q2,Adult
220425585,22042558,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Metabolic acidosis,,2023,Q2,5,F,,20230613.0,20230228,20230615,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230615,,HP,CA,CA,2023,Q2,Adult
220425585,22042558,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,C-reactive protein increased,,2023,Q2,5,F,,20230613.0,20230228,20230615,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230615,,HP,CA,CA,2023,Q2,Adult
220425585,22042558,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Hyperglycaemia,,2023,Q2,5,F,,20230613.0,20230228,20230615,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230615,,HP,CA,CA,2023,Q2,Adult
220425585,22042558,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Pulmonary oedema,,2023,Q2,5,F,,20230613.0,20230228,20230615,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230615,,HP,CA,CA,2023,Q2,Adult
220425585,22042558,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Headache,,2023,Q2,5,F,,20230613.0,20230228,20230615,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230615,,HP,CA,CA,2023,Q2,Adult
220425585,22042558,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Hypotension,,2023,Q2,5,F,,20230613.0,20230228,20230615,EXP,,NVSC2023CA042656,NOVARTIS,,64.0,YR,,M,Y,89.0,KG,20230615,,HP,CA,CA,2023,Q2,Adult
221431302,22143130,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,,2023,Q2,Cushing's syndrome,,2023,Q2,2,F,,20230406.0,20230327,20230407,EXP,,JP-ABBVIE-4701815,ABBVIE,"T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.; T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.",65.0,YR,,F,Y,,,20230407,,MD,JP,JP,2023,Q2,Elderly
221431302,22143130,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,,2023,Q2,Drug ineffective,,2023,Q2,2,F,,20230406.0,20230327,20230407,EXP,,JP-ABBVIE-4701815,ABBVIE,"T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.; T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.",65.0,YR,,F,Y,,,20230407,,MD,JP,JP,2023,Q2,Elderly
221431302,22143130,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,,2023,Q2,Benign neoplasm of adrenal gland,,2023,Q2,2,F,,20230406.0,20230327,20230407,EXP,,JP-ABBVIE-4701815,ABBVIE,"T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.; T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.",65.0,YR,,F,Y,,,20230407,,MD,JP,JP,2023,Q2,Elderly
221496062,22149606,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2023,Q2,Blood glucose increased,,2023,Q2,2,F,20221001.0,20230403.0,20230329,20230414,EXP,,CN-NOVOPROD-1036817,NOVO NORDISK,,60.0,YR,,M,Y,75.0,KG,20230414,,CN,CN,CN,2023,Q2,Adult
221496062,22149606,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2023,Q2,COVID-19,,2023,Q2,2,F,20221001.0,20230403.0,20230329,20230414,EXP,,CN-NOVOPROD-1036817,NOVO NORDISK,,60.0,YR,,M,Y,75.0,KG,20230414,,CN,CN,CN,2023,Q2,Adult
221496062,22149606,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2023,Q2,Pneumonia,,2023,Q2,2,F,20221001.0,20230403.0,20230329,20230414,EXP,,CN-NOVOPROD-1036817,NOVO NORDISK,,60.0,YR,,M,Y,75.0,KG,20230414,,CN,CN,CN,2023,Q2,Adult
221525113,22152511,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg, OW",,,U,,,,,15.0,MG,,/WK,2023,Q2,Melaena,,2023,Q2,3,F,,20230327.0,20230329,20230403,EXP,,NVSC2023HR070486,NOVARTIS,"Simicevic L, Sliskovic AM, Kirhmajer MV, Ganoci L, Holik H, Palic J et al.. Risk factors for rivaroxaban-related bleeding events-possible role of pharmacogenetics: Case series. PHARMACY (BASEL). 2023;11(1):29",75.0,YR,,F,Y,,,20230403,,HP,HR,HR,2023,Q2,Elderly
221525113,22152511,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg, OW",,,U,,,,,15.0,MG,,/WK,2023,Q2,Epistaxis,,2023,Q2,3,F,,20230327.0,20230329,20230403,EXP,,NVSC2023HR070486,NOVARTIS,"Simicevic L, Sliskovic AM, Kirhmajer MV, Ganoci L, Holik H, Palic J et al.. Risk factors for rivaroxaban-related bleeding events-possible role of pharmacogenetics: Case series. PHARMACY (BASEL). 2023;11(1):29",75.0,YR,,F,Y,,,20230403,,HP,HR,HR,2023,Q2,Elderly
221525113,22152511,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg, OW",,,U,,,,,15.0,MG,,/WK,2023,Q2,Drug interaction,,2023,Q2,3,F,,20230327.0,20230329,20230403,EXP,,NVSC2023HR070486,NOVARTIS,"Simicevic L, Sliskovic AM, Kirhmajer MV, Ganoci L, Holik H, Palic J et al.. Risk factors for rivaroxaban-related bleeding events-possible role of pharmacogenetics: Case series. PHARMACY (BASEL). 2023;11(1):29",75.0,YR,,F,Y,,,20230403,,HP,HR,HR,2023,Q2,Elderly
221699922,22169992,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Metabolic acidosis,,2023,Q2,2,F,,20230326.0,20230404,20230404,EXP,GB-MHRA-MIDB-5ba6fa56-fb0c-4c94-8f1e-4b776a7d0792,GB-JNJFOC-20230365899,JOHNSON AND JOHNSON,,67.0,YR,E,,Y,,,20230404,,PH,GB,GB,2023,Q2,Elderly
221699922,22169992,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2023,Q2,Accidental overdose,,2023,Q2,2,F,,20230326.0,20230404,20230404,EXP,GB-MHRA-MIDB-5ba6fa56-fb0c-4c94-8f1e-4b776a7d0792,GB-JNJFOC-20230365899,JOHNSON AND JOHNSON,,67.0,YR,E,,Y,,,20230404,,PH,GB,GB,2023,Q2,Elderly
221795901,22179590,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Accidental overdose,,2023,Q2,1,I,,20230326.0,20230406,20230406,EXP,,GB-AUROBINDO-AUR-APL-2023-014395,AUROBINDO,,67.0,YR,,,Y,,,20230406,,PH,GB,GB,2023,Q2,Elderly
221934161,22193416,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,use as directed,,,,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,,20230405.0,20230410,20230410,EXP,GB-MHRA-TPP30979117C7738063YC1679912542015,GB-MYLANLABS-2023M1036913,MYLAN,,58.0,YR,,F,Y,72.0,KG,20230410,,MD,GB,GB,2023,Q2,Adult
221934161,22193416,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,use as directed,,,,,,,,,,,,2023,Q2,Pruritus,,2023,Q2,1,I,,20230405.0,20230410,20230410,EXP,GB-MHRA-TPP30979117C7738063YC1679912542015,GB-MYLANLABS-2023M1036913,MYLAN,,58.0,YR,,F,Y,72.0,KG,20230410,,MD,GB,GB,2023,Q2,Adult
221987851,22198785,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Vitreous haemorrhage,,2023,Q2,1,I,,20230402.0,20230411,20230411,EXP,,US-ELI_LILLY_AND_COMPANY-US202304002737,ELI LILLY AND CO,"Kim D.S.,Latollari A.,Khaimova R..Vitreous hemorrhage during GLP-1 receptor agonist treatment..Journal of the American Pharmacists Association : JAPhA. 2023;:.DOI:doi.org/10.1016/j.japh.2023.02.018",64.0,YR,,M,Y,,,20230411,,HP,US,US,2023,Q2,Adult
221987851,22198785,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, weekly (1/W)",,,Y,,,,125469.0,3.0,MG,,/WK,2023,Q2,Vitreous haemorrhage,,2023,Q2,1,I,,20230402.0,20230411,20230411,EXP,,US-ELI_LILLY_AND_COMPANY-US202304002737,ELI LILLY AND CO,"Kim D.S.,Latollari A.,Khaimova R..Vitreous hemorrhage during GLP-1 receptor agonist treatment..Journal of the American Pharmacists Association : JAPhA. 2023;:.DOI:doi.org/10.1016/j.japh.2023.02.018",64.0,YR,,M,Y,,,20230411,,HP,US,US,2023,Q2,Adult
221987851,22198785,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, weekly (1/W)",,,Y,,,,125469.0,4.5,MG,,/WK,2023,Q2,Vitreous haemorrhage,,2023,Q2,1,I,,20230402.0,20230411,20230411,EXP,,US-ELI_LILLY_AND_COMPANY-US202304002737,ELI LILLY AND CO,"Kim D.S.,Latollari A.,Khaimova R..Vitreous hemorrhage during GLP-1 receptor agonist treatment..Journal of the American Pharmacists Association : JAPhA. 2023;:.DOI:doi.org/10.1016/j.japh.2023.02.018",64.0,YR,,M,Y,,,20230411,,HP,US,US,2023,Q2,Adult
222016032,22201603,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,U,,,,,,,Solution for injection,,2023,Q2,Illness,,2023,Q2,2,F,20230301.0,20230516.0,20230412,20230531,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-051307,BRISTOL MYERS SQUIBB,,71.0,YR,E,F,Y,,,20230531,,CN,US,US,2023,Q2,Elderly
222050092,22205009,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,Unknown,,,,,,,2023,Q2,Pigmentation disorder,,2023,Q2,2,F,,20230517.0,20230413,20230529,EXP,,EG-NOVOPROD-1047257,NOVO NORDISK,,70.0,YR,,F,Y,,,20230529,,MD,EG,EG,2023,Q2,Elderly
222050092,22205009,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,Unknown,,,,,,,2023,Q2,Pancreatic carcinoma,,2023,Q2,2,F,,20230517.0,20230413,20230529,EXP,,EG-NOVOPROD-1047257,NOVO NORDISK,,70.0,YR,,F,Y,,,20230529,,MD,EG,EG,2023,Q2,Elderly
222058921,22205892,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg,,,,,,,,1.5,MG,,,2023,Q2,Loss of consciousness,,2023,Q2,1,I,,20220425.0,20230413,20230413,EXP,,HR-JNJFOC-20220458786,JOHNSON AND JOHNSON,,72.0,YR,E,,Y,,,20230413,,MD,HR,HR,2023,Q2,Elderly
222058921,22205892,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg,,,,,,,,1.5,MG,,,2023,Q2,Atrial fibrillation,,2023,Q2,1,I,,20220425.0,20230413,20230413,EXP,,HR-JNJFOC-20220458786,JOHNSON AND JOHNSON,,72.0,YR,E,,Y,,,20230413,,MD,HR,HR,2023,Q2,Elderly
222148771,22214877,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, As Directed",,,U,,,,,,,,,2023,Q2,Pruritus,,2023,Q2,1,I,,20230405.0,20230415,20230415,EXP,,GB-AUROBINDO-AUR-APL-2023-029605,AUROBINDO,,58.0,YR,,F,Y,72.0,KG,20230415,,MD,GB,GB,2023,Q2,Adult
222148771,22214877,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, As Directed",,,U,,,,,,,,,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,,20230405.0,20230415,20230415,EXP,,GB-AUROBINDO-AUR-APL-2023-029605,AUROBINDO,,58.0,YR,,F,Y,72.0,KG,20230415,,MD,GB,GB,2023,Q2,Adult
222235351,22223535,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",4.5,MG,Y,,LYVI36C,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q2,Abdominal discomfort,,2023,Q2,1,I,20230323.0,20230411.0,20230418,20230418,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304005529,ELI LILLY AND CO,,72.0,YR,,M,Y,88.0,KG,20230418,,CN,CN,CN,2023,Q2,Elderly
222235351,22223535,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",4.5,MG,Y,,LYVI36C,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230323.0,20230411.0,20230418,20230418,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304005529,ELI LILLY AND CO,,72.0,YR,,M,Y,88.0,KG,20230418,,CN,CN,CN,2023,Q2,Elderly
222235351,22223535,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",4.5,MG,Y,,LYVI36C,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q2,Dehydration,,2023,Q2,1,I,20230323.0,20230411.0,20230418,20230418,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304005529,ELI LILLY AND CO,,72.0,YR,,M,Y,88.0,KG,20230418,,CN,CN,CN,2023,Q2,Elderly
222235351,22223535,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",4.5,MG,Y,,LYVI36C,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q2,Abdominal distension,,2023,Q2,1,I,20230323.0,20230411.0,20230418,20230418,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304005529,ELI LILLY AND CO,,72.0,YR,,M,Y,88.0,KG,20230418,,CN,CN,CN,2023,Q2,Elderly
222235351,22223535,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",4.5,MG,Y,,LYVI36C,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q2,Abdominal pain,,2023,Q2,1,I,20230323.0,20230411.0,20230418,20230418,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304005529,ELI LILLY AND CO,,72.0,YR,,M,Y,88.0,KG,20230418,,CN,CN,CN,2023,Q2,Elderly
222259081,22225908,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,3mg/0.5ml soln: WEEKLY on SUNDAYS,,,,,,,,,,Solution,,2023,Q2,Accidental overdose,,2023,Q2,1,I,,20230406.0,20230419,20230419,EXP,GB-MHRA-MIDB-5ba6fa56-fb0c-4c94-8f1e-4b776a7d0792,GB-STRIDES ARCOLAB LIMITED-2023SP005295,STRIDES,,67.0,YR,,,Y,,,20230419,,PH,GB,GB,2023,Q2,Elderly
222302151,22230215,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Medication error,,2023,Q2,1,I,20230415.0,20230418.0,20230419,20230419,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-232451",BOEHRINGER INGELHEIM,,41.0,YR,A,F,Y,,,20230419,,PH,GB,GB,2023,Q2,Adult
222302151,22230215,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,20230415.0,20230418.0,20230419,20230419,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-232451",BOEHRINGER INGELHEIM,,41.0,YR,A,F,Y,,,20230419,,PH,GB,GB,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Dizziness,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Peripheral coldness,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Asthenia,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Dry mouth,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Infection,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Vulvovaginal pruritus,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Hepatic function abnormal,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Haematemesis,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222400531,22240053,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,,,125469.0,1.5,MG,,/WK,2023,Q2,Haematochezia,,2023,Q2,1,I,20210309.0,20230409.0,20230421,20230421,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202304004197,ELI LILLY AND CO,,41.0,YR,,F,Y,,,20230421,,MD,CN,CN,2023,Q2,Adult
222531131,22253113,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Hypotension,,2023,Q2,1,I,,20230414.0,20230426,20230426,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230426,,HP,CA,CA,2023,Q2,Adult
222531131,22253113,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,,20230414.0,20230426,20230426,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230426,,HP,CA,CA,2023,Q2,Adult
222531131,22253113,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Pulmonary oedema,,2023,Q2,1,I,,20230414.0,20230426,20230426,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230426,,HP,CA,CA,2023,Q2,Adult
222531131,22253113,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Dyspnoea,,2023,Q2,1,I,,20230414.0,20230426,20230426,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230426,,HP,CA,CA,2023,Q2,Adult
222531131,22253113,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,C-reactive protein increased,,2023,Q2,1,I,,20230414.0,20230426,20230426,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230426,,HP,CA,CA,2023,Q2,Adult
222531131,22253113,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Headache,,2023,Q2,1,I,,20230414.0,20230426,20230426,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230426,,HP,CA,CA,2023,Q2,Adult
222531131,22253113,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q2,Hyperglycaemia,,2023,Q2,1,I,,20230414.0,20230426,20230426,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20230426,,HP,CA,CA,2023,Q2,Adult
222540811,22254081,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"strength:1.5 mg, solution for injection in pre-filled pen, 4 pre-filled pens",,,Y,,,,,1.5,MG,,,2023,Q2,Tubulointerstitial nephritis,,2023,Q2,1,I,20221105.0,20230415.0,20230426,20230426,EXP,ES-AEMPS-1350585,ES-Accord-355479,ACCORD,,56.0,YR,A,F,Y,,,20230426,,MD,ES,ES,2023,Q2,Adult
222540811,22254081,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"strength:1.5 mg, solution for injection in pre-filled pen, 4 pre-filled pens",,,Y,,,,,1.5,MG,,,2023,Q2,Anticoagulation drug level above therapeutic,,2023,Q2,1,I,20221105.0,20230415.0,20230426,20230426,EXP,ES-AEMPS-1350585,ES-Accord-355479,ACCORD,,56.0,YR,A,F,Y,,,20230426,,MD,ES,ES,2023,Q2,Adult
222540811,22254081,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"strength:1.5 mg, solution for injection in pre-filled pen, 4 pre-filled pens",,,Y,,,,,1.5,MG,,,2023,Q2,Drug interaction,,2023,Q2,1,I,20221105.0,20230415.0,20230426,20230426,EXP,ES-AEMPS-1350585,ES-Accord-355479,ACCORD,,56.0,YR,A,F,Y,,,20230426,,MD,ES,ES,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Vulvovaginal pruritus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Haematochezia,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Type 2 diabetes mellitus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Hypothyroidism,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Haematemesis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Lipids abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Infection,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Hepatic function abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,1.5,MG,Injection,/WK,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Vulvovaginal pruritus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Haematochezia,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Diabetic ketoacidosis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Decreased appetite,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Type 2 diabetes mellitus,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Hypothyroidism,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Haematemesis,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Lipids abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Infection,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Hepatic function abnormal,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222565641,22256564,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,Y,U,Unknown,,,,,Injection,,2023,Q2,Gastrooesophageal reflux disease,,2023,Q2,1,I,20210228.0,20230419.0,20230426,20230426,EXP,,"CN-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-231398",BOEHRINGER INGELHEIM,"Junling C, Xue Z, Yanli Z, Fan L, Xiao Z. Diabetic ketoacidosis induced by combination use of dulaglutide and empagliflozin. Adverse Drug Reactions Journal. 2022 Mar;24(3): 147-149. doi:10.3760/cma.j.cn114015-20210401-00399.",41.0,YR,A,F,Y,,,20230426,,HP,CN,CN,2023,Q2,Adult
222686851,22268685,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Acute kidney injury,,2023,Q2,1,I,20230217.0,20230419.0,20230501,20230501,EXP,SE-SEMPA-2023-010453,SE-Accord-355626,ACCORD,,79.0,YR,E,F,Y,,,20230429,,MD,SE,SE,2023,Q2,Elderly
222935741,22293574,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, qw",,,,U,,,,0.75,MG,,/WK,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,JP-MYLANLABS-2023M1047534,MYLAN,"Noda K, Kato T, Nomura N, Sakai M, Kubota S, Hirose T, et al. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabet-Int 2022;13(4):693-697.. 2022;13(4):693-697",50.0,YR,,F,Y,,,20230508,,HP,JP,JP,2023,Q2,Adult
222950871,22295087,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q2,Pulmonary oedema,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883459,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222950871,22295087,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q2,Hyperglycaemia,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883459,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222950871,22295087,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883459,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Hyperglycaemia,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Dyspnoea,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,C-reactive protein increased,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Pulmonary oedema,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Hyperglycaemia,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Headache,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Dyspnoea,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,C-reactive protein increased,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Hypotension,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Pulmonary oedema,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
222961521,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q2,Metabolic acidosis,,2023,Q2,1,I,,20230428.0,20230508,20230508,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,89.0,KG,20230508,,HP,CA,CA,2023,Q2,Adult
223043042,22304304,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown",,,,,,,,0.75,MG,,,2023,Q2,Transient ischaemic attack,,2023,Q2,2,F,20220305.0,20230525.0,20230510,20230601,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202304014994,ELI LILLY AND CO,,73.0,YR,,F,Y,88.5,KG,20230601,,HP,GB,GB,2023,Q2,Elderly
223047211,22304721,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",3.0,MG,Y,,,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q2,Ketoacidosis,,2023,Q2,1,I,20230313.0,20230506.0,20230510,20230510,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305003978,ELI LILLY AND CO,,29.0,YR,,F,Y,81.2,KG,20230510,,CN,CN,CN,2023,Q2,Young Adult
223047211,22304721,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",3.0,MG,Y,,,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q2,Nausea,,2023,Q2,1,I,20230313.0,20230506.0,20230510,20230510,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305003978,ELI LILLY AND CO,,29.0,YR,,F,Y,81.2,KG,20230510,,CN,CN,CN,2023,Q2,Young Adult
223047211,22304721,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",3.0,MG,Y,,,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2023,Q2,Vomiting,,2023,Q2,1,I,20230313.0,20230506.0,20230510,20230510,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305003978,ELI LILLY AND CO,,29.0,YR,,F,Y,81.2,KG,20230510,,CN,CN,CN,2023,Q2,Young Adult
223054501,22305450,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,/WK,2023,Q2,Thyroiditis,,2023,Q2,1,I,20220501.0,20230504.0,20230510,20230510,EXP,FR-AFSSAPS-CN2023000405,FR-EMD Serono-E2B_90091666,EMD SERONO INC,,69.0,YR,E,M,Y,91.0,KG,20230510,,MD,FR,FR,2023,Q2,Elderly
223054501,22305450,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,/WK,2023,Q2,Polyarthritis,,2023,Q2,1,I,20220501.0,20230504.0,20230510,20230510,EXP,FR-AFSSAPS-CN2023000405,FR-EMD Serono-E2B_90091666,EMD SERONO INC,,69.0,YR,E,M,Y,91.0,KG,20230510,,MD,FR,FR,2023,Q2,Elderly
223068821,22306882,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,Unknown,,2023,Q2,Death,,2023,Q2,1,I,20230508.0,20230509.0,20230511,20230511,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-066567,BRISTOL MYERS SQUIBB,,76.0,YR,E,M,Y,,,20230511,,HP,US,US,2023,Q2,Elderly
223185092,22318509,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Cholestasis,,2023,Q2,2,F,20230412.0,20230615.0,20230515,20230626,EXP,FR-AFSSAPS-AM2023000416,FR-Axellia-004733,XELLIA PHARMACEUTICALS,,71.0,YR,E,M,Y,83.0,KG,20230624,,PH,FR,FR,2023,Q2,Elderly
223185092,22318509,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Hepatic cytolysis,,2023,Q2,2,F,20230412.0,20230615.0,20230515,20230626,EXP,FR-AFSSAPS-AM2023000416,FR-Axellia-004733,XELLIA PHARMACEUTICALS,,71.0,YR,E,M,Y,83.0,KG,20230624,,PH,FR,FR,2023,Q2,Elderly
223237861,22323786,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Inadequate analgesia,,2023,Q2,1,I,20230414.0,,20230512,20230512,DIR,660043,,FDA-CTU,,76.0,YR,,F,N,103.5,KG,20230512,N,CN,US,,2023,Q2,Elderly
223237861,22323786,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Emotional distress,,2023,Q2,1,I,20230414.0,,20230512,20230512,DIR,660043,,FDA-CTU,,76.0,YR,,F,N,103.5,KG,20230512,N,CN,US,,2023,Q2,Elderly
223237861,22323786,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Incorrect dose administered,,2023,Q2,1,I,20230414.0,,20230512,20230512,DIR,660043,,FDA-CTU,,76.0,YR,,F,N,103.5,KG,20230512,N,CN,US,,2023,Q2,Elderly
223237861,22323786,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Product dispensing error,,2023,Q2,1,I,20230414.0,,20230512,20230512,DIR,660043,,FDA-CTU,,76.0,YR,,F,N,103.5,KG,20230512,N,CN,US,,2023,Q2,Elderly
223237861,22323786,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q2,Malaise,,2023,Q2,1,I,20230414.0,,20230512,20230512,DIR,660043,,FDA-CTU,,76.0,YR,,F,N,103.5,KG,20230512,N,CN,US,,2023,Q2,Elderly
223249072,22324907,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75mg once a week,,,D,,,,,0.75,MG,,/WK,2023,Q2,Drug ineffective,,2023,Q2,2,F,,20230519.0,20230516,20230529,EXP,,JP-TEVA-2023-JP-2887948,TEVA,,50.0,YR,A,F,Y,,,20230529,,HP,JP,JP,2023,Q2,Adult
223249072,22324907,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75mg once a week,,,D,,,,,0.75,MG,,/WK,2023,Q2,Hyperphagia,,2023,Q2,2,F,,20230519.0,20230516,20230529,EXP,,JP-TEVA-2023-JP-2887948,TEVA,,50.0,YR,A,F,Y,,,20230529,,HP,JP,JP,2023,Q2,Adult
223387081,22338708,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, 1/week",,,,,,,,0.75,MG,,/WK,2023,Q2,Drug ineffective,,2023,Q2,1,I,,20230503.0,20230518,20230518,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-388318,RANBAXY,"Noda K, Kato T, Nomura N, Sakai M, Kubota S, Hirose T, et al. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabet Int. 2022;13(4):693-697",50.0,YR,,F,Y,,,20230518,,HP,JP,JP,2023,Q2,Adult
223509631,22350963,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,942526D,,,,,,,2023,Q2,Cough,,2023,Q2,1,I,,20230428.0,20230522,20230522,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-239011",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230522,,CN,US,US,2023,Q2,Adult
223509631,22350963,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,942526D,,,,,,,2023,Q2,Dyspnoea,,2023,Q2,1,I,,20230428.0,20230522,20230522,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-239011",BOEHRINGER INGELHEIM,,60.0,YR,A,M,Y,,,20230522,,CN,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Affect lability,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Mood altered,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Depression,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Liver function test increased,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Seizure,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Dizziness,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Somnolence,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Anxiety,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223675051,22367505,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Weekly (qw)",,,,,,,,0.75,MG,,/WK,2023,Q2,Fatigue,,2023,Q2,1,I,20230401.0,20230523.0,20230525,20230525,EXP,,US-UCBSA-2023026502,UCB,,62.0,YR,,M,Y,90.0,KG,20230525,,MD,US,US,2023,Q2,Adult
223991921,22399192,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,U,,,,125469.0,1.5,MG,,/WK,2023,Q2,Decreased appetite,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,U,,,,125469.0,1.5,MG,,/WK,2023,Q2,Nausea,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,U,,,,125469.0,1.5,MG,,/WK,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,U,,,,125469.0,1.5,MG,,/WK,2023,Q2,Blood glucose decreased,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,U,,,,125469.0,,,,,2023,Q2,Decreased appetite,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,U,,,,125469.0,,,,,2023,Q2,Nausea,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,U,,,,125469.0,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,U,,,,125469.0,,,,,2023,Q2,Blood glucose decreased,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,U,,,,125469.0,,,,,2023,Q2,Decreased appetite,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,U,,,,125469.0,,,,,2023,Q2,Nausea,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,U,,,,125469.0,,,,,2023,Q2,Diarrhoea,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
223991921,22399192,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,U,,,,125469.0,,,,,2023,Q2,Blood glucose decreased,,2023,Q2,1,I,20230429.0,20230530.0,20230602,20230602,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202305017889,ELI LILLY AND CO,,45.0,YR,,M,Y,110.0,KG,20230602,,CN,CN,CN,2023,Q2,Adult
225252181,22525218,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,,,Desconocido,,125469.0,1.5,MG,,/WK,2023,Q2,Syncope,,2023,Q2,1,I,20230511.0,20230530.0,20230606,20230606,EXP,ES-AEMPS-1374745,ES-ELI_LILLY_AND_COMPANY-ES202305017124,ELI LILLY AND CO,,76.0,YR,,F,Y,,,20230606,,CN,ES,ES,2023,Q2,Elderly
225252181,22525218,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,,,Desconocido,,125469.0,1.5,MG,,/WK,2023,Q2,Hypoglycaemia,,2023,Q2,1,I,20230511.0,20230530.0,20230606,20230606,EXP,ES-AEMPS-1374745,ES-ELI_LILLY_AND_COMPANY-ES202305017124,ELI LILLY AND CO,,76.0,YR,,F,Y,,,20230606,,CN,ES,ES,2023,Q2,Elderly
225365571,22536557,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"UNK, unknown",,,,,,,125469.0,,,,,2023,Q2,Pruritus,,2023,Q2,1,I,20220601.0,20230605.0,20230608,20230608,EXP,FR-AFSSAPS-TS2023000677,FR-ELI_LILLY_AND_COMPANY-FR202306002331,ELI LILLY AND CO,,76.0,YR,,F,Y,,,20230608,,CN,FR,FR,2023,Q2,Elderly
225365571,22536557,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"UNK, unknown",,,,,,,125469.0,,,,,2023,Q2,Incorrect route of product administration,,2023,Q2,1,I,20220601.0,20230605.0,20230608,20230608,EXP,FR-AFSSAPS-TS2023000677,FR-ELI_LILLY_AND_COMPANY-FR202306002331,ELI LILLY AND CO,,76.0,YR,,F,Y,,,20230608,,CN,FR,FR,2023,Q2,Elderly
226213601,22621360,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q2,Haematoma muscle,,2023,Q2,1,I,20230529.0,20230619.0,20230620,20230620,EXP,FR-AFSSAPS-LY2023000918,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-086750,BRISTOL MYERS SQUIBB,,74.0,YR,E,F,Y,,,20230620,,PH,FR,FR,2023,Q2,Elderly
226213601,22621360,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q2,Prothrombin time ratio decreased,,2023,Q2,1,I,20230529.0,20230619.0,20230620,20230620,EXP,FR-AFSSAPS-LY2023000918,FR-BRISTOL-MYERS SQUIBB COMPANY-2023-086750,BRISTOL MYERS SQUIBB,,74.0,YR,E,F,Y,,,20230620,,PH,FR,FR,2023,Q2,Elderly
226238411,22623841,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,D,,,,,,,,,2023,Q2,Arthralgia,,2023,Q2,1,I,,20230609.0,20230621,20230621,EXP,,"PT-ARBOR PHARMACEUTICALS, LLC-PT-2023ARB004314",ARBOR,,64.0,YR,,F,Y,,,20230621,,PH,PT,PT,2023,Q2,Adult
226238411,22623841,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,D,,,,,,,,,2023,Q2,Gait disturbance,,2023,Q2,1,I,,20230609.0,20230621,20230621,EXP,,"PT-ARBOR PHARMACEUTICALS, LLC-PT-2023ARB004314",ARBOR,,64.0,YR,,F,Y,,,20230621,,PH,PT,PT,2023,Q2,Adult
226262451,22626245,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,U,,,,125469.0,,,,,2023,Q2,Neuropathy peripheral,,2023,Q2,1,I,,20230613.0,20230621,20230621,EXP,,PT-ELI_LILLY_AND_COMPANY-PT202306009398,ELI LILLY AND CO,,68.0,YR,,F,Y,,,20230621,,HP,PT,PT,2023,Q2,Elderly
226363381,22636338,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,U,,,125469.0,1.5,MG,,/WK,2023,Q2,Euglycaemic diabetic ketoacidosis,,2023,Q2,1,I,20230613.0,20230620.0,20230623,20230623,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202306012510,ELI LILLY AND CO,,72.0,YR,,F,Y,,,20230623,,CN,GB,GB,2023,Q2,Elderly
226422391,22642239,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Orthostatic hypotension,,2023,Q2,1,I,,20230623.0,20230626,20230626,EXP,,NVSC2023PT145028,NOVARTIS,"Gouveia R, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. Neuropaa induzida pelo tratamento da Diabetes ? uma endade pouco reconhecida. MEDICINA INTERNA. 2023;29(Sup1):81",68.0,YR,,F,Y,,,20230626,,HP,PT,PT,2023,Q2,Elderly
226422391,22642239,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Syncope,,2023,Q2,1,I,,20230623.0,20230626,20230626,EXP,,NVSC2023PT145028,NOVARTIS,"Gouveia R, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. Neuropaa induzida pelo tratamento da Diabetes ? uma endade pouco reconhecida. MEDICINA INTERNA. 2023;29(Sup1):81",68.0,YR,,F,Y,,,20230626,,HP,PT,PT,2023,Q2,Elderly
226422391,22642239,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q2,Neuropathy peripheral,,2023,Q2,1,I,,20230623.0,20230626,20230626,EXP,,NVSC2023PT145028,NOVARTIS,"Gouveia R, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. Neuropaa induzida pelo tratamento da Diabetes ? uma endade pouco reconhecida. MEDICINA INTERNA. 2023;29(Sup1):81",68.0,YR,,F,Y,,,20230626,,HP,PT,PT,2023,Q2,Elderly
146691712,14669171,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,2.0,MG,,/WK,2023,Q3,Blood calcitonin increased,,2023,Q3,2,F,,20230720.0,20180322,20230730,EXP,,US-TEVA-2018-US-872992,TEVA,,56.0,YR,A,F,Y,,,20230730,,HP,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Pain,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Fatigue,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,End stage renal disease,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Loss of personal independence in daily activities,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Renal impairment,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Chronic kidney disease,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Quality of life decreased,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Renal failure,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Fear,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Decreased activity,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Economic problem,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Hyperkalaemia,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Anhedonia,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Emotional distress,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
168551674,16855167,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Anxiety,,2023,Q3,4,F,20120710.0,20230913.0,20190926,20230918,EXP,,US-GILEAD-2019-0429566,GILEAD,,56.0,YR,A,M,Y,78.912,KG,20230918,,LW,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Hypovolaemia,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Death,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Small intestinal obstruction,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Lactic acidosis,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Septic shock,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Cardio-respiratory arrest,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Acute kidney injury,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Emphysematous pyelonephritis,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Leukocytosis,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Thrombocytopenia,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Portal venous gas,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Brain injury,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Glycosuria,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
176206002,17620600,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,Injection,/WK,2023,Q3,Colitis ischaemic,,2023,Q3,2,F,,20230713.0,20200403,20230717,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2020-NB-017586",BOEHRINGER INGELHEIM,"Echeverria P, Rynerson Z, Saa J. Emphysematous kidney and pyelonephritis in a diabetic woman managed with empagliflozin. Critical Care Medicine. 2020;48(1):",60.0,YR,A,F,Y,,,20230717,,MD,US,US,2023,Q3,Adult
192336034,19233603,37,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Renal failure,,2023,Q3,4,F,20170707.0,20230907.0,20210507,20230915,EXP,,US-AstraZeneca-2021A390571,ASTRAZENECA,,19801.0,DY,,M,Y,110.2,KG,20230915,,LW,US,,2023,Q3,Elderly
192336034,19233603,37,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,4,F,20170707.0,20230907.0,20210507,20230915,EXP,,US-AstraZeneca-2021A390571,ASTRAZENECA,,19801.0,DY,,M,Y,110.2,KG,20230915,,LW,US,,2023,Q3,Elderly
192336034,19233603,37,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Hyperkalaemia,,2023,Q3,4,F,20170707.0,20230907.0,20210507,20230915,EXP,,US-AstraZeneca-2021A390571,ASTRAZENECA,,19801.0,DY,,M,Y,110.2,KG,20230915,,LW,US,,2023,Q3,Elderly
192336034,19233603,37,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Tubulointerstitial nephritis,,2023,Q3,4,F,20170707.0,20230907.0,20210507,20230915,EXP,,US-AstraZeneca-2021A390571,ASTRAZENECA,,19801.0,DY,,M,Y,110.2,KG,20230915,,LW,US,,2023,Q3,Elderly
192336034,19233603,37,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Renal tubular necrosis,,2023,Q3,4,F,20170707.0,20230907.0,20210507,20230915,EXP,,US-AstraZeneca-2021A390571,ASTRAZENECA,,19801.0,DY,,M,Y,110.2,KG,20230915,,LW,US,,2023,Q3,Elderly
192336034,19233603,37,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,4,F,20170707.0,20230907.0,20210507,20230915,EXP,,US-AstraZeneca-2021A390571,ASTRAZENECA,,19801.0,DY,,M,Y,110.2,KG,20230915,,LW,US,,2023,Q3,Elderly
192336034,19233603,37,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Chronic kidney disease,,2023,Q3,4,F,20170707.0,20230907.0,20210507,20230915,EXP,,US-AstraZeneca-2021A390571,ASTRAZENECA,,19801.0,DY,,M,Y,110.2,KG,20230915,,LW,US,,2023,Q3,Elderly
194083285,19408328,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Breast cancer metastatic,,2023,Q3,5,F,20210120.0,20230804.0,20210611,20230809,EXP,,US-ROCHE-2846463,ROCHE,,64.0,YR,,F,Y,,,20230809,,MD,US,,2023,Q3,Adult
194890382,19489038,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Intramuscular,"UNK (Once a week, solution for injection / infusion)",,,,,,,,,,,,2023,Q3,Syncope,,2023,Q3,2,F,,20230904.0,20210703,20230915,EXP,,DE-AUROBINDO-AUR-APL-2021-027326,AUROBINDO,,80.0,YR,,F,Y,,,20230915,,MD,DE,DE,2023,Q3,Elderly
194890382,19489038,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Intramuscular,"UNK (Once a week, solution for injection / infusion)",,,,,,,,,,,,2023,Q3,Nausea,,2023,Q3,2,F,,20230904.0,20210703,20230915,EXP,,DE-AUROBINDO-AUR-APL-2021-027326,AUROBINDO,,80.0,YR,,F,Y,,,20230915,,MD,DE,DE,2023,Q3,Elderly
196619272,19661927,16,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Alopecia,,2023,Q3,2,F,20150101.0,20230324.0,20210805,20230805,EXP,,US-Accord-186568,ACCORD,,54.0,YR,A,F,Y,69.85,KG,20230805,,LW,US,US,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Taste disorder,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Thirst decreased,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Swelling face,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Abscess,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Weight increased,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Cardiac disorder,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Blood glucose fluctuation,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Constipation,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Swelling,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Night sweats,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Headache,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Adverse event,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
201546252,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2023,Q3,Hypoaesthesia,,2023,Q3,2,F,,20230912.0,20211207,20230925,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20230925,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q3,Metabolic acidosis,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q3,Hypotension,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q3,C-reactive protein increased,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q3,Hyperglycaemia,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q3,Headache,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q3,Dyspnoea,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2023,Q3,Pulmonary oedema,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q3,C-reactive protein increased,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q3,Hyperglycaemia,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q3,Headache,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q3,Dyspnoea,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
2079457210,20794572,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q3,Pulmonary oedema,,2023,Q3,10,F,20220310.0,20230919.0,20220506,20230921,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20230921,,HP,CA,CA,2023,Q3,Adult
208643992,20864399,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2023,Q3,Fall,,2023,Q3,2,F,20220422.0,20230609.0,20220523,20230704,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2022-PIM-001536,ACADIA PHARMACEUTICALS,,71.0,YR,,M,Y,,,20230704,,CN,US,US,2023,Q3,Elderly
208643992,20864399,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,2,F,20220422.0,20230609.0,20220523,20230704,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2022-PIM-001536,ACADIA PHARMACEUTICALS,,71.0,YR,,M,Y,,,20230704,,CN,US,US,2023,Q3,Elderly
208643992,20864399,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2023,Q3,Weight decreased,,2023,Q3,2,F,20220422.0,20230609.0,20220523,20230704,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2022-PIM-001536,ACADIA PHARMACEUTICALS,,71.0,YR,,M,Y,,,20230704,,CN,US,US,2023,Q3,Elderly
208643992,20864399,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2023,Q3,Mobility decreased,,2023,Q3,2,F,20220422.0,20230609.0,20220523,20230704,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2022-PIM-001536,ACADIA PHARMACEUTICALS,,71.0,YR,,M,Y,,,20230704,,CN,US,US,2023,Q3,Elderly
208643992,20864399,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2023,Q3,Confusional state,,2023,Q3,2,F,20220422.0,20230609.0,20220523,20230704,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2022-PIM-001536,ACADIA PHARMACEUTICALS,,71.0,YR,,M,Y,,,20230704,,CN,US,US,2023,Q3,Elderly
208643992,20864399,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,2,F,20220422.0,20230609.0,20220523,20230704,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2022-PIM-001536,ACADIA PHARMACEUTICALS,,71.0,YR,,M,Y,,,20230704,,CN,US,US,2023,Q3,Elderly
2121847712,21218477,33,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Pyrexia,,2023,Q3,12,F,20220729.0,20230922.0,20220816,20230928,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230928,,MD,US,US,2023,Q3,Elderly
2121847712,21218477,33,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,12,F,20220729.0,20230922.0,20220816,20230928,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230928,,MD,US,US,2023,Q3,Elderly
2121847712,21218477,33,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Neutrophil count decreased,,2023,Q3,12,F,20220729.0,20230922.0,20220816,20230928,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230928,,MD,US,US,2023,Q3,Elderly
2121847712,21218477,33,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Cardiac failure,,2023,Q3,12,F,20220729.0,20230922.0,20220816,20230928,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230928,,MD,US,US,2023,Q3,Elderly
2121847712,21218477,33,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Blood lactic acid increased,,2023,Q3,12,F,20220729.0,20230922.0,20220816,20230928,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230928,,MD,US,US,2023,Q3,Elderly
2121847712,21218477,33,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Tachycardia,,2023,Q3,12,F,20220729.0,20230922.0,20220816,20230928,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230928,,MD,US,US,2023,Q3,Elderly
2121847712,21218477,33,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Cytokine release syndrome,,2023,Q3,12,F,20220729.0,20230922.0,20220816,20230928,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230928,,MD,US,US,2023,Q3,Elderly
2121847712,21218477,33,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Stomatitis,,2023,Q3,12,F,20220729.0,20230922.0,20220816,20230928,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20230928,,MD,US,US,2023,Q3,Elderly
2134907022,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q3,Cataract,,2023,Q3,22,F,20220912.0,20230828.0,20220919,20230830,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20230830,,MD,US,,2023,Q3,Adult
2134907022,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q3,Vitreous haemorrhage,,2023,Q3,22,F,20220912.0,20230828.0,20220919,20230830,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20230830,,MD,US,,2023,Q3,Adult
2134907022,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q3,Rhegmatogenous retinal detachment,,2023,Q3,22,F,20220912.0,20230828.0,20220919,20230830,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20230830,,MD,US,,2023,Q3,Adult
216805402,21680540,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Gastrointestinal haemorrhage,,2023,Q3,2,F,20221128.0,20230815.0,20221205,20230818,EXP,,NVSC2022US280052,NOVARTIS,,67.0,YR,,F,Y,73.0,KG,20230818,,MD,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Bradycardia,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Abdominal distension,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Cardiac failure congestive,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Malaise,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Urine output decreased,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Oedema peripheral,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Contraindicated product administered,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Drug interaction,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Chronic kidney disease,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217229274,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,4,F,,20230713.0,20221213,20230725,EXP,,US-PFIZER INC-PV202200120014,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230725,,PH,US,US,2023,Q3,Elderly
217283653,21728365,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Drug ineffective,,2023,Q3,3,F,,20230720.0,20221214,20230801,PER,,US-PFIZER INC-PV202200122039,PFIZER,"Rauser, M.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2022;1-2",79.0,YR,,F,Y,,,20230801,,PH,US,US,2023,Q3,Elderly
218880932,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q3,Dysarthria,,2023,Q3,2,F,,20230716.0,20230120,20230725,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",70.0,YR,,M,Y,,,20230725,,HP,AU,AU,2023,Q3,Elderly
218880932,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q3,Nephropathy toxic,,2023,Q3,2,F,,20230716.0,20230120,20230725,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",70.0,YR,,M,Y,,,20230725,,HP,AU,AU,2023,Q3,Elderly
218880932,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q3,Ataxia,,2023,Q3,2,F,,20230716.0,20230120,20230725,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",70.0,YR,,M,Y,,,20230725,,HP,AU,AU,2023,Q3,Elderly
218880932,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q3,Acute kidney injury,,2023,Q3,2,F,,20230716.0,20230120,20230725,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",70.0,YR,,M,Y,,,20230725,,HP,AU,AU,2023,Q3,Elderly
218880932,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q3,Nausea,,2023,Q3,2,F,,20230716.0,20230120,20230725,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",70.0,YR,,M,Y,,,20230725,,HP,AU,AU,2023,Q3,Elderly
218880932,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q3,Decreased appetite,,2023,Q3,2,F,,20230716.0,20230120,20230725,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",70.0,YR,,M,Y,,,20230725,,HP,AU,AU,2023,Q3,Elderly
218880932,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q3,Malaise,,2023,Q3,2,F,,20230716.0,20230120,20230725,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",70.0,YR,,M,Y,,,20230725,,HP,AU,AU,2023,Q3,Elderly
218880932,21888093,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW",,,U,,,,,,,Injection,/WK,2023,Q3,Pruritus,,2023,Q3,2,F,,20230716.0,20230120,20230725,EXP,,NVSC2023AU011766,NOVARTIS,"Kirkland J, Suganthan P. Valacyclovir-associated acute kidney injury. BMJ CASE REPORTS. 2022;15(6):1-4",70.0,YR,,M,Y,,,20230725,,HP,AU,AU,2023,Q3,Elderly
2197263311,21972633,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,75.0,MG,Injection,,2023,Q3,Dyspnoea,,2023,Q3,11,F,20221201.0,20230922.0,20230209,20230929,PER,,IT-Eisai Medical Research-EC-2023-131492,EISAI,,70.0,YR,E,M,Y,94.0,KG,20230929,,MD,IT,,2023,Q3,Elderly
2197263311,21972633,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,75.0,MG,Injection,,2023,Q3,Cardiac failure,,2023,Q3,11,F,20221201.0,20230922.0,20230209,20230929,PER,,IT-Eisai Medical Research-EC-2023-131492,EISAI,,70.0,YR,E,M,Y,94.0,KG,20230929,,MD,IT,,2023,Q3,Elderly
220327502,22032750,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Pulmonary oedema,,2023,Q3,2,F,,20230629.0,20230224,20230703,EXP,,CA-AstraZeneca-2023A046216,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230703,,MD,CA,,2023,Q3,Adult
220327502,22032750,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Hyperglycaemia,,2023,Q3,2,F,,20230629.0,20230224,20230703,EXP,,CA-AstraZeneca-2023A046216,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230703,,MD,CA,,2023,Q3,Adult
220327502,22032750,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Metabolic acidosis,,2023,Q3,2,F,,20230629.0,20230224,20230703,EXP,,CA-AstraZeneca-2023A046216,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230703,,MD,CA,,2023,Q3,Adult
220327502,22032750,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Hypotension,,2023,Q3,2,F,,20230629.0,20230224,20230703,EXP,,CA-AstraZeneca-2023A046216,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230703,,MD,CA,,2023,Q3,Adult
220327502,22032750,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Headache,,2023,Q3,2,F,,20230629.0,20230224,20230703,EXP,,CA-AstraZeneca-2023A046216,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20230703,,MD,CA,,2023,Q3,Adult
221591072,22159107,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Glycosylated haemoglobin increased,,2023,Q3,2,F,20230130.0,20230804.0,20230331,20230811,EXP,,JP-EMD Serono-9392650,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230811,,MD,JP,JP,2023,Q3,Elderly
221591072,22159107,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Nausea,,2023,Q3,2,F,20230130.0,20230804.0,20230331,20230811,EXP,,JP-EMD Serono-9392650,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230811,,MD,JP,JP,2023,Q3,Elderly
221591072,22159107,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Orthopaedic procedure,,2023,Q3,2,F,20230130.0,20230804.0,20230331,20230811,EXP,,JP-EMD Serono-9392650,EMD SERONO INC,,74.0,YR,E,F,Y,,,20230811,,MD,JP,JP,2023,Q3,Elderly
222531132,22253113,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q3,Pulmonary oedema,,2023,Q3,2,F,,20230811.0,20230426,20230825,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,90.0,KG,20230826,,HP,CA,CA,2023,Q3,Adult
222531132,22253113,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q3,Dyspnoea,,2023,Q3,2,F,,20230811.0,20230426,20230825,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,90.0,KG,20230826,,HP,CA,CA,2023,Q3,Adult
222531132,22253113,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q3,Metabolic acidosis,,2023,Q3,2,F,,20230811.0,20230426,20230825,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,90.0,KG,20230826,,HP,CA,CA,2023,Q3,Adult
222531132,22253113,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q3,Hyperglycaemia,,2023,Q3,2,F,,20230811.0,20230426,20230825,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,90.0,KG,20230826,,HP,CA,CA,2023,Q3,Adult
222531132,22253113,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q3,C-reactive protein increased,,2023,Q3,2,F,,20230811.0,20230426,20230825,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,90.0,KG,20230826,,HP,CA,CA,2023,Q3,Adult
222531132,22253113,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q3,Headache,,2023,Q3,2,F,,20230811.0,20230426,20230825,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,90.0,KG,20230826,,HP,CA,CA,2023,Q3,Adult
222531132,22253113,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,Injection,,2023,Q3,Hypotension,,2023,Q3,2,F,,20230811.0,20230426,20230825,EXP,,CA-AUROBINDO-AUR-APL-2023-032524,AUROBINDO,,64.0,YR,,M,Y,90.0,KG,20230826,,HP,CA,CA,2023,Q3,Adult
223376042,22337604,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Cholestasis,,2023,Q3,2,F,20230412.0,20230623.0,20230518,20230705,EXP,FR-AFSSAPS-AM2023000416,FR-Accord-357689,ACCORD,,71.0,YR,E,M,Y,83.0,KG,20230705,,PH,FR,FR,2023,Q3,Elderly
223376042,22337604,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Hepatic cytolysis,,2023,Q3,2,F,20230412.0,20230623.0,20230518,20230705,EXP,FR-AFSSAPS-AM2023000416,FR-Accord-357689,ACCORD,,71.0,YR,E,M,Y,83.0,KG,20230705,,PH,FR,FR,2023,Q3,Elderly
223788262,22378826,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Pulmonary arterial hypertension,,2023,Q3,2,F,20201201.0,20230627.0,20230529,20230710,EXP,FR-AFSSAPS-2023035798,FR-Accord-360123,ACCORD,,44.0,YR,A,F,Y,,,20230709,,MD,FR,FR,2023,Q3,Adult
225877404,22587740,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Syncope,,2023,Q3,4,F,,20230712.0,20230612,20230725,EXP,,PT-AUROBINDO-AUR-APL-2023-041200,AUROBINDO,"Rita Gouveia, Catarina Elias, Rocha M, Ribeiro A, Oliveira J, Almeida J.. Diabetes treatment induced neuropathy - an underrecognized entity. Congresses of the Portuguese Society of Internal Medicine: 29th National congres. 2023;29(Sup 1):81",68.0,YR,,F,Y,,,20230725,,MD,PT,PT,2023,Q3,Elderly
225877404,22587740,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Orthostatic hypotension,,2023,Q3,4,F,,20230712.0,20230612,20230725,EXP,,PT-AUROBINDO-AUR-APL-2023-041200,AUROBINDO,"Rita Gouveia, Catarina Elias, Rocha M, Ribeiro A, Oliveira J, Almeida J.. Diabetes treatment induced neuropathy - an underrecognized entity. Congresses of the Portuguese Society of Internal Medicine: 29th National congres. 2023;29(Sup 1):81",68.0,YR,,F,Y,,,20230725,,MD,PT,PT,2023,Q3,Elderly
225877404,22587740,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Neuropathy peripheral,,2023,Q3,4,F,,20230712.0,20230612,20230725,EXP,,PT-AUROBINDO-AUR-APL-2023-041200,AUROBINDO,"Rita Gouveia, Catarina Elias, Rocha M, Ribeiro A, Oliveira J, Almeida J.. Diabetes treatment induced neuropathy - an underrecognized entity. Congresses of the Portuguese Society of Internal Medicine: 29th National congres. 2023;29(Sup 1):81",68.0,YR,,F,Y,,,20230725,,MD,PT,PT,2023,Q3,Elderly
225877404,22587740,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Blood pressure decreased,,2023,Q3,4,F,,20230712.0,20230612,20230725,EXP,,PT-AUROBINDO-AUR-APL-2023-041200,AUROBINDO,"Rita Gouveia, Catarina Elias, Rocha M, Ribeiro A, Oliveira J, Almeida J.. Diabetes treatment induced neuropathy - an underrecognized entity. Congresses of the Portuguese Society of Internal Medicine: 29th National congres. 2023;29(Sup 1):81",68.0,YR,,F,Y,,,20230725,,MD,PT,PT,2023,Q3,Elderly
225964656,22596465,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Orthostatic hypotension,,2023,Q3,6,F,,20230724.0,20230613,20230728,EXP,,PT-MYLANLABS-2023M1056878,MYLAN,"Rita Gouveia, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. Diabetes treatment-induced neuropathy - an underrecognized entity.. Congresses of the Portuguese Society of Internal Medicine: 29th National Congres. 2023;29(Sup 1):81",68.0,YR,,F,Y,,,20230728,,MD,PT,PT,2023,Q3,Elderly
225964656,22596465,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Syncope,,2023,Q3,6,F,,20230724.0,20230613,20230728,EXP,,PT-MYLANLABS-2023M1056878,MYLAN,"Rita Gouveia, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. Diabetes treatment-induced neuropathy - an underrecognized entity.. Congresses of the Portuguese Society of Internal Medicine: 29th National Congres. 2023;29(Sup 1):81",68.0,YR,,F,Y,,,20230728,,MD,PT,PT,2023,Q3,Elderly
225964656,22596465,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Blood pressure decreased,,2023,Q3,6,F,,20230724.0,20230613,20230728,EXP,,PT-MYLANLABS-2023M1056878,MYLAN,"Rita Gouveia, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. Diabetes treatment-induced neuropathy - an underrecognized entity.. Congresses of the Portuguese Society of Internal Medicine: 29th National Congres. 2023;29(Sup 1):81",68.0,YR,,F,Y,,,20230728,,MD,PT,PT,2023,Q3,Elderly
225964656,22596465,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2023,Q3,Neuropathy peripheral,,2023,Q3,6,F,,20230724.0,20230613,20230728,EXP,,PT-MYLANLABS-2023M1056878,MYLAN,"Rita Gouveia, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. Diabetes treatment-induced neuropathy - an underrecognized entity.. Congresses of the Portuguese Society of Internal Medicine: 29th National Congres. 2023;29(Sup 1):81",68.0,YR,,F,Y,,,20230728,,MD,PT,PT,2023,Q3,Elderly
226374953,22637495,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Neuropathy peripheral,,2023,Q3,3,F,,20230627.0,20230626,20230710,EXP,,PT-AUROBINDO-AUR-APL-2023-043516,AUROBINDO,"Monteiro M, Miranda I, Samji V. Serotoninergic Syndrome: Clinical Nonspecificity as a Factor of Diagnostic Complexity. Congresses of the Portuguese Society of Internal Medicine: 29th National Congres. 2023;68",68.0,YR,,F,Y,,,20230710,,MD,PT,PT,2023,Q3,Elderly
227086753,22708675,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Every Week",,,,,,,,1.5,MG,,/WK,2023,Q3,Insomnia,,2023,Q3,3,F,20230530.0,20230905.0,20230716,20230915,EXP,,FR-AUROBINDO-AUR-APL-2023-046857,AUROBINDO,,68.0,YR,,F,Y,65.0,KG,20230915,,CN,FR,FR,2023,Q3,Elderly
227086753,22708675,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Every Week",,,,,,,,1.5,MG,,/WK,2023,Q3,Gastrooesophageal reflux disease,,2023,Q3,3,F,20230530.0,20230905.0,20230716,20230915,EXP,,FR-AUROBINDO-AUR-APL-2023-046857,AUROBINDO,,68.0,YR,,F,Y,65.0,KG,20230915,,CN,FR,FR,2023,Q3,Elderly
227086753,22708675,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Every Week",,,,,,,,1.5,MG,,/WK,2023,Q3,Abdominal distension,,2023,Q3,3,F,20230530.0,20230905.0,20230716,20230915,EXP,,FR-AUROBINDO-AUR-APL-2023-046857,AUROBINDO,,68.0,YR,,F,Y,65.0,KG,20230915,,CN,FR,FR,2023,Q3,Elderly
227086753,22708675,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Every Week",,,,,,,,1.5,MG,,/WK,2023,Q3,Fatigue,,2023,Q3,3,F,20230530.0,20230905.0,20230716,20230915,EXP,,FR-AUROBINDO-AUR-APL-2023-046857,AUROBINDO,,68.0,YR,,F,Y,65.0,KG,20230915,,CN,FR,FR,2023,Q3,Elderly
227086753,22708675,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Every Week",,,,,,,,1.5,MG,,/WK,2023,Q3,Abdominal pain,,2023,Q3,3,F,20230530.0,20230905.0,20230716,20230915,EXP,,FR-AUROBINDO-AUR-APL-2023-046857,AUROBINDO,,68.0,YR,,F,Y,65.0,KG,20230915,,CN,FR,FR,2023,Q3,Elderly
227086753,22708675,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Every Week",,,,,,,,1.5,MG,,/WK,2023,Q3,Malaise,,2023,Q3,3,F,20230530.0,20230905.0,20230716,20230915,EXP,,FR-AUROBINDO-AUR-APL-2023-046857,AUROBINDO,,68.0,YR,,F,Y,65.0,KG,20230915,,CN,FR,FR,2023,Q3,Elderly
227086753,22708675,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Every Week",,,,,,,,1.5,MG,,/WK,2023,Q3,Constipation,,2023,Q3,3,F,20230530.0,20230905.0,20230716,20230915,EXP,,FR-AUROBINDO-AUR-APL-2023-046857,AUROBINDO,,68.0,YR,,F,Y,65.0,KG,20230915,,CN,FR,FR,2023,Q3,Elderly
227086753,22708675,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Every Week",,,,,,,,1.5,MG,,/WK,2023,Q3,Vertigo,,2023,Q3,3,F,20230530.0,20230905.0,20230716,20230915,EXP,,FR-AUROBINDO-AUR-APL-2023-046857,AUROBINDO,,68.0,YR,,F,Y,65.0,KG,20230915,,CN,FR,FR,2023,Q3,Elderly
227136691,22713669,27,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,COVID-19,,2023,Q3,1,I,20200311.0,20230712.0,20230717,20230717,EXP,,GB-AMGEN-GBRSP2023121585,AMGEN,,64.0,YR,A,M,Y,97.0,KG,20230717,,HP,GB,GB,2023,Q3,Adult
227136691,22713669,27,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Sleep apnoea syndrome,,2023,Q3,1,I,20200311.0,20230712.0,20230717,20230717,EXP,,GB-AMGEN-GBRSP2023121585,AMGEN,,64.0,YR,A,M,Y,97.0,KG,20230717,,HP,GB,GB,2023,Q3,Adult
227141603,22714160,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Constipation,,2023,Q3,3,F,20230530.0,20230724.0,20230718,20230731,EXP,FR-AFSSAPS-BS2023000519,NVSC2023FR156393,NOVARTIS,,68.0,YR,,F,Y,65.0,KG,20230731,,CN,FR,FR,2023,Q3,Elderly
227141603,22714160,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Malaise,,2023,Q3,3,F,20230530.0,20230724.0,20230718,20230731,EXP,FR-AFSSAPS-BS2023000519,NVSC2023FR156393,NOVARTIS,,68.0,YR,,F,Y,65.0,KG,20230731,,CN,FR,FR,2023,Q3,Elderly
227141603,22714160,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Abdominal pain,,2023,Q3,3,F,20230530.0,20230724.0,20230718,20230731,EXP,FR-AFSSAPS-BS2023000519,NVSC2023FR156393,NOVARTIS,,68.0,YR,,F,Y,65.0,KG,20230731,,CN,FR,FR,2023,Q3,Elderly
227141603,22714160,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Fatigue,,2023,Q3,3,F,20230530.0,20230724.0,20230718,20230731,EXP,FR-AFSSAPS-BS2023000519,NVSC2023FR156393,NOVARTIS,,68.0,YR,,F,Y,65.0,KG,20230731,,CN,FR,FR,2023,Q3,Elderly
227141603,22714160,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Abdominal distension,,2023,Q3,3,F,20230530.0,20230724.0,20230718,20230731,EXP,FR-AFSSAPS-BS2023000519,NVSC2023FR156393,NOVARTIS,,68.0,YR,,F,Y,65.0,KG,20230731,,CN,FR,FR,2023,Q3,Elderly
227141603,22714160,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Vertigo,,2023,Q3,3,F,20230530.0,20230724.0,20230718,20230731,EXP,FR-AFSSAPS-BS2023000519,NVSC2023FR156393,NOVARTIS,,68.0,YR,,F,Y,65.0,KG,20230731,,CN,FR,FR,2023,Q3,Elderly
227141603,22714160,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Gastrooesophageal reflux disease,,2023,Q3,3,F,20230530.0,20230724.0,20230718,20230731,EXP,FR-AFSSAPS-BS2023000519,NVSC2023FR156393,NOVARTIS,,68.0,YR,,F,Y,65.0,KG,20230731,,CN,FR,FR,2023,Q3,Elderly
227141603,22714160,8,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Insomnia,,2023,Q3,3,F,20230530.0,20230724.0,20230718,20230731,EXP,FR-AFSSAPS-BS2023000519,NVSC2023FR156393,NOVARTIS,,68.0,YR,,F,Y,65.0,KG,20230731,,CN,FR,FR,2023,Q3,Elderly
227229451,22722945,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"0.75 milligram, qw",,,,,,,,0.75,MG,,/WK,2023,Q3,Toxic skin eruption,,2023,Q3,1,I,20230315.0,20230713.0,20230719,20230719,EXP,FR-AFSSAPS-AN2023000805,FR-MYLANLABS-2023M1075740,MYLAN,,66.0,YR,,M,Y,88.4,KG,20230719,,MD,FR,FR,2023,Q3,Elderly
227229451,22722945,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"0.75 milligram, qw",,,,,,,,0.75,MG,,/WK,2023,Q3,Eosinophilia,,2023,Q3,1,I,20230315.0,20230713.0,20230719,20230719,EXP,FR-AFSSAPS-AN2023000805,FR-MYLANLABS-2023M1075740,MYLAN,,66.0,YR,,M,Y,88.4,KG,20230719,,MD,FR,FR,2023,Q3,Elderly
227229451,22722945,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"0.75 milligram, qw",,,,,,,,0.75,MG,,/WK,2023,Q3,Renal impairment,,2023,Q3,1,I,20230315.0,20230713.0,20230719,20230719,EXP,FR-AFSSAPS-AN2023000805,FR-MYLANLABS-2023M1075740,MYLAN,,66.0,YR,,M,Y,88.4,KG,20230719,,MD,FR,FR,2023,Q3,Elderly
227247601,22724760,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Neutrophil count decreased,,2023,Q3,1,I,20220822.0,20230707.0,20230719,20230719,EXP,,US-Accord-368213,ACCORD,,47.0,YR,A,F,Y,125.2,KG,20230719,,HP,US,US,2023,Q3,Adult
227247601,22724760,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Sepsis,,2023,Q3,1,I,20220822.0,20230707.0,20230719,20230719,EXP,,US-Accord-368213,ACCORD,,47.0,YR,A,F,Y,125.2,KG,20230719,,HP,US,US,2023,Q3,Adult
227247601,22724760,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Abdominal pain,,2023,Q3,1,I,20220822.0,20230707.0,20230719,20230719,EXP,,US-Accord-368213,ACCORD,,47.0,YR,A,F,Y,125.2,KG,20230719,,HP,US,US,2023,Q3,Adult
227247601,22724760,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Blood bilirubin increased,,2023,Q3,1,I,20220822.0,20230707.0,20230719,20230719,EXP,,US-Accord-368213,ACCORD,,47.0,YR,A,F,Y,125.2,KG,20230719,,HP,US,US,2023,Q3,Adult
227247601,22724760,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Anaemia,,2023,Q3,1,I,20220822.0,20230707.0,20230719,20230719,EXP,,US-Accord-368213,ACCORD,,47.0,YR,A,F,Y,125.2,KG,20230719,,HP,US,US,2023,Q3,Adult
227247601,22724760,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Platelet count decreased,,2023,Q3,1,I,20220822.0,20230707.0,20230719,20230719,EXP,,US-Accord-368213,ACCORD,,47.0,YR,A,F,Y,125.2,KG,20230719,,HP,US,US,2023,Q3,Adult
227251881,22725188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,Solution for injection in pre-filled pen,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230707.0,20230719,20230719,EXP,,SA-ELI_LILLY_AND_COMPANY-SA202307008635,ELI LILLY AND CO,"Rabia Khalid Alduraibi, Yazeed Mohammed Alrebdi, Yosef Fahad Altowayan.Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes.Medicine 2023;102(23):e34027.DOI:http://dx.doi.org/10.1097/MD.0000000000034027",45.0,YR,,M,Y,,,20230719,,HP,SA,SA,2023,Q3,Adult
227367441,22736744,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Oedema,,2023,Q3,1,I,20230101.0,20230718.0,20230721,20230721,EXP,,US-Osmotica_Pharmaceutical_US_LLC-POI0573202300168,OSMOTICA,"McGrane I. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992.",79.0,YR,E,F,Y,,,20230721,,PH,US,US,2023,Q3,Elderly
227367441,22736744,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Drug interaction,,2023,Q3,1,I,20230101.0,20230718.0,20230721,20230721,EXP,,US-Osmotica_Pharmaceutical_US_LLC-POI0573202300168,OSMOTICA,"McGrane I. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992.",79.0,YR,E,F,Y,,,20230721,,PH,US,US,2023,Q3,Elderly
227367441,22736744,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,20230101.0,20230718.0,20230721,20230721,EXP,,US-Osmotica_Pharmaceutical_US_LLC-POI0573202300168,OSMOTICA,"McGrane I. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992.",79.0,YR,E,F,Y,,,20230721,,PH,US,US,2023,Q3,Elderly
227367441,22736744,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q3,Oliguria,,2023,Q3,1,I,20230101.0,20230718.0,20230721,20230721,EXP,,US-Osmotica_Pharmaceutical_US_LLC-POI0573202300168,OSMOTICA,"McGrane I. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992.",79.0,YR,E,F,Y,,,20230721,,PH,US,US,2023,Q3,Elderly
227399082,22739908,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Abdominal pain,,2023,Q3,2,F,20230530.0,20230724.0,20230723,20230802,EXP,,FR-SANDOZ-SDZ2023FR003952,SANDOZ,,68.0,YR,,F,Y,65.0,KG,20230802,,CN,FR,FR,2023,Q3,Elderly
227399082,22739908,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Constipation,,2023,Q3,2,F,20230530.0,20230724.0,20230723,20230802,EXP,,FR-SANDOZ-SDZ2023FR003952,SANDOZ,,68.0,YR,,F,Y,65.0,KG,20230802,,CN,FR,FR,2023,Q3,Elderly
227399082,22739908,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Abdominal distension,,2023,Q3,2,F,20230530.0,20230724.0,20230723,20230802,EXP,,FR-SANDOZ-SDZ2023FR003952,SANDOZ,,68.0,YR,,F,Y,65.0,KG,20230802,,CN,FR,FR,2023,Q3,Elderly
227399082,22739908,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Vertigo,,2023,Q3,2,F,20230530.0,20230724.0,20230723,20230802,EXP,,FR-SANDOZ-SDZ2023FR003952,SANDOZ,,68.0,YR,,F,Y,65.0,KG,20230802,,CN,FR,FR,2023,Q3,Elderly
227399082,22739908,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Gastrooesophageal reflux disease,,2023,Q3,2,F,20230530.0,20230724.0,20230723,20230802,EXP,,FR-SANDOZ-SDZ2023FR003952,SANDOZ,,68.0,YR,,F,Y,65.0,KG,20230802,,CN,FR,FR,2023,Q3,Elderly
227399082,22739908,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Insomnia,,2023,Q3,2,F,20230530.0,20230724.0,20230723,20230802,EXP,,FR-SANDOZ-SDZ2023FR003952,SANDOZ,,68.0,YR,,F,Y,65.0,KG,20230802,,CN,FR,FR,2023,Q3,Elderly
227399082,22739908,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Fatigue,,2023,Q3,2,F,20230530.0,20230724.0,20230723,20230802,EXP,,FR-SANDOZ-SDZ2023FR003952,SANDOZ,,68.0,YR,,F,Y,65.0,KG,20230802,,CN,FR,FR,2023,Q3,Elderly
227399082,22739908,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Malaise,,2023,Q3,2,F,20230530.0,20230724.0,20230723,20230802,EXP,,FR-SANDOZ-SDZ2023FR003952,SANDOZ,,68.0,YR,,F,Y,65.0,KG,20230802,,CN,FR,FR,2023,Q3,Elderly
227449811,22744981,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Chest pain,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,DE-SANDOZ-SDZ2023DE004609,SANDOZ,,47.0,YR,,M,Y,,,20230725,,HP,DE,DE,2023,Q3,Adult
227449811,22744981,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,DE-SANDOZ-SDZ2023DE004609,SANDOZ,,47.0,YR,,M,Y,,,20230725,,HP,DE,DE,2023,Q3,Adult
227449811,22744981,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2023,Q3,Syncope,,2023,Q3,1,I,,20230712.0,20230725,20230725,EXP,,DE-SANDOZ-SDZ2023DE004609,SANDOZ,,47.0,YR,,M,Y,,,20230725,,HP,DE,DE,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Bone disorder,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Foot fracture,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Condition aggravated,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Necrotising soft tissue infection,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Pseudomonas infection,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Skin hypertrophy,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Gangrene,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Sensory disturbance,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227529771,22752977,10,C,dulaglutide 4.5mg weekly,,2,,,,,,,,,,,,,,2023,Q3,Finger amputation,,2023,Q3,1,I,20230507.0,,20230726,20230726,DIR,668128,,FDA-CTU,,51.0,YR,,M,N,156.0,KG,20230726,N,PH,US,,2023,Q3,Adult
227638241,22763824,13,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Dose Description : 1DF,,,,U,Asked But Unknown,,,,,Unknown,,2023,Q3,Photosensitivity reaction,,2023,Q3,1,I,20220711.0,20230714.0,20230730,20230730,EXP,,FR-CHATTEMPRD-2022SA330407,CHATTEM,,75.0,YR,E,M,Y,74.0,KG,20230730,,PH,FR,FR,2023,Q3,Elderly
227712412,22771241,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,1.5,MG,,,,,,1.5,MG,,/WK,2023,Q3,Gastrooesophageal reflux disease,,2023,Q3,2,F,20230530.0,20230724.0,20230801,20230911,EXP,,FR-AstraZeneca-2023A167856,ASTRAZENECA,,68.0,YR,,F,Y,65.0,KG,20230911,,MD,FR,,2023,Q3,Elderly
227712412,22771241,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,1.5,MG,,,,,,1.5,MG,,/WK,2023,Q3,Vertigo,,2023,Q3,2,F,20230530.0,20230724.0,20230801,20230911,EXP,,FR-AstraZeneca-2023A167856,ASTRAZENECA,,68.0,YR,,F,Y,65.0,KG,20230911,,MD,FR,,2023,Q3,Elderly
227712412,22771241,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,1.5,MG,,,,,,1.5,MG,,/WK,2023,Q3,Abdominal distension,,2023,Q3,2,F,20230530.0,20230724.0,20230801,20230911,EXP,,FR-AstraZeneca-2023A167856,ASTRAZENECA,,68.0,YR,,F,Y,65.0,KG,20230911,,MD,FR,,2023,Q3,Elderly
227712412,22771241,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,1.5,MG,,,,,,1.5,MG,,/WK,2023,Q3,Malaise,,2023,Q3,2,F,20230530.0,20230724.0,20230801,20230911,EXP,,FR-AstraZeneca-2023A167856,ASTRAZENECA,,68.0,YR,,F,Y,65.0,KG,20230911,,MD,FR,,2023,Q3,Elderly
227712412,22771241,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,1.5,MG,,,,,,1.5,MG,,/WK,2023,Q3,Fatigue,,2023,Q3,2,F,20230530.0,20230724.0,20230801,20230911,EXP,,FR-AstraZeneca-2023A167856,ASTRAZENECA,,68.0,YR,,F,Y,65.0,KG,20230911,,MD,FR,,2023,Q3,Elderly
227712412,22771241,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,1.5,MG,,,,,,1.5,MG,,/WK,2023,Q3,Abdominal pain,,2023,Q3,2,F,20230530.0,20230724.0,20230801,20230911,EXP,,FR-AstraZeneca-2023A167856,ASTRAZENECA,,68.0,YR,,F,Y,65.0,KG,20230911,,MD,FR,,2023,Q3,Elderly
227712412,22771241,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,1.5,MG,,,,,,1.5,MG,,/WK,2023,Q3,Constipation,,2023,Q3,2,F,20230530.0,20230724.0,20230801,20230911,EXP,,FR-AstraZeneca-2023A167856,ASTRAZENECA,,68.0,YR,,F,Y,65.0,KG,20230911,,MD,FR,,2023,Q3,Elderly
227712412,22771241,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,1.5,MG,,,,,,1.5,MG,,/WK,2023,Q3,Insomnia,,2023,Q3,2,F,20230530.0,20230724.0,20230801,20230911,EXP,,FR-AstraZeneca-2023A167856,ASTRAZENECA,,68.0,YR,,F,Y,65.0,KG,20230911,,MD,FR,,2023,Q3,Elderly
227777841,22777784,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Other,"0.75 mg/0.5 mL, subcutaneous pen injector,",,,,,,,,,,Unknown,/WK,2023,Q3,Partial seizures,,2023,Q3,1,I,20220314.0,20230726.0,20230802,20230802,EXP,,US-BIOGEN-2023BI01218703,BIOGEN,,39.0,YR,,F,Y,97.32,KG,20230802,,HP,US,US,2023,Q3,Adult
227927751,22792775,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2023,Q3,Fatigue,,2023,Q3,1,I,20230530.0,20230726.0,20230807,20230807,EXP,FR-AFSSAPS-BS2023000519,FR-Accord-371214,ACCORD,,68.0,YR,E,F,Y,65.0,KG,20230807,,CN,FR,FR,2023,Q3,Elderly
227927751,22792775,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2023,Q3,Vertigo,,2023,Q3,1,I,20230530.0,20230726.0,20230807,20230807,EXP,FR-AFSSAPS-BS2023000519,FR-Accord-371214,ACCORD,,68.0,YR,E,F,Y,65.0,KG,20230807,,CN,FR,FR,2023,Q3,Elderly
227927751,22792775,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2023,Q3,Gastrooesophageal reflux disease,,2023,Q3,1,I,20230530.0,20230726.0,20230807,20230807,EXP,FR-AFSSAPS-BS2023000519,FR-Accord-371214,ACCORD,,68.0,YR,E,F,Y,65.0,KG,20230807,,CN,FR,FR,2023,Q3,Elderly
227927751,22792775,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2023,Q3,Constipation,,2023,Q3,1,I,20230530.0,20230726.0,20230807,20230807,EXP,FR-AFSSAPS-BS2023000519,FR-Accord-371214,ACCORD,,68.0,YR,E,F,Y,65.0,KG,20230807,,CN,FR,FR,2023,Q3,Elderly
227927751,22792775,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2023,Q3,Abdominal pain,,2023,Q3,1,I,20230530.0,20230726.0,20230807,20230807,EXP,FR-AFSSAPS-BS2023000519,FR-Accord-371214,ACCORD,,68.0,YR,E,F,Y,65.0,KG,20230807,,CN,FR,FR,2023,Q3,Elderly
227927751,22792775,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2023,Q3,Malaise,,2023,Q3,1,I,20230530.0,20230726.0,20230807,20230807,EXP,FR-AFSSAPS-BS2023000519,FR-Accord-371214,ACCORD,,68.0,YR,E,F,Y,65.0,KG,20230807,,CN,FR,FR,2023,Q3,Elderly
227927751,22792775,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2023,Q3,Insomnia,,2023,Q3,1,I,20230530.0,20230726.0,20230807,20230807,EXP,FR-AFSSAPS-BS2023000519,FR-Accord-371214,ACCORD,,68.0,YR,E,F,Y,65.0,KG,20230807,,CN,FR,FR,2023,Q3,Elderly
227927751,22792775,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2023,Q3,Abdominal distension,,2023,Q3,1,I,20230530.0,20230726.0,20230807,20230807,EXP,FR-AFSSAPS-BS2023000519,FR-Accord-371214,ACCORD,,68.0,YR,E,F,Y,65.0,KG,20230807,,CN,FR,FR,2023,Q3,Elderly
227999483,22799948,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,,,,1.5,MG,,/WK,2023,Q3,Syncope,,2023,Q3,3,F,,20230810.0,20230808,20230816,EXP,,DE-AstraZeneca-2023A177909,ASTRAZENECA,,47.0,YR,,M,Y,,,20230816,,MD,DE,,2023,Q3,Adult
227999483,22799948,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,,,,1.5,MG,,/WK,2023,Q3,Chest pain,,2023,Q3,3,F,,20230810.0,20230808,20230816,EXP,,DE-AstraZeneca-2023A177909,ASTRAZENECA,,47.0,YR,,M,Y,,,20230816,,MD,DE,,2023,Q3,Adult
227999483,22799948,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,,,,1.5,MG,,/WK,2023,Q3,Dyspnoea,,2023,Q3,3,F,,20230810.0,20230808,20230816,EXP,,DE-AstraZeneca-2023A177909,ASTRAZENECA,,47.0,YR,,M,Y,,,20230816,,MD,DE,,2023,Q3,Adult
227999491,22799949,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Weekly",,,,,Unk,,,0.75,MG,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,1,I,,20230726.0,20230808,20230808,EXP,,JP-LAURUS LABS LIMITED-2023LAU000064,LAURUS LABS LIMITED,"Yamagishi H, Hoshino S, Hirano A, Oshima A, Imai T.. Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes.. Cureus. 2023;15(6)",74.0,YR,,F,Y,41.4,KG,20230807,,HP,JP,JP,2023,Q3,Elderly
228001661,22800166,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,,/WK,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230802.0,20230808,20230808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202308001715,ELI LILLY AND CO,,47.0,YR,,M,Y,,,20230808,,CN,CH,DE,2023,Q3,Adult
228001661,22800166,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,,/WK,2023,Q3,Chest pain,,2023,Q3,1,I,,20230802.0,20230808,20230808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202308001715,ELI LILLY AND CO,,47.0,YR,,M,Y,,,20230808,,CN,CH,DE,2023,Q3,Adult
228001661,22800166,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,,/WK,2023,Q3,Syncope,,2023,Q3,1,I,,20230802.0,20230808,20230808,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202308001715,ELI LILLY AND CO,,47.0,YR,,M,Y,,,20230808,,CN,CH,DE,2023,Q3,Adult
228054181,22805418,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Weekly",,,,,UNK,,,0.75,MG,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,1,I,,20230728.0,20230809,20230809,EXP,,JP-NOVAST LABORATORIES INC.-2023NOV000285,NOVAST,"Yamagishi H, Hoshino S, Hirano A, Oshima A, Imai T.. Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes.. Cureus. 2023;15(6)",74.0,YR,,F,Y,41.4,KG,20230809,,HP,JP,JP,2023,Q3,Elderly
228057591,22805759,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,1.5,MG,,/WK,2023,Q3,Chest pain,,2023,Q3,1,I,,20230805.0,20230809,20230809,EXP,,DE-BAUSCH-BL-2023-011986,BAUSCH AND LOMB,,47.0,YR,,M,Y,,,20230809,,HP,DE,DE,2023,Q3,Adult
228057591,22805759,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,1.5,MG,,/WK,2023,Q3,Syncope,,2023,Q3,1,I,,20230805.0,20230809,20230809,EXP,,DE-BAUSCH-BL-2023-011986,BAUSCH AND LOMB,,47.0,YR,,M,Y,,,20230809,,HP,DE,DE,2023,Q3,Adult
228057591,22805759,7,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,1.5,MG,,/WK,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230805.0,20230809,20230809,EXP,,DE-BAUSCH-BL-2023-011986,BAUSCH AND LOMB,,47.0,YR,,M,Y,,,20230809,,HP,DE,DE,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Cholelithiasis,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Abdominal pain,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Liver injury,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Hepatic enzyme abnormal,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Drug intolerance,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Abdominal discomfort,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Liver function test abnormal,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Pruritus,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228140561,22814056,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"(0.5 ml), Solution for injection in pre-filled pen",0.21428571,MG,,,,,148950085.0,1.5,MG,,/WK,2023,Q3,Jaundice,,2023,Q3,1,I,20230213.0,20230802.0,20230811,20230811,EXP,GB-MHRA-ADR 28077363,GB-Accord-372426,ACCORD,,44.0,YR,A,F,Y,80.2,KG,20230811,,MD,GB,GB,2023,Q3,Adult
228180011,22818001,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,weekly,,,U,,,,,0.75,MG,,,2023,Q3,Drug interaction,,2023,Q3,1,I,,20230730.0,20230814,20230814,EXP,,JP-Indicus Pharma-000967,INDICUS,"Yamagishi H, Hoshino S, Hirano A, Oshima A, Imai T. Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes. Cureus. 2023 Jun 20;15(6):e40702.",74.0,YR,E,F,Y,41.4,KG,20230812,,HP,JP,JP,2023,Q3,Elderly
228180011,22818001,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,weekly,,,U,,,,,0.75,MG,,,2023,Q3,Diabetic ketoacidosis,,2023,Q3,1,I,,20230730.0,20230814,20230814,EXP,,JP-Indicus Pharma-000967,INDICUS,"Yamagishi H, Hoshino S, Hirano A, Oshima A, Imai T. Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes. Cureus. 2023 Jun 20;15(6):e40702.",74.0,YR,E,F,Y,41.4,KG,20230812,,HP,JP,JP,2023,Q3,Elderly
228180011,22818001,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,weekly,,,U,,,,,0.75,MG,,,2023,Q3,Nausea,,2023,Q3,1,I,,20230730.0,20230814,20230814,EXP,,JP-Indicus Pharma-000967,INDICUS,"Yamagishi H, Hoshino S, Hirano A, Oshima A, Imai T. Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes. Cureus. 2023 Jun 20;15(6):e40702.",74.0,YR,E,F,Y,41.4,KG,20230812,,HP,JP,JP,2023,Q3,Elderly
228200881,22820088,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Renal injury,,2023,Q3,1,I,,20230808.0,20230814,20230814,EXP,,US-PFIZER INC-PV202300137275,PFIZER,"Rauser, M. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230814,,PH,US,US,2023,Q3,Elderly
228200881,22820088,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Drug interaction,,2023,Q3,1,I,,20230808.0,20230814,20230814,EXP,,US-PFIZER INC-PV202300137275,PFIZER,"Rauser, M. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230814,,PH,US,US,2023,Q3,Elderly
228200881,22820088,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q3,Cardiac failure congestive,,2023,Q3,1,I,,20230808.0,20230814,20230814,EXP,,US-PFIZER INC-PV202300137275,PFIZER,"Rauser, M. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230814,,PH,US,US,2023,Q3,Elderly
228267331,22826733,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,U,,,,,1.5,MG,,/WK,2023,Q3,Chest pain,,2023,Q3,1,I,,20230808.0,20230816,20230816,EXP,DE-EMA-2023802-AUTODUP-1691003199410,DE-ORGANON-O2308DEU000817,ORGANON,,47.0,YR,,M,Y,,,20230816,,HP,DE,DE,2023,Q3,Adult
228267331,22826733,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,U,,,,,1.5,MG,,/WK,2023,Q3,Syncope,,2023,Q3,1,I,,20230808.0,20230816,20230816,EXP,DE-EMA-2023802-AUTODUP-1691003199410,DE-ORGANON-O2308DEU000817,ORGANON,,47.0,YR,,M,Y,,,20230816,,HP,DE,DE,2023,Q3,Adult
228267331,22826733,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,U,,,,,1.5,MG,,/WK,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230808.0,20230816,20230816,EXP,DE-EMA-2023802-AUTODUP-1691003199410,DE-ORGANON-O2308DEU000817,ORGANON,,47.0,YR,,M,Y,,,20230816,,HP,DE,DE,2023,Q3,Adult
228278561,22827856,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230802.0,20230816,20230816,EXP,,DE-AUROBINDO-AUR-APL-2023-052531,AUROBINDO,,47.0,YR,,M,Y,,,20230816,,HP,DE,DE,2023,Q3,Adult
228278561,22827856,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q3,Chest pain,,2023,Q3,1,I,,20230802.0,20230816,20230816,EXP,,DE-AUROBINDO-AUR-APL-2023-052531,AUROBINDO,,47.0,YR,,M,Y,,,20230816,,HP,DE,DE,2023,Q3,Adult
228278561,22827856,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Every Week",,,U,,,,,1.5,MG,,/WK,2023,Q3,Syncope,,2023,Q3,1,I,,20230802.0,20230816,20230816,EXP,,DE-AUROBINDO-AUR-APL-2023-052531,AUROBINDO,,47.0,YR,,M,Y,,,20230816,,HP,DE,DE,2023,Q3,Adult
228321881,22832188,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,U,,,,,1.5,MG,UNK,,2023,Q3,Chest pain,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,DE-SANDOZ-SDZ2023DE004609,DE-TORRENT-00025164,TORRENT,,47.0,YR,A,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228321881,22832188,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,U,,,,,1.5,MG,UNK,,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,DE-SANDOZ-SDZ2023DE004609,DE-TORRENT-00025164,TORRENT,,47.0,YR,A,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228321881,22832188,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,U,,,,,1.5,MG,UNK,,2023,Q3,Syncope,,2023,Q3,1,I,,20230807.0,20230817,20230817,EXP,DE-SANDOZ-SDZ2023DE004609,DE-TORRENT-00025164,TORRENT,,47.0,YR,A,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228340171,22834017,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg WEEK,,,U,N,,,,,,,,2023,Q3,Chest pain,,2023,Q3,1,I,,20230814.0,20230817,20230817,EXP,,DE-ANIPHARMA-2023-DE-000141,ANI,,47.0,YR,,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228340171,22834017,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg WEEK,,,U,N,,,,,,,,2023,Q3,Syncope,,2023,Q3,1,I,,20230814.0,20230817,20230817,EXP,,DE-ANIPHARMA-2023-DE-000141,ANI,,47.0,YR,,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228340171,22834017,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg WEEK,,,U,N,,,,,,,,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230814.0,20230817,20230817,EXP,,DE-ANIPHARMA-2023-DE-000141,ANI,,47.0,YR,,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228345001,22834500,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q3,Hepatic enzyme increased,,2023,Q3,1,I,20230601.0,20230807.0,20230817,20230817,EXP,,DE-Calliditas-2023CAL00991,CALLIDITAS THERAPEUTICS,,55.0,YR,A,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228345001,22834500,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q3,Gamma-glutamyltransferase increased,,2023,Q3,1,I,20230601.0,20230807.0,20230817,20230817,EXP,,DE-Calliditas-2023CAL00991,CALLIDITAS THERAPEUTICS,,55.0,YR,A,M,Y,,,20230817,,HP,DE,DE,2023,Q3,Adult
228430421,22843042,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q3,Drug interaction,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q3,Cardiac failure congestive,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q3,Oliguria,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2023,Q3,Oedema,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (restarted dose),,,,,Unknown,,,,,,,2023,Q3,Drug interaction,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (restarted dose),,,,,Unknown,,,,,,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (restarted dose),,,,,Unknown,,,,,,,2023,Q3,Cardiac failure congestive,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (restarted dose),,,,,Unknown,,,,,,,2023,Q3,Oliguria,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228430421,22843042,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (restarted dose),,,,,Unknown,,,,,,,2023,Q3,Oedema,,2023,Q3,1,I,,20230807.0,20230821,20230821,EXP,,US-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-09228,ALKEM,"Rauser MS, McGrane IR. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report. Annals of Pharmacotherapy. 2023;57(8):991-992",79.0,YR,,F,Y,,,20230821,,HP,US,US,2023,Q3,Elderly
228538421,22853842,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Unknown,/WK,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230816.0,20230823,20230823,EXP,,DE-MYLANLABS-2023M1087248,MYLAN,,47.0,YR,,M,Y,,,20230823,,HP,DE,DE,2023,Q3,Adult
228538421,22853842,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Unknown,/WK,2023,Q3,Syncope,,2023,Q3,1,I,,20230816.0,20230823,20230823,EXP,,DE-MYLANLABS-2023M1087248,MYLAN,,47.0,YR,,M,Y,,,20230823,,HP,DE,DE,2023,Q3,Adult
228538421,22853842,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,Unknown,/WK,2023,Q3,Chest pain,,2023,Q3,1,I,,20230816.0,20230823,20230823,EXP,,DE-MYLANLABS-2023M1087248,MYLAN,,47.0,YR,,M,Y,,,20230823,,HP,DE,DE,2023,Q3,Adult
228564962,22856496,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg once a week,,,,,,,,0.75,MG,,/WK,2023,Q3,Gastrointestinal disorder,,2023,Q3,2,F,,20230825.0,20230823,20230904,EXP,,US-TEVA-2023-US-2918650,TEVA,,68.0,YR,E,F,Y,77.27,KG,20230904,,HP,US,US,2023,Q3,Elderly
228564962,22856496,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg once a week,,,,,,,,0.75,MG,,/WK,2023,Q3,Hyperglycaemia,,2023,Q3,2,F,,20230825.0,20230823,20230904,EXP,,US-TEVA-2023-US-2918650,TEVA,,68.0,YR,E,F,Y,77.27,KG,20230904,,HP,US,US,2023,Q3,Elderly
228608441,22860844,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,U,,,,,,,,2023,Q3,Product use in unapproved indication,,2023,Q3,1,I,20221210.0,20230809.0,20230824,20230824,EXP,,"US-Innogenix, LLC-2145209",INNOGENIX,N/AP,47.0,YR,,M,Y,96.7,KG,20230824,,MD,US,US,2023,Q3,Adult
228608441,22860844,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,U,,,,,,,,2023,Q3,Orthostatic hypotension,,2023,Q3,1,I,20221210.0,20230809.0,20230824,20230824,EXP,,"US-Innogenix, LLC-2145209",INNOGENIX,N/AP,47.0,YR,,M,Y,96.7,KG,20230824,,MD,US,US,2023,Q3,Adult
228674481,22867448,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,UNKNOWN,,,1.5,MG,,,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230816.0,20230825,20230825,EXP,,DE-TEVA-2023-DE-2919331,TEVA,,47.0,YR,A,M,Y,,,20230825,,HP,DE,DE,2023,Q3,Adult
228674481,22867448,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,UNKNOWN,,,1.5,MG,,,2023,Q3,Syncope,,2023,Q3,1,I,,20230816.0,20230825,20230825,EXP,,DE-TEVA-2023-DE-2919331,TEVA,,47.0,YR,A,M,Y,,,20230825,,HP,DE,DE,2023,Q3,Adult
228674481,22867448,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,UNKNOWN,,,1.5,MG,,,2023,Q3,Chest pain,,2023,Q3,1,I,,20230816.0,20230825,20230825,EXP,,DE-TEVA-2023-DE-2919331,TEVA,,47.0,YR,A,M,Y,,,20230825,,HP,DE,DE,2023,Q3,Adult
229147831,22914783,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,,2023,Q3,Gastrointestinal disorder,,2023,Q3,1,I,20210101.0,20230726.0,20230907,20230907,EXP,,US-drreddys-SPO/USA/23/0173473,DR REDDYS,"Goldman J, Sangave N. Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit. Clin Diabetes. 2023;41(2):322-6. doi:10.2337/ cd22-0049.",68.0,YR,E,F,Y,77.27,KG,20230907,,PH,US,US,2023,Q3,Elderly
229181431,22918143,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Weekly",,,,,,,,0.75,MG,,,2023,Q3,Condition aggravated,,2023,Q3,1,I,,20230823.0,20230907,20230907,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-407176,RANBAXY,"Goldman JD, Sangave N. Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit. Clin Diabet. 2023;SPR; 41(2):322-326",68.0,YR,,F,Y,77.27,KG,20230907,,HP,US,US,2023,Q3,Elderly
229181431,22918143,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Weekly",,,,,,,,0.75,MG,,,2023,Q3,Gastrointestinal disorder,,2023,Q3,1,I,,20230823.0,20230907,20230907,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-407176,RANBAXY,"Goldman JD, Sangave N. Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit. Clin Diabet. 2023;SPR; 41(2):322-326",68.0,YR,,F,Y,77.27,KG,20230907,,HP,US,US,2023,Q3,Elderly
229274882,22927488,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q3,Acute myocardial infarction,,2023,Q3,2,F,20230810.0,20230912.0,20230911,20230914,EXP,,NVSC2023PT194205,NOVARTIS,,70.0,YR,,F,Y,66.0,KG,20230914,,MD,PT,PT,2023,Q3,Elderly
229399621,22939962,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,,,,1.5,MG,,,2023,Q3,Syncope,,2023,Q3,1,I,,20230901.0,20230913,20230913,EXP,DE-EMA-2023802-AUTODUP-1691003199410,DE-Accord-378029,ACCORD,,47.0,YR,,M,Y,,,20230913,,HP,DE,DE,2023,Q3,Adult
229399621,22939962,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,,,,1.5,MG,,,2023,Q3,Dyspnoea,,2023,Q3,1,I,,20230901.0,20230913,20230913,EXP,DE-EMA-2023802-AUTODUP-1691003199410,DE-Accord-378029,ACCORD,,47.0,YR,,M,Y,,,20230913,,HP,DE,DE,2023,Q3,Adult
229399621,22939962,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,,,,,1.5,MG,,,2023,Q3,Chest pain,,2023,Q3,1,I,,20230901.0,20230913,20230913,EXP,DE-EMA-2023802-AUTODUP-1691003199410,DE-Accord-378029,ACCORD,,47.0,YR,,M,Y,,,20230913,,HP,DE,DE,2023,Q3,Adult
229421081,22942108,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2023,Q3,Intentional product misuse,,2023,Q3,1,I,,20230209.0,20230914,20230914,PER,,US-STRIDES ARCOLAB LIMITED-2023SP002285,STRIDES,"Rauser MS, McGrane IR.. A CYP3A4 Drug-Drug Interaction Between Nirmatrelvir/Ritonavir and Nifedipine Leading to Edema, Oliguria, and Acute Kidney Injury: A Case Report.. Ann-Pharmacother. 2022;1-2",79.0,YR,,F,Y,,,20230914,,PH,US,US,2023,Q3,Elderly
229556841,22955684,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,Y,,Not Available,,,,,,,2023,Q3,Malaise,,2023,Q3,1,I,20230101.0,20230913.0,20230918,20230918,EXP,,GB-ABBVIE-5409089,ABBVIE,,59.0,YR,,M,Y,,,20230918,,CN,GB,GB,2023,Q3,Adult
229556841,22955684,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,Y,,Not Available,,,,,,,2023,Q3,Diarrhoea,,2023,Q3,1,I,20230101.0,20230913.0,20230918,20230918,EXP,,GB-ABBVIE-5409089,ABBVIE,,59.0,YR,,M,Y,,,20230918,,CN,GB,GB,2023,Q3,Adult
229556841,22955684,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,Y,,Not Available,,,,,,,2023,Q3,Diabetes mellitus,,2023,Q3,1,I,20230101.0,20230913.0,20230918,20230918,EXP,,GB-ABBVIE-5409089,ABBVIE,,59.0,YR,,M,Y,,,20230918,,CN,GB,GB,2023,Q3,Adult
229686751,22968675,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 dosage form,,,,,,,,,,Unknown,,2023,Q3,Removal of internal fixation,,2023,Q3,1,I,20141001.0,20230913.0,20230921,20230921,EXP,,JP-JNJFOC-20230947154,JOHNSON AND JOHNSON,,85.0,YR,E,F,Y,,,20230922,,MD,JP,JP,2023,Q3,Elderly
229686751,22968675,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 dosage form,,,,,,,,,,Unknown,,2023,Q3,Diarrhoea,,2023,Q3,1,I,20141001.0,20230913.0,20230921,20230921,EXP,,JP-JNJFOC-20230947154,JOHNSON AND JOHNSON,,85.0,YR,E,F,Y,,,20230922,,MD,JP,JP,2023,Q3,Elderly
229686751,22968675,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 dosage form,,,,,,,,,,Unknown,,2023,Q3,Coronary angioplasty,,2023,Q3,1,I,20141001.0,20230913.0,20230921,20230921,EXP,,JP-JNJFOC-20230947154,JOHNSON AND JOHNSON,,85.0,YR,E,F,Y,,,20230922,,MD,JP,JP,2023,Q3,Elderly
229686751,22968675,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 dosage form,,,,,,,,,,Unknown,,2023,Q3,Pneumonia,,2023,Q3,1,I,20141001.0,20230913.0,20230921,20230921,EXP,,JP-JNJFOC-20230947154,JOHNSON AND JOHNSON,,85.0,YR,E,F,Y,,,20230922,,MD,JP,JP,2023,Q3,Elderly
229686751,22968675,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 dosage form,,,,,,,,,,Unknown,,2023,Q3,Dehydration,,2023,Q3,1,I,20141001.0,20230913.0,20230921,20230921,EXP,,JP-JNJFOC-20230947154,JOHNSON AND JOHNSON,,85.0,YR,E,F,Y,,,20230922,,MD,JP,JP,2023,Q3,Elderly
229770621,22977062,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"strength: 3 mg, solution for injection in pre-filled pen",,,Y,,,,,,,Solution for injection,,2023,Q3,Acute kidney injury,,2023,Q3,1,I,,20230913.0,20230925,20230925,EXP,FR-AFSSAPS-AN2023001032,FR-Accord-379847,ACCORD,,88.0,YR,E,F,Y,82.5,KG,20230925,,PH,FR,FR,2023,Q3,Elderly
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Glycosylated haemoglobin increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Intervertebral disc protrusion,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Blood glucose increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Renal impairment,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Weight increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Blood glucose abnormal,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Coronary artery disease,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Osteoarthritis,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q3,Intervertebral disc disorder,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Glycosylated haemoglobin increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Intervertebral disc protrusion,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Blood glucose increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Renal impairment,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Weight increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Blood glucose abnormal,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Coronary artery disease,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Osteoarthritis,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q3,Intervertebral disc disorder,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Glycosylated haemoglobin increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Intervertebral disc protrusion,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Vulvovaginal mycotic infection,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Blood glucose increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Renal impairment,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Weight increased,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Blood glucose abnormal,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Coronary artery disease,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Osteoarthritis,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230041061,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q3,Intervertebral disc disorder,,2023,Q3,1,I,20181001.0,20230919.0,20230928,20230928,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20230928,,MD,DE,DE,2023,Q3,Adult
230114411,23011441,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2023,Q3,Drug interaction,,2023,Q3,1,I,,20230922.0,20230929,20230929,EXP,,US-AstraZeneca-2023A217179,ASTRAZENECA,"Kuppanda, N; Cotarelo, A.A.; Liu, D; Nassef, Y. A Case of Euglycemic DKA Associated with an SGLT2 Inhibitor and Exogenous Hormone Use. 12th Mediterranean Emergency Medicine Congress (MEMC) - American Academy of Emergency Medicine (AAEM) 2023;",35.0,YR,,F,Y,,,20230929,,MD,US,,2023,Q3,Adult
230114411,23011441,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2023,Q3,Euglycaemic diabetic ketoacidosis,,2023,Q3,1,I,,20230922.0,20230929,20230929,EXP,,US-AstraZeneca-2023A217179,ASTRAZENECA,"Kuppanda, N; Cotarelo, A.A.; Liu, D; Nassef, Y. A Case of Euglycemic DKA Associated with an SGLT2 Inhibitor and Exogenous Hormone Use. 12th Mediterranean Emergency Medicine Congress (MEMC) - American Academy of Emergency Medicine (AAEM) 2023;",35.0,YR,,F,Y,,,20230929,,MD,US,,2023,Q3,Adult
161214732,16121473,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Ophthalmic,,,,U,U,,,,,,,,2023,Q4,Atrioventricular block first degree,,2023,Q4,2,F,20180223.0,20231207.0,20190327,20231219,EXP,,FR-AUROBINDO-AUR-APL-2019-014604,AUROBINDO,,40.0,YR,,F,Y,97.0,KG,20231219,,MD,FR,FR,2023,Q4,Adult
161214732,16121473,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Ophthalmic,,,,U,U,,,,,,,,2023,Q4,Hypovolaemic shock,,2023,Q4,2,F,20180223.0,20231207.0,20190327,20231219,EXP,,FR-AUROBINDO-AUR-APL-2019-014604,AUROBINDO,,40.0,YR,,F,Y,97.0,KG,20231219,,MD,FR,FR,2023,Q4,Adult
161214732,16121473,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Ophthalmic,,,,U,U,,,,,,,,2023,Q4,Suicide attempt,,2023,Q4,2,F,20180223.0,20231207.0,20190327,20231219,EXP,,FR-AUROBINDO-AUR-APL-2019-014604,AUROBINDO,,40.0,YR,,F,Y,97.0,KG,20231219,,MD,FR,FR,2023,Q4,Adult
161214732,16121473,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Ophthalmic,,,,U,U,,,,,,,,2023,Q4,Coma,,2023,Q4,2,F,20180223.0,20231207.0,20190327,20231219,EXP,,FR-AUROBINDO-AUR-APL-2019-014604,AUROBINDO,,40.0,YR,,F,Y,97.0,KG,20231219,,MD,FR,FR,2023,Q4,Adult
161214732,16121473,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Ophthalmic,,,,U,U,,,,,,,,2023,Q4,Miosis,,2023,Q4,2,F,20180223.0,20231207.0,20190327,20231219,EXP,,FR-AUROBINDO-AUR-APL-2019-014604,AUROBINDO,,40.0,YR,,F,Y,97.0,KG,20231219,,MD,FR,FR,2023,Q4,Adult
161214732,16121473,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Ophthalmic,,,,U,U,,,,,,,,2023,Q4,Hypoxia,,2023,Q4,2,F,20180223.0,20231207.0,20190327,20231219,EXP,,FR-AUROBINDO-AUR-APL-2019-014604,AUROBINDO,,40.0,YR,,F,Y,97.0,KG,20231219,,MD,FR,FR,2023,Q4,Adult
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Fournier's gangrene,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Cellulitis,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Anal abscess,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Genital abscess,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Abscess limb,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Subcutaneous abscess,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Necrotising fasciitis,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Perirectal abscess,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
168745596,16874559,74,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Panic attack,,2023,Q4,6,F,20180601.0,20231010.0,20191001,20231018,EXP,,US-AstraZeneca-2019SF36586,ASTRAZENECA,,714.0,MON,,F,Y,,,20231018,,LW,US,,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Gastrointestinal haemorrhage,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Weight decreased,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Haemoglobin decreased,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,General physical health deterioration,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Atrial fibrillation,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Inflammation,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Hypercalcaemia,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Asthenia,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Cardiac disorder,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Localised oedema,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Melaena,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,COVID-19,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Blood pressure increased,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Myocardial infarction,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Chest wall haematoma,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Eye haemorrhage,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Pulmonary oedema,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Ocular hyperaemia,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Pulmonary congestion,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Lacrimation increased,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Oedema peripheral,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Gait disturbance,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Dyspnoea,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Pneumonia,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Fall,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Fluid retention,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Haemarthrosis,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Cough,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
1856126124,18561261,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,UNK,,2023,Q4,Coronary artery disease,,2023,Q4,24,F,20200510.0,20231002.0,20201130,20231010,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20231010,,HP,DE,DE,2023,Q4,Elderly
192612556,19261255,14,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg/week,,,U,,,,,,,,,2023,Q4,Altered state of consciousness,,2023,Q4,6,F,20201211.0,20231208.0,20210515,20231218,EXP,,JP-ABBVIE-21K-087-3906136-00,ABBVIE,,83.0,YR,,F,Y,72.0,KG,20231217,,MD,JP,JP,2023,Q4,Elderly
192612556,19261255,14,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg/week,,,U,,,,,,,,,2023,Q4,Death,,2023,Q4,6,F,20201211.0,20231208.0,20210515,20231218,EXP,,JP-ABBVIE-21K-087-3906136-00,ABBVIE,,83.0,YR,,F,Y,72.0,KG,20231217,,MD,JP,JP,2023,Q4,Elderly
192612556,19261255,14,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg/week,,,U,,,,,,,,,2023,Q4,Brain stem haemorrhage,,2023,Q4,6,F,20201211.0,20231208.0,20210515,20231218,EXP,,JP-ABBVIE-21K-087-3906136-00,ABBVIE,,83.0,YR,,F,Y,72.0,KG,20231217,,MD,JP,JP,2023,Q4,Elderly
192612556,19261255,14,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg/week,,,U,,,,,,,,,2023,Q4,Hypoglycaemia,,2023,Q4,6,F,20201211.0,20231208.0,20210515,20231218,EXP,,JP-ABBVIE-21K-087-3906136-00,ABBVIE,,83.0,YR,,F,Y,72.0,KG,20231217,,MD,JP,JP,2023,Q4,Elderly
192612556,19261255,14,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg/week,,,U,,,,,,,,,2023,Q4,Femur fracture,,2023,Q4,6,F,20201211.0,20231208.0,20210515,20231218,EXP,,JP-ABBVIE-21K-087-3906136-00,ABBVIE,,83.0,YR,,F,Y,72.0,KG,20231217,,MD,JP,JP,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Arthritis,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,COVID-19,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Depressed mood,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Body temperature decreased,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Balance disorder,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Pulmonary oedema,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Illness,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Nasopharyngitis,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Rash,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Oropharyngeal discomfort,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Back pain,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Arthralgia,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Onychalgia,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Seasonal allergy,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Skin discolouration,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Pain in extremity,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Dyspnoea,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Blood glucose increased,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Product dose omission issue,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Visual impairment,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Pharyngitis streptococcal,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Scab,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Blood potassium decreased,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Pneumonia,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
212521118,21252111,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1/week",,,,,,,,1.5,MG,,/WK,2023,Q4,Cough,,2023,Q4,8,F,20230201.0,20231208.0,20220825,20231215,EXP,,US-TAKEDA-2021TUS058454,TAKEDA,,72.0,YR,,F,Y,117.0,KG,20231215,,HP,US,US,2023,Q4,Elderly
2134907024,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q4,Cataract,,2023,Q4,24,F,20220912.0,20231116.0,20220919,20231121,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20231121,,MD,US,,2023,Q4,Adult
2134907024,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q4,Vitreous haemorrhage,,2023,Q4,24,F,20220912.0,20231116.0,20220919,20231121,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20231121,,MD,US,,2023,Q4,Adult
2134907024,21349070,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,/WK,2023,Q4,Rhegmatogenous retinal detachment,,2023,Q4,24,F,20220912.0,20231116.0,20220919,20231121,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20231121,,MD,US,,2023,Q4,Adult
214369327,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q4,Neutrophil count decreased,,2023,Q4,7,F,20220729.0,20230922.0,20221010,20231002,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20231002,,MD,US,US,2023,Q4,Elderly
214369327,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q4,Cytokine release syndrome,,2023,Q4,7,F,20220729.0,20230922.0,20221010,20231002,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20231002,,MD,US,US,2023,Q4,Elderly
214369327,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q4,Stomatitis,,2023,Q4,7,F,20220729.0,20230922.0,20221010,20231002,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20231002,,MD,US,US,2023,Q4,Elderly
214369327,21436932,31,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,7,F,20220729.0,20230922.0,20221010,20231002,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20231002,,MD,US,US,2023,Q4,Elderly
217377253,21737725,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Pulmonary oedema,,2023,Q4,3,F,,20230921.0,20221216,20231004,EXP,,CA-AUROBINDO-AUR-APL-2022-052021,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20231001,,HP,CA,CA,2023,Q4,Adult
217377253,21737725,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Metabolic acidosis,,2023,Q4,3,F,,20230921.0,20221216,20231004,EXP,,CA-AUROBINDO-AUR-APL-2022-052021,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20231001,,HP,CA,CA,2023,Q4,Adult
217377253,21737725,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Hyperglycaemia,,2023,Q4,3,F,,20230921.0,20221216,20231004,EXP,,CA-AUROBINDO-AUR-APL-2022-052021,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20231001,,HP,CA,CA,2023,Q4,Adult
221431303,22143130,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg,,,,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,3,F,,20231018.0,20230327,20231025,EXP,,JP-ABBVIE-4701815,ABBVIE,"Narita T, Okamoto T, Konishi M, et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.; T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.",65.0,YR,,F,Y,,,20231025,,MD,JP,JP,2023,Q4,Elderly
221431303,22143130,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg,,,,,,,,,,,,2023,Q4,Benign neoplasm of adrenal gland,,2023,Q4,3,F,,20231018.0,20230327,20231025,EXP,,JP-ABBVIE-4701815,ABBVIE,"Narita T, Okamoto T, Konishi M, et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.; T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.",65.0,YR,,F,Y,,,20231025,,MD,JP,JP,2023,Q4,Elderly
221431303,22143130,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg,,,,,,,,,,,,2023,Q4,Cushing's syndrome,,2023,Q4,3,F,,20231018.0,20230327,20231025,EXP,,JP-ABBVIE-4701815,ABBVIE,"Narita T, Okamoto T, Konishi M, et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.; T Narita ,T Okamoto ,M Konishi , et al.. 23 A case of diabetes mellitus with long-term history of rheumatoid arthritis that developed Cushing^s syndrome. The 249th Hokuriku Branch Meeting of the Japanese Society of Internal Medicine. 2023.",65.0,YR,,F,Y,,,20231025,,MD,JP,JP,2023,Q4,Elderly
222961522,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Headache,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Hyperglycaemia,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Metabolic acidosis,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Pulmonary oedema,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Headache,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Hyperglycaemia,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Metabolic acidosis,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
222961522,22296152,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Pulmonary oedema,,2023,Q4,2,F,,20231030.0,20230508,20231109,EXP,,CA-TEVA-2023-CA-2883460,TEVA,,64.0,YR,A,M,Y,90.0,KG,20231109,,HP,CA,CA,2023,Q4,Adult
223387082,22338708,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, 1/week",,,,,,,,0.75,MG,,/WK,2023,Q4,Drug ineffective,,2023,Q4,2,F,,20231023.0,20230518,20231026,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-388318,RANBAXY,"Noda K, Kato T, Nomura N, Sakai M, Kubota S, Hirose T, et al. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabet Int. 2022;13(4):693-697",50.0,YR,,F,Y,,,20231026,,HP,JP,JP,2023,Q4,Adult
227039785,22703978,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Acute myocardial infarction,,2023,Q4,5,F,20230525.0,20231018.0,20230714,20231019,EXP,,NVSC2023HR154220,NOVARTIS,,70.0,YR,,F,Y,71.5,KG,20231019,,MD,HR,HR,2023,Q4,Elderly
227410322,22741032,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg,,,U,,,,,1.5,MG,,,2023,Q4,Femur fracture,,2023,Q4,2,F,20230713.0,20231023.0,20230724,20231025,EXP,,AU-SA-2023SA216023,SANOFI AVENTIS,,75.0,YR,E,F,Y,,,20231025,,HP,AU,AU,2023,Q4,Elderly
229636843,22963684,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,3,F,20181115.0,20230928.0,20230921,20231008,EXP,,JP-ABBVIE-19K-087-2903218-00,ABBVIE,,77.0,YR,,M,Y,63.0,KG,20231008,,MD,JP,JP,2023,Q4,Elderly
229636843,22963684,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Dysphagia,,2023,Q4,3,F,20181115.0,20230928.0,20230921,20231008,EXP,,JP-ABBVIE-19K-087-2903218-00,ABBVIE,,77.0,YR,,M,Y,63.0,KG,20231008,,MD,JP,JP,2023,Q4,Elderly
229636843,22963684,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2023,Q4,Stoma site infection,,2023,Q4,3,F,20181115.0,20230928.0,20230921,20231008,EXP,,JP-ABBVIE-19K-087-2903218-00,ABBVIE,,77.0,YR,,M,Y,63.0,KG,20231008,,MD,JP,JP,2023,Q4,Elderly
229784722,22978472,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Portal hypertension,,2023,Q4,2,F,,20231003.0,20230925,20231006,EXP,,GR-MYLANLABS-2023M1099958,MYLAN,"Papageorgiou E, Panagiotouni M, Kavouri E, Vlachou S, Eleusiniotis I. Questionmark on the relationship of pioglitazone and autoimmunce hepatitis. 21st Panhellenic Hepatology Congress. 2023",57.0,YR,,F,Y,,,20231006,,MD,GR,GR,2023,Q4,Adult
229784722,22978472,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Portal fibrosis,,2023,Q4,2,F,,20231003.0,20230925,20231006,EXP,,GR-MYLANLABS-2023M1099958,MYLAN,"Papageorgiou E, Panagiotouni M, Kavouri E, Vlachou S, Eleusiniotis I. Questionmark on the relationship of pioglitazone and autoimmunce hepatitis. 21st Panhellenic Hepatology Congress. 2023",57.0,YR,,F,Y,,,20231006,,MD,GR,GR,2023,Q4,Adult
229784722,22978472,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Autoimmune hepatitis,,2023,Q4,2,F,,20231003.0,20230925,20231006,EXP,,GR-MYLANLABS-2023M1099958,MYLAN,"Papageorgiou E, Panagiotouni M, Kavouri E, Vlachou S, Eleusiniotis I. Questionmark on the relationship of pioglitazone and autoimmunce hepatitis. 21st Panhellenic Hepatology Congress. 2023",57.0,YR,,F,Y,,,20231006,,MD,GR,GR,2023,Q4,Adult
229784722,22978472,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Hypertransaminasaemia,,2023,Q4,2,F,,20231003.0,20230925,20231006,EXP,,GR-MYLANLABS-2023M1099958,MYLAN,"Papageorgiou E, Panagiotouni M, Kavouri E, Vlachou S, Eleusiniotis I. Questionmark on the relationship of pioglitazone and autoimmunce hepatitis. 21st Panhellenic Hepatology Congress. 2023",57.0,YR,,F,Y,,,20231006,,MD,GR,GR,2023,Q4,Adult
229784722,22978472,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Hepatosplenomegaly,,2023,Q4,2,F,,20231003.0,20230925,20231006,EXP,,GR-MYLANLABS-2023M1099958,MYLAN,"Papageorgiou E, Panagiotouni M, Kavouri E, Vlachou S, Eleusiniotis I. Questionmark on the relationship of pioglitazone and autoimmunce hepatitis. 21st Panhellenic Hepatology Congress. 2023",57.0,YR,,F,Y,,,20231006,,MD,GR,GR,2023,Q4,Adult
229784722,22978472,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Hepatic steatosis,,2023,Q4,2,F,,20231003.0,20230925,20231006,EXP,,GR-MYLANLABS-2023M1099958,MYLAN,"Papageorgiou E, Panagiotouni M, Kavouri E, Vlachou S, Eleusiniotis I. Questionmark on the relationship of pioglitazone and autoimmunce hepatitis. 21st Panhellenic Hepatology Congress. 2023",57.0,YR,,F,Y,,,20231006,,MD,GR,GR,2023,Q4,Adult
229784722,22978472,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Chronic hepatitis,,2023,Q4,2,F,,20231003.0,20230925,20231006,EXP,,GR-MYLANLABS-2023M1099958,MYLAN,"Papageorgiou E, Panagiotouni M, Kavouri E, Vlachou S, Eleusiniotis I. Questionmark on the relationship of pioglitazone and autoimmunce hepatitis. 21st Panhellenic Hepatology Congress. 2023",57.0,YR,,F,Y,,,20231006,,MD,GR,GR,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Weight increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Intervertebral disc protrusion,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Blood glucose increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Blood glucose abnormal,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Coronary artery disease,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Intervertebral disc disorder,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2023,Q4,Osteoarthritis,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Weight increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Intervertebral disc protrusion,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Blood glucose increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Blood glucose abnormal,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Coronary artery disease,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Intervertebral disc disorder,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,U,,,,125469.0,3.0,MG,,,2023,Q4,Osteoarthritis,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Weight increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Vulvovaginal mycotic infection,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Intervertebral disc protrusion,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Blood glucose increased,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Blood glucose abnormal,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Coronary artery disease,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Intervertebral disc disorder,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230041062,23004106,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, unknown",,,U,,,,125469.0,4.5,MG,,,2023,Q4,Osteoarthritis,,2023,Q4,2,F,20181001.0,20231218.0,20230928,20231221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202309010510,ELI LILLY AND CO,,57.0,YR,,F,Y,110.0,KG,20231221,,MD,DE,DE,2023,Q4,Adult
230297411,23029741,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,4.5 Milligram,,,,,,,,,,,,2023,Q4,Knee arthroplasty,,2023,Q4,1,I,20220401.0,20230929.0,20231004,20231004,EXP,,FR-ABBVIE-5433572,ABBVIE,,63.0,YR,,M,Y,,,20231004,,MD,FR,FR,2023,Q4,Adult
230297411,23029741,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,3 Milligram,,,,,,,,,,,,2023,Q4,Knee arthroplasty,,2023,Q4,1,I,20220401.0,20230929.0,20231004,20231004,EXP,,FR-ABBVIE-5433572,ABBVIE,,63.0,YR,,M,Y,,,20231004,,MD,FR,FR,2023,Q4,Adult
230297411,23029741,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,1.5 Milligram,,,,,,,,,,,,2023,Q4,Knee arthroplasty,,2023,Q4,1,I,20220401.0,20230929.0,20231004,20231004,EXP,,FR-ABBVIE-5433572,ABBVIE,,63.0,YR,,M,Y,,,20231004,,MD,FR,FR,2023,Q4,Adult
230396371,23039637,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,use as directed,,,U,,,,,,,,,2023,Q4,Abdominal discomfort,,2023,Q4,1,I,,20230405.0,20231006,20231006,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-404705,RANBAXY,,58.0,YR,,F,Y,72.0,KG,20231006,,MD,GB,GB,2023,Q4,Adult
230396371,23039637,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,use as directed,,,U,,,,,,,,,2023,Q4,Pruritus,,2023,Q4,1,I,,20230405.0,20231006,20231006,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-404705,RANBAXY,,58.0,YR,,F,Y,72.0,KG,20231006,,MD,GB,GB,2023,Q4,Adult
230521561,23052156,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q4,C-reactive protein increased,,2023,Q4,1,I,,20231010.0,20231010,20231010,EXP,,CA-SANDOZ INC.-NVSC2023CA042656,SANDOZ,,64.0,YR,,M,Y,89.0,KG,20231010,,HP,CA,CA,2023,Q4,Adult
230521561,23052156,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,,20231010.0,20231010,20231010,EXP,,CA-SANDOZ INC.-NVSC2023CA042656,SANDOZ,,64.0,YR,,M,Y,89.0,KG,20231010,,HP,CA,CA,2023,Q4,Adult
230521561,23052156,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q4,Metabolic acidosis,,2023,Q4,1,I,,20231010.0,20231010,20231010,EXP,,CA-SANDOZ INC.-NVSC2023CA042656,SANDOZ,,64.0,YR,,M,Y,89.0,KG,20231010,,HP,CA,CA,2023,Q4,Adult
230521561,23052156,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,,20231010.0,20231010,20231010,EXP,,CA-SANDOZ INC.-NVSC2023CA042656,SANDOZ,,64.0,YR,,M,Y,89.0,KG,20231010,,HP,CA,CA,2023,Q4,Adult
230521561,23052156,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q4,Hypotension,,2023,Q4,1,I,,20231010.0,20231010,20231010,EXP,,CA-SANDOZ INC.-NVSC2023CA042656,SANDOZ,,64.0,YR,,M,Y,89.0,KG,20231010,,HP,CA,CA,2023,Q4,Adult
230521561,23052156,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q4,Pulmonary oedema,,2023,Q4,1,I,,20231010.0,20231010,20231010,EXP,,CA-SANDOZ INC.-NVSC2023CA042656,SANDOZ,,64.0,YR,,M,Y,89.0,KG,20231010,,HP,CA,CA,2023,Q4,Adult
230521561,23052156,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2023,Q4,Headache,,2023,Q4,1,I,,20231010.0,20231010,20231010,EXP,,CA-SANDOZ INC.-NVSC2023CA042656,SANDOZ,,64.0,YR,,M,Y,89.0,KG,20231010,,HP,CA,CA,2023,Q4,Adult
230643821,23064382,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,OTHER QUANTITY : 4.5;?Frequency : Weekly;?,,,,,D521607D,,,4.5,MG,,QW,2023,Q4,Vomiting,,2023,Q4,1,I,20230126.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75273,,FDA-CTU,,55.0,YR,,M,N,101.0,KG,20230131,N,PH,US,,2023,Q4,Adult
230643821,23064382,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,OTHER QUANTITY : 4.5;?Frequency : Weekly;?,,,,,D521607D,,,4.5,MG,,QW,2023,Q4,Epigastric discomfort,,2023,Q4,1,I,20230126.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75273,,FDA-CTU,,55.0,YR,,M,N,101.0,KG,20230131,N,PH,US,,2023,Q4,Adult
230643821,23064382,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,OTHER QUANTITY : 4.5;?Frequency : Weekly;?,,,,,D521607D,,,4.5,MG,,QW,2023,Q4,Dyspepsia,,2023,Q4,1,I,20230126.0,,20231013,20231013,DIR,FDA-CDER-CTU-2023-75273,,FDA-CTU,,55.0,YR,,M,N,101.0,KG,20230131,N,PH,US,,2023,Q4,Adult
230645411,23064541,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Febrile neutropenia,,2023,Q4,1,I,,20231002.0,20231013,20231013,EXP,CA-MHPD-E2B_001048826,CA-Accord-383046,ACCORD,,76.0,YR,E,F,Y,94.0,KG,20231013,,HP,CA,CA,2023,Q4,Elderly
230645411,23064541,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Bacterial translocation,,2023,Q4,1,I,,20231002.0,20231013,20231013,EXP,CA-MHPD-E2B_001048826,CA-Accord-383046,ACCORD,,76.0,YR,E,F,Y,94.0,KG,20231013,,HP,CA,CA,2023,Q4,Elderly
230671751,23067175,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2023,Q4,Wound,,2023,Q4,1,I,,20231013.0,20231016,20231016,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266913",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,113.0,KG,20231016,,MD,CA,CA,2023,Q4,Adult
230733171,23073317,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,4.5,MG,,,2023,Q4,Dizziness,,2023,Q4,1,I,,20231010.0,20231017,20231017,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266082",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230733171,23073317,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,4.5,MG,,,2023,Q4,Hypotension,,2023,Q4,1,I,,20231010.0,20231017,20231017,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266082",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230733171,23073317,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,4.5,MG,,,2023,Q4,Tachycardia,,2023,Q4,1,I,,20231010.0,20231017,20231017,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266082",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230733171,23073317,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,4.5,MG,,,2023,Q4,Hypovolaemia,,2023,Q4,1,I,,20231010.0,20231017,20231017,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266082",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230733171,23073317,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,4.5,MG,,,2023,Q4,Blood creatinine increased,,2023,Q4,1,I,,20231010.0,20231017,20231017,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266082",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230733171,23073317,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,4.5,MG,,,2023,Q4,Blood urea decreased,,2023,Q4,1,I,,20231010.0,20231017,20231017,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266082",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230733171,23073317,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,4.5,MG,,,2023,Q4,Weight decreased,,2023,Q4,1,I,,20231010.0,20231017,20231017,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266082",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230733171,23073317,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,4.5,MG,,,2023,Q4,Blood potassium increased,,2023,Q4,1,I,,20231010.0,20231017,20231017,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-266082",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20231017,,MD,US,US,2023,Q4,Elderly
230825991,23082599,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, once weekly, started 6 weeks before conception",,,D,,Unknown,,,1.5,MG,,/WK,2023,Q4,Exposure during pregnancy,,2023,Q4,1,I,,20230926.0,20231019,20231019,EXP,,IT-ALKEM LABORATORIES LIMITED-US-ALKEM-2023-11143,ALKEM,"Burlina S, Dalfra MG, Caprino R, Lapolla A.. A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus. Acta Diabetologica. 2023;60:137-38",38.0,YR,,F,Y,,,20231019,,HP,IT,IT,2023,Q4,Adult
230851051,23085105,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Every other week;?,,,,,,,,0.75,MG,,QOW,2023,Q4,Urticaria,,2023,Q4,1,I,20220907.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76839,,FDA-CTU,,69.0,YR,,M,N,133.0,KG,20221119,N,PH,US,,2023,Q4,Elderly
230851051,23085105,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Every other week;?,,,,,,,,0.75,MG,,QOW,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,1,I,20220907.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76839,,FDA-CTU,,69.0,YR,,M,N,133.0,KG,20221119,N,PH,US,,2023,Q4,Elderly
230851051,23085105,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Every other week;?,,,,,,,,0.75,MG,,QOW,2023,Q4,Pruritus,,2023,Q4,1,I,20220907.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76839,,FDA-CTU,,69.0,YR,,M,N,133.0,KG,20221119,N,PH,US,,2023,Q4,Elderly
230851051,23085105,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Every other week;?,,,,,,,,0.75,MG,,QOW,2023,Q4,Angioedema,,2023,Q4,1,I,20220907.0,,20231019,20231019,DIR,FDA-CDER-CTU-2023-76839,,FDA-CTU,,69.0,YR,,M,N,133.0,KG,20221119,N,PH,US,,2023,Q4,Elderly
230877991,23087799,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Toxic neuropathy,,2023,Q4,1,I,,20231012.0,20231020,20231020,EXP,,PT-AUROBINDO-AUR-APL-2023-064317,AUROBINDO,"Gouveia R, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. N? 058 Neuropatia induzida pelo tratamento da Diabetes - uma entidade pouco reconhecida. Medicina Interna - Congressos Nacionais,29CNMI. 2023",68.0,YR,,F,Y,,,20231020,,MD,PT,PT,2023,Q4,Elderly
230877991,23087799,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Diabetic neuropathy,,2023,Q4,1,I,,20231012.0,20231020,20231020,EXP,,PT-AUROBINDO-AUR-APL-2023-064317,AUROBINDO,"Gouveia R, Elias C, Rocha M, Ribeiro A, Oliveira J, Almeida J. N? 058 Neuropatia induzida pelo tratamento da Diabetes - uma entidade pouco reconhecida. Medicina Interna - Congressos Nacionais,29CNMI. 2023",68.0,YR,,F,Y,,,20231020,,MD,PT,PT,2023,Q4,Elderly
230896931,23089693,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,Brand name not specified,,,,,,,,,,,,2023,Q4,Hypomagnesaemia,,2023,Q4,1,I,,20231010.0,20231020,20231020,EXP,NL-LRB-00911982,NL-TEVA-2023-NL-2935696,TEVA,,68.0,YR,E,M,Y,,,20231020,,MD,NL,NL,2023,Q4,Elderly
230896931,23089693,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,Brand name not specified,,,,,,,,,,,,2023,Q4,Hypocalcaemia,,2023,Q4,1,I,,20231010.0,20231020,20231020,EXP,NL-LRB-00911982,NL-TEVA-2023-NL-2935696,TEVA,,68.0,YR,E,M,Y,,,20231020,,MD,NL,NL,2023,Q4,Elderly
230932512,23093251,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Cutaneous vasculitis,,2023,Q4,2,F,20230801.0,20231114.0,20231022,20231120,EXP,,NVSC2023DE225665,NOVARTIS,,46.0,YR,,M,Y,138.0,KG,20231120,,MD,DE,DE,2023,Q4,Adult
230932512,23093251,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Scar,,2023,Q4,2,F,20230801.0,20231114.0,20231022,20231120,EXP,,NVSC2023DE225665,NOVARTIS,,46.0,YR,,M,Y,138.0,KG,20231120,,MD,DE,DE,2023,Q4,Adult
230932512,23093251,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Skin hyperpigmentation,,2023,Q4,2,F,20230801.0,20231114.0,20231022,20231120,EXP,,NVSC2023DE225665,NOVARTIS,,46.0,YR,,M,Y,138.0,KG,20231120,,MD,DE,DE,2023,Q4,Adult
230976232,23097623,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.2143 Milligram Daily;,,,,,,,,1.5,MG,,/WK,2023,Q4,Abortion spontaneous,,2023,Q4,2,F,20230825.0,20231103.0,20231023,20231109,EXP,,PT-TEVA-2023-PT-2937671,TEVA,,43.0,YR,A,F,Y,,,20231109,,MD,PT,PT,2023,Q4,Adult
230976232,23097623,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.2143 Milligram Daily;,,,,,,,,1.5,MG,,/WK,2023,Q4,Maternal exposure during pregnancy,,2023,Q4,2,F,20230825.0,20231103.0,20231023,20231109,EXP,,PT-TEVA-2023-PT-2937671,TEVA,,43.0,YR,A,F,Y,,,20231109,,MD,PT,PT,2023,Q4,Adult
230998241,23099824,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,Y,,,,,1.5,MG,,QW,2023,Q4,Pancreatitis,,2023,Q4,1,I,20230320.0,,20231020,20231020,DIR,FDA-CDER-CTU-2023-77734,,FDA-CTU,,74.0,YR,,M,N,,,20230326,N,PH,US,,2023,Q4,Elderly
231009331,23100933,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,1.5,MG,,QW,2023,Q4,Depressed mood,,2023,Q4,1,I,20230106.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77996,,FDA-CTU,,53.0,YR,,F,N,99.7,KG,20230320,N,PH,US,,2023,Q4,Adult
231009331,23100933,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,1.5,MG,,QW,2023,Q4,Cholelithiasis,,2023,Q4,1,I,20230106.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77996,,FDA-CTU,,53.0,YR,,F,N,99.7,KG,20230320,N,PH,US,,2023,Q4,Adult
231009331,23100933,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,1.5,MG,,QW,2023,Q4,Cholelithiasis,,2023,Q4,1,I,20230106.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77996,,FDA-CTU,,53.0,YR,,F,N,99.7,KG,20230320,N,PH,US,,2023,Q4,Adult
231009331,23100933,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,1.5,MG,,QW,2023,Q4,Hepatomegaly,,2023,Q4,1,I,20230106.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77996,,FDA-CTU,,53.0,YR,,F,N,99.7,KG,20230320,N,PH,US,,2023,Q4,Adult
231009331,23100933,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,1.5,MG,,QW,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,20230106.0,,20231021,20231021,DIR,FDA-CDER-CTU-2023-77996,,FDA-CTU,,53.0,YR,,F,N,99.7,KG,20230320,N,PH,US,,2023,Q4,Adult
231057631,23105763,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,0.75,MG,,QW,2023,Q4,Constipation,,2023,Q4,1,I,20220516.0,,20231024,20231024,DIR,FDA-CDER-CTU-2023-78556,,FDA-CTU,,52.0,YR,,M,N,,,20220719,N,,US,,2023,Q4,Adult
231062121,23106212,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,20230601.0,20231025.0,20231025,20231025,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268925",BOEHRINGER INGELHEIM,,61.0,YR,A,F,Y,,,20231025,,MD,AU,AU,2023,Q4,Adult
231062121,23106212,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Dehydration,,2023,Q4,1,I,20230601.0,20231025.0,20231025,20231025,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268925",BOEHRINGER INGELHEIM,,61.0,YR,A,F,Y,,,20231025,,MD,AU,AU,2023,Q4,Adult
231062121,23106212,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Ketoacidosis,,2023,Q4,1,I,20230601.0,20231025.0,20231025,20231025,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268925",BOEHRINGER INGELHEIM,,61.0,YR,A,F,Y,,,20231025,,MD,AU,AU,2023,Q4,Adult
231062121,23106212,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,20230601.0,20231025.0,20231025,20231025,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268925",BOEHRINGER INGELHEIM,,61.0,YR,A,F,Y,,,20231025,,MD,AU,AU,2023,Q4,Adult
231062121,23106212,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20230601.0,20231025.0,20231025,20231025,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-268925",BOEHRINGER INGELHEIM,,61.0,YR,A,F,Y,,,20231025,,MD,AU,AU,2023,Q4,Adult
231346542,23134654,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,D,,,,,,,,,2023,Q4,Product use issue,,2023,Q4,2,F,20231001.0,20231121.0,20231101,20231129,EXP,,"US-RIGEL PHARMACEUTICALS, INC.-2023FOS001133",RIGEL PHARMACEUTICALS,,75.0,YR,,F,Y,,,20231129,,HP,US,US,2023,Q4,Elderly
231346542,23134654,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,D,,,,,,,,,2023,Q4,Heart rate decreased,,2023,Q4,2,F,20231001.0,20231121.0,20231101,20231129,EXP,,"US-RIGEL PHARMACEUTICALS, INC.-2023FOS001133",RIGEL PHARMACEUTICALS,,75.0,YR,,F,Y,,,20231129,,HP,US,US,2023,Q4,Elderly
231346542,23134654,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,D,,,,,,,,,2023,Q4,Fatigue,,2023,Q4,2,F,20231001.0,20231121.0,20231101,20231129,EXP,,"US-RIGEL PHARMACEUTICALS, INC.-2023FOS001133",RIGEL PHARMACEUTICALS,,75.0,YR,,F,Y,,,20231129,,HP,US,US,2023,Q4,Elderly
231346542,23134654,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,D,,,,,,,,,2023,Q4,Product dose omission issue,,2023,Q4,2,F,20231001.0,20231121.0,20231101,20231129,EXP,,"US-RIGEL PHARMACEUTICALS, INC.-2023FOS001133",RIGEL PHARMACEUTICALS,,75.0,YR,,F,Y,,,20231129,,HP,US,US,2023,Q4,Elderly
231435441,23143544,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.5,ML,Injection,/WK,2023,Q4,Neck pain,,2023,Q4,1,I,20231020.0,20231024.0,20231103,20231103,EXP,GB-MHRA-ADR 28265706,GB-Accord-388091,ACCORD,,75.0,YR,E,M,Y,89.0,KG,20231103,,HP,GB,GB,2023,Q4,Elderly
231435441,23143544,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.5,ML,Injection,/WK,2023,Q4,Hypotension,,2023,Q4,1,I,20231020.0,20231024.0,20231103,20231103,EXP,GB-MHRA-ADR 28265706,GB-Accord-388091,ACCORD,,75.0,YR,E,M,Y,89.0,KG,20231103,,HP,GB,GB,2023,Q4,Elderly
231450831,23145083,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.5 mL once a week,,,,,,,,,,,,2023,Q4,Arrhythmia,,2023,Q4,1,I,,20231025.0,20231103,20231103,EXP,,US-Fresenius Medical Care Renal Therapies Group-FMC-2311-001199,FRESENIUS MEDICAL CARE,,66.0,YR,E,M,Y,,,20231103,,HP,US,US,2023,Q4,Elderly
231465381,23146538,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,U,UNKNOWN,,,1.5,MG,,/WK,2023,Q4,Syncope,,2023,Q4,1,I,,20231028.0,20231105,20231105,EXP,,DE-drreddys-SPO/GER/23/0182158,DR REDDYS,,47.0,YR,A,M,Y,,,20231105,,HP,DE,DE,2023,Q4,Adult
231465381,23146538,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,U,UNKNOWN,,,1.5,MG,,/WK,2023,Q4,Dyspnoea,,2023,Q4,1,I,,20231028.0,20231105,20231105,EXP,,DE-drreddys-SPO/GER/23/0182158,DR REDDYS,,47.0,YR,A,M,Y,,,20231105,,HP,DE,DE,2023,Q4,Adult
231465381,23146538,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, QW",,,U,U,UNKNOWN,,,1.5,MG,,/WK,2023,Q4,Chest pain,,2023,Q4,1,I,,20231028.0,20231105,20231105,EXP,,DE-drreddys-SPO/GER/23/0182158,DR REDDYS,,47.0,YR,A,M,Y,,,20231105,,HP,DE,DE,2023,Q4,Adult
231482801,23148280,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,As Directed,,,,,,,,,,,,2023,Q4,Confusional state,,2023,Q4,1,I,20231016.0,20231026.0,20231106,20231106,EXP,GB-MHRA-ADR 28272324,GB-Accord-388144,ACCORD,,57.0,YR,A,F,Y,91.5,KG,20231106,,PH,GB,GB,2023,Q4,Adult
231482801,23148280,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,As Directed,,,,,,,,,,,,2023,Q4,Depressed level of consciousness,,2023,Q4,1,I,20231016.0,20231026.0,20231106,20231106,EXP,GB-MHRA-ADR 28272324,GB-Accord-388144,ACCORD,,57.0,YR,A,F,Y,91.5,KG,20231106,,PH,GB,GB,2023,Q4,Adult
231482801,23148280,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,As Directed,,,,,,,,,,,,2023,Q4,Tearfulness,,2023,Q4,1,I,20231016.0,20231026.0,20231106,20231106,EXP,GB-MHRA-ADR 28272324,GB-Accord-388144,ACCORD,,57.0,YR,A,F,Y,91.5,KG,20231106,,PH,GB,GB,2023,Q4,Adult
231482801,23148280,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,As Directed,,,,,,,,,,,,2023,Q4,Depressed mood,,2023,Q4,1,I,20231016.0,20231026.0,20231106,20231106,EXP,GB-MHRA-ADR 28272324,GB-Accord-388144,ACCORD,,57.0,YR,A,F,Y,91.5,KG,20231106,,PH,GB,GB,2023,Q4,Adult
231650501,23165050,8,C,Dulaglutide 1.5 mg SubQ Weekly,,2,,,,,,,,,,,,,,2023,Q4,Dyspnoea,,2023,Q4,1,I,20231027.0,,20231108,20231108,DIR,680470,,FDA-CTU,,63.0,YR,,F,N,121.8,KG,20231108,N,PH,US,,2023,Q4,Adult
231650501,23165050,8,C,Dulaglutide 1.5 mg SubQ Weekly,,2,,,,,,,,,,,,,,2023,Q4,Unresponsive to stimuli,,2023,Q4,1,I,20231027.0,,20231108,20231108,DIR,680470,,FDA-CTU,,63.0,YR,,F,N,121.8,KG,20231108,N,PH,US,,2023,Q4,Adult
231650501,23165050,8,C,Dulaglutide 1.5 mg SubQ Weekly,,2,,,,,,,,,,,,,,2023,Q4,Cardiac arrest,,2023,Q4,1,I,20231027.0,,20231108,20231108,DIR,680470,,FDA-CTU,,63.0,YR,,F,N,121.8,KG,20231108,N,PH,US,,2023,Q4,Adult
231788431,23178843,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75mcg once a week,,,Y,,,,,,,,,2023,Q4,Hypophagia,,2023,Q4,1,I,,20231030.0,20231113,20231113,EXP,,JP-NOVOPROD-1136134,NOVO NORDISK,"Hiranuma. M, et al. A case of hypoglycaemic encephalopathy resulting from prolonged hypoglycaemia. The 689th Kanto Regional Meeting held by Kanto Branch of the Japanese Society. 2023;p45",75.0,YR,,M,Y,,,20231113,,MD,JP,JP,2023,Q4,Elderly
231788431,23178843,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75mcg once a week,,,Y,,,,,,,,,2023,Q4,Fall,,2023,Q4,1,I,,20231030.0,20231113,20231113,EXP,,JP-NOVOPROD-1136134,NOVO NORDISK,"Hiranuma. M, et al. A case of hypoglycaemic encephalopathy resulting from prolonged hypoglycaemia. The 689th Kanto Regional Meeting held by Kanto Branch of the Japanese Society. 2023;p45",75.0,YR,,M,Y,,,20231113,,MD,JP,JP,2023,Q4,Elderly
231788431,23178843,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75mcg once a week,,,Y,,,,,,,,,2023,Q4,Hypoglycaemic encephalopathy,,2023,Q4,1,I,,20231030.0,20231113,20231113,EXP,,JP-NOVOPROD-1136134,NOVO NORDISK,"Hiranuma. M, et al. A case of hypoglycaemic encephalopathy resulting from prolonged hypoglycaemia. The 689th Kanto Regional Meeting held by Kanto Branch of the Japanese Society. 2023;p45",75.0,YR,,M,Y,,,20231113,,MD,JP,JP,2023,Q4,Elderly
231790211,23179021,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,N,,,,,,,,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,20200401.0,20231109.0,20231113,20231113,EXP,,FR-ANIPHARMA-2023-FR-000186,ANI,,75.0,YR,,M,Y,,,20231113,,HP,FR,FR,2023,Q4,Elderly
231793381,23179338,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,Unknown,,,,,,,2023,Q4,Hospitalisation,,2023,Q4,1,I,,20231103.0,20231113,20231113,EXP,,MX-NOVOPROD-1139444,NOVO NORDISK,,51.0,YR,,F,Y,,,20231114,,HP,MX,MX,2023,Q4,Adult
231793442,23179344,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,UNKNOWN,,,,,,,2023,Q4,Pyelonephritis,,2023,Q4,2,F,20230929.0,20231120.0,20231113,20231201,EXP,,MX-NOVOPROD-1139448,NOVO NORDISK,,51.0,YR,,F,Y,,,20231201,,HP,MX,MX,2023,Q4,Adult
231878451,23187845,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Rash,,2023,Q4,1,I,20220401.0,20231101.0,20231115,20231115,EXP,,JP-EMD Serono-2023485703,EMD SERONO INC,,87.0,YR,E,F,Y,37.0,KG,20231115,,MD,JP,JP,2023,Q4,Elderly
231878451,23187845,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Dementia,,2023,Q4,1,I,20220401.0,20231101.0,20231115,20231115,EXP,,JP-EMD Serono-2023485703,EMD SERONO INC,,87.0,YR,E,F,Y,37.0,KG,20231115,,MD,JP,JP,2023,Q4,Elderly
231878451,23187845,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Weight decreased,,2023,Q4,1,I,20220401.0,20231101.0,20231115,20231115,EXP,,JP-EMD Serono-2023485703,EMD SERONO INC,,87.0,YR,E,F,Y,37.0,KG,20231115,,MD,JP,JP,2023,Q4,Elderly
231878451,23187845,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,20220401.0,20231101.0,20231115,20231115,EXP,,JP-EMD Serono-2023485703,EMD SERONO INC,,87.0,YR,E,F,Y,37.0,KG,20231115,,MD,JP,JP,2023,Q4,Elderly
231878451,23187845,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Decreased appetite,,2023,Q4,1,I,20220401.0,20231101.0,20231115,20231115,EXP,,JP-EMD Serono-2023485703,EMD SERONO INC,,87.0,YR,E,F,Y,37.0,KG,20231115,,MD,JP,JP,2023,Q4,Elderly
231878451,23187845,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,20220401.0,20231101.0,20231115,20231115,EXP,,JP-EMD Serono-2023485703,EMD SERONO INC,,87.0,YR,E,F,Y,37.0,KG,20231115,,MD,JP,JP,2023,Q4,Elderly
231878451,23187845,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Malabsorption,,2023,Q4,1,I,20220401.0,20231101.0,20231115,20231115,EXP,,JP-EMD Serono-2023485703,EMD SERONO INC,,87.0,YR,E,F,Y,37.0,KG,20231115,,MD,JP,JP,2023,Q4,Elderly
231878451,23187845,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Glycosylated haemoglobin increased,,2023,Q4,1,I,20220401.0,20231101.0,20231115,20231115,EXP,,JP-EMD Serono-2023485703,EMD SERONO INC,,87.0,YR,E,F,Y,37.0,KG,20231115,,MD,JP,JP,2023,Q4,Elderly
231938251,23193825,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly (1/W)",,,U,,,,125469.0,0.75,MG,,/WK,2023,Q4,Hypotension,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly (1/W)",,,U,,,,125469.0,0.75,MG,,/WK,2023,Q4,Cholecystitis,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly (1/W)",,,U,,,,125469.0,0.75,MG,,/WK,2023,Q4,Pancreatitis necrotising,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly (1/W)",,,U,,,,125469.0,0.75,MG,,/WK,2023,Q4,Hypoxia,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,,/WK,2023,Q4,Hypotension,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,,/WK,2023,Q4,Cholecystitis,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,,/WK,2023,Q4,Pancreatitis necrotising,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938251,23193825,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,,/WK,2023,Q4,Hypoxia,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008524,ELI LILLY AND CO,"Bhat S.Z.,Goudarzi A..Necrotizing Pancreatitis Secondary to Dulaglutide Use..Journal of the Endocrine Society 2021;5 (supp. 1):A393.DOI:https://dx.doi.org/10.1210/jendso/bvab048.800",69.0,YR,,M,Y,,,20231116,,MD,US,US,2023,Q4,Elderly
231938331,23193833,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,Y,,,,125469.0,,,,,2023,Q4,Hypersensitivity,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008528,ELI LILLY AND CO,"Quadri H.,Ataallah B.,Haggerty G..Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist..Journal of the Endocrine Society 2021;5(Supp.1):A367-A368.DOI:https://dx.doi.org/10.1210/jendso/bvab048.748",53.0,YR,,F,Y,,,20231116,,MD,US,US,2023,Q4,Adult
231938331,23193833,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,Y,,,,125469.0,,,,,2023,Q4,Anaphylactic reaction,,2023,Q4,1,I,,20231112.0,20231116,20231116,EXP,,US-ELI_LILLY_AND_COMPANY-US202311008528,ELI LILLY AND CO,"Quadri H.,Ataallah B.,Haggerty G..Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist..Journal of the Endocrine Society 2021;5(Supp.1):A367-A368.DOI:https://dx.doi.org/10.1210/jendso/bvab048.748",53.0,YR,,F,Y,,,20231116,,MD,US,US,2023,Q4,Adult
231953651,23195365,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,dulaglutide ((MAMMAL/HAMSTER/CHO CELLS)),,,U,,UNKNOWN,,,,,,,2023,Q4,Pancreatitis acute,,2023,Q4,1,I,,20231107.0,20231117,20231117,EXP,FR-AFSSAPS-LL20220987,FR-TEVA-2023-FR-2944746,TEVA,,75.0,YR,E,M,Y,,,20231117,,PH,FR,FR,2023,Q4,Elderly
231970955,23197095,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Pneumonia,,2023,Q4,5,F,20231104.0,20231128.0,20231117,20231130,EXP,,US-ROCHE-3456763,ROCHE,,78.0,YR,,F,Y,83.4,KG,20231130,,MD,US,,2023,Q4,Elderly
231970955,23197095,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Pneumonitis,,2023,Q4,5,F,20231104.0,20231128.0,20231117,20231130,EXP,,US-ROCHE-3456763,ROCHE,,78.0,YR,,F,Y,83.4,KG,20231130,,MD,US,,2023,Q4,Elderly
231980863,23198086,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Urticaria,,2023,Q4,3,F,20231105.0,20231123.0,20231117,20231205,EXP,,NVSC2023NZ240298,NOVARTIS,,57.0,YR,,F,Y,82.8,KG,20231205,,MD,NZ,NZ,2023,Q4,Adult
232131901,23213190,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 1/week",,,U,,,,,1.5,MG,,/WK,2023,Q4,Chest pain,,2023,Q4,1,I,,20231106.0,20231121,20231121,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-418883,RANBAXY,,47.0,YR,,M,Y,,,20231121,,HP,DE,DE,2023,Q4,Adult
232131901,23213190,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 1/week",,,U,,,,,1.5,MG,,/WK,2023,Q4,Dyspnoea,,2023,Q4,1,I,,20231106.0,20231121,20231121,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-418883,RANBAXY,,47.0,YR,,M,Y,,,20231121,,HP,DE,DE,2023,Q4,Adult
232131901,23213190,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 1/week",,,U,,,,,1.5,MG,,/WK,2023,Q4,Syncope,,2023,Q4,1,I,,20231106.0,20231121,20231121,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2023RR-418883,RANBAXY,,47.0,YR,,M,Y,,,20231121,,HP,DE,DE,2023,Q4,Adult
232175071,23217507,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,Y,,,,125469.0,,,,,2023,Q4,Heart rate irregular,,2023,Q4,1,I,20230508.0,20231109.0,20231122,20231122,EXP,GB-MHRA-MED-202311080934114390-VZNKS,GB-ELI_LILLY_AND_COMPANY-GB202311005979,ELI LILLY AND CO,,57.0,YR,,F,Y,89.0,KG,20231122,,CN,GB,GB,2023,Q4,Adult
232177401,23217740,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Death,,2023,Q4,1,I,20231107.0,20231110.0,20231122,20231122,EXP,,JP-MYLANLABS-2023M1123508,MYLAN,,88.0,YR,,F,Y,,,20231122,,MD,JP,JP,2023,Q4,Elderly
232184021,23218402,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5mg/0.5ml,,,,,,,,,,,,2023,Q4,Toe amputation,,2023,Q4,1,I,,20231114.0,20231122,20231122,EXP,,GB-AstraZeneca-2023A259057,ASTRAZENECA,,55.0,YR,,M,Y,,,20231122,,MD,GB,,2023,Q4,Adult
232226031,23222603,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, Weekly",,,U,,,,,1.5,MG,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231108.0,20231123,20231123,EXP,,CA-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-418816,RANBAXY,"Chaudhry A, Roels C, Lee J. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery. Can J Diab. 2022;46(8):843-850",70.0,YR,,F,Y,,,20231123,,MD,CA,CA,2023,Q4,Elderly
232245221,23224522,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Post procedural complication,,2023,Q4,1,I,,20231117.0,20231124,20231124,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273441",BOEHRINGER INGELHEIM,"Vaghasia N, Bononi P, Custodio P. EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.. Journal of the Endocrine Society. 2022;6(1): 312. doi:10.1210/jendso/bvac150.647.",31.0,YR,A,F,Y,,,20231124,,MD,US,US,2023,Q4,Young Adult
232245221,23224522,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Euglycaemic diabetic ketoacidosis,,2023,Q4,1,I,,20231117.0,20231124,20231124,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-273441",BOEHRINGER INGELHEIM,"Vaghasia N, Bononi P, Custodio P. EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY IN ASSOCIATION WITH USE OF SGLT2I.. Journal of the Endocrine Society. 2022;6(1): 312. doi:10.1210/jendso/bvac150.647.",31.0,YR,A,F,Y,,,20231124,,MD,US,US,2023,Q4,Young Adult
232304721,23230472,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,UNK,,,,,,,2023,Q4,Adrenal insufficiency,,2023,Q4,1,I,,20231120.0,20231127,20231127,EXP,,US-SANDOZ INC.-SDZ2023US058027,SANDOZ,"Ying Chen,, Beatrice Y Wong,, Sejal Shah,. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. Journal of the Endocrine Society. 2022;6:A75-A76",58.0,YR,,F,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232304721,23230472,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,UNK,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231120.0,20231127,20231127,EXP,,US-SANDOZ INC.-SDZ2023US058027,SANDOZ,"Ying Chen,, Beatrice Y Wong,, Sejal Shah,. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. Journal of the Endocrine Society. 2022;6:A75-A76",58.0,YR,,F,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232309961,23230996,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Treatment noncompliance,,2023,Q4,1,I,,20231115.0,20231127,20231127,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420395,RANBAXY,"Panjawatanan P, Jha S, Hughes J, Riesenfeld E. A Case of Concomitant COVID-19 Infection- Induced Acute Respiratory Distress Syndrome and Diabetic Ketoacidosis: Another Challenge in Fluid Management. J Endocrine Soc. 2021;5(Suppl.):A357-A358",59.0,YR,,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232309961,23230996,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2023,Q4,Drug ineffective,,2023,Q4,1,I,,20231115.0,20231127,20231127,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-420395,RANBAXY,"Panjawatanan P, Jha S, Hughes J, Riesenfeld E. A Case of Concomitant COVID-19 Infection- Induced Acute Respiratory Distress Syndrome and Diabetic Ketoacidosis: Another Challenge in Fluid Management. J Endocrine Soc. 2021;5(Suppl.):A357-A358",59.0,YR,,M,Y,,,20231127,,MD,US,US,2023,Q4,Adult
232329831,23232983,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Treatment noncompliance,,2023,Q4,1,I,,20231115.0,20231128,20231128,EXP,,US-drreddys-LIT/USA/23/0187152,DR REDDYS,"Panjawatanan P, Jha S, Hughes J, Riesenfeld E. A Case of Concomitant COVID-19 Infection- Induced Acute Respiratory Distress Syndrome and Diabetic Ketoacidosis: Another Challenge in Fluid Management. Journal of the Endocrine Society. 2021;5:. doi:/10.1210/jendso/bvab048.727",59.0,YR,A,M,Y,,,20231128,,HP,US,US,2023,Q4,Adult
232329831,23232983,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,,,,,2023,Q4,Acute respiratory distress syndrome,,2023,Q4,1,I,,20231115.0,20231128,20231128,EXP,,US-drreddys-LIT/USA/23/0187152,DR REDDYS,"Panjawatanan P, Jha S, Hughes J, Riesenfeld E. A Case of Concomitant COVID-19 Infection- Induced Acute Respiratory Distress Syndrome and Diabetic Ketoacidosis: Another Challenge in Fluid Management. Journal of the Endocrine Society. 2021;5:. doi:/10.1210/jendso/bvab048.727",59.0,YR,A,M,Y,,,20231128,,HP,US,US,2023,Q4,Adult
232425871,23242587,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"UNK, 1x/week",,,,,,,,,,,/WK,2023,Q4,Adrenal insufficiency,,2023,Q4,1,I,,20231115.0,20231129,20231129,EXP,,US-CMP PHARMA-2023CMP00074,CMP PHARMA,"Chen Y., Wong B.Y., Shah S.. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir.. J. Endocr. Soc.. 2022;6:A75-A76",58.0,YR,,F,Y,,,20231129,,MD,US,US,2023,Q4,Adult
232425871,23242587,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"UNK, 1x/week",,,,,,,,,,,/WK,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231115.0,20231129,20231129,EXP,,US-CMP PHARMA-2023CMP00074,CMP PHARMA,"Chen Y., Wong B.Y., Shah S.. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir.. J. Endocr. Soc.. 2022;6:A75-A76",58.0,YR,,F,Y,,,20231129,,MD,US,US,2023,Q4,Adult
232436711,23243671,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,/WK,2023,Q4,Adrenal insufficiency,,2023,Q4,1,I,,20231120.0,20231130,20231130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-169393,BRISTOL MYERS SQUIBB,"Chen Y, Wong BY, Shah S. Central adrenal insufficiency after intra-articular triamcinolone injection in a patient on dolutegravir and cobicistat boosted darunavir. Journal of the Endocrine Society. 2022;6(Suppl 1):A75-A6. doi:10.1210/jendso/bvac150.",58.0,YR,A,F,Y,,,20231130,,MD,US,US,2023,Q4,Adult
232436711,23243671,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,/WK,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231120.0,20231130,20231130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-169393,BRISTOL MYERS SQUIBB,"Chen Y, Wong BY, Shah S. Central adrenal insufficiency after intra-articular triamcinolone injection in a patient on dolutegravir and cobicistat boosted darunavir. Journal of the Endocrine Society. 2022;6(Suppl 1):A75-A6. doi:10.1210/jendso/bvac150.",58.0,YR,A,F,Y,,,20231130,,MD,US,US,2023,Q4,Adult
232436711,23243671,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,/WK,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,,20231120.0,20231130,20231130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2023-169393,BRISTOL MYERS SQUIBB,"Chen Y, Wong BY, Shah S. Central adrenal insufficiency after intra-articular triamcinolone injection in a patient on dolutegravir and cobicistat boosted darunavir. Journal of the Endocrine Society. 2022;6(Suppl 1):A75-A6. doi:10.1210/jendso/bvac150.",58.0,YR,A,F,Y,,,20231130,,MD,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Contraindicated product administered,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Binge drinking,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Blood ketone body increased,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Vomiting,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Blood glucose decreased,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232444051,23244405,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,Unknown,,,,,,,2023,Q4,Dehydration,,2023,Q4,1,I,,20231121.0,20231130,20231130,EXP,,US-EMD Serono-2023490202,EMD SERONO INC,,62.0,YR,A,M,Y,,,20231130,,HP,US,US,2023,Q4,Adult
232476251,23247625,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,restarted,,,Y,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231122.0,20231130,20231130,EXP,,US-BAUSCH-BL-2023-017509,BAUSCH AND LOMB,"Maki M, Manivannan N. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm. Journal of the Endocrine Society. 2022;6(SUPPLEMENT 1):A267. doi:10.1210/jendso/bvac150.548",62.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
232476251,23247625,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,restarted,,,Y,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231122.0,20231130,20231130,EXP,,US-BAUSCH-BL-2023-017509,BAUSCH AND LOMB,"Maki M, Manivannan N. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm. Journal of the Endocrine Society. 2022;6(SUPPLEMENT 1):A267. doi:10.1210/jendso/bvac150.548",62.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
232478061,23247806,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,U,,,,125469.0,,,,,2023,Q4,Pancreatitis necrotising,,2023,Q4,1,I,,20231119.0,20231130,20231130,EXP,,US-ELI_LILLY_AND_COMPANY-US202311013268,ELI LILLY AND CO,"Yau A.,Reisman T.,Chen Z.Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides.Journal of the Endocrine Society. Conference:Endocrine Society^s Annual Meeting 2022;6(Supplement 1):A399-A400.DOI:10.1210/jendso/bvac150",46.0,YR,,M,Y,,,20231130,,MD,US,US,2023,Q4,Adult
232499431,23249943,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,Y,,,,125469.0,,,,,2023,Q4,Drug-induced liver injury,,2023,Q4,1,I,,20231119.0,20231201,20231201,EXP,,US-ELI_LILLY_AND_COMPANY-US202311012481,ELI LILLY AND CO,"Shahid M.,Hamza A.,Vather-Wu D.,Sultan S.,Nabizadeh P..Dulaglutide-induced Acute Liver Injury - A Case Report.Journal of the Endocrine Society. Conference:Endocrine Society^s Annual Meeting 2023;7(Supplement 1):A464-A465.DOI:https://doi.org/10.1210/jendso/bvad114",38.0,YR,,F,Y,,,20231201,,MD,US,US,2023,Q4,Adult
232505651,23250565,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231123.0,20231201,20231201,PER,,US-APOTEX-2023AP017337,APOTEX,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm. Journal of the Endocrine Society. 2022;6 (Suppl.1):A267",62.0,YR,,M,Y,,,20231201,,HP,US,US,2023,Q4,Adult
232511571,23251157,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231123.0,20231201,20231201,EXP,,US-MYLANLABS-2023M1127121,MYLAN,"Maki MK, Manivannan N. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm. J-Endocr-Soc 2022; 6 A267.",62.0,YR,,M,Y,,,20231201,,MD,US,US,2023,Q4,Adult
232511571,23251157,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,Unknown,,2023,Q4,Labelled drug-drug interaction medication error,,2023,Q4,1,I,,20231123.0,20231201,20231201,EXP,,US-MYLANLABS-2023M1127121,MYLAN,"Maki MK, Manivannan N. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm. J-Endocr-Soc 2022; 6 A267.",62.0,YR,,M,Y,,,20231201,,MD,US,US,2023,Q4,Adult
232511571,23251157,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (then resumed),,,U,U,,,,,,Unknown,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231123.0,20231201,20231201,EXP,,US-MYLANLABS-2023M1127121,MYLAN,"Maki MK, Manivannan N. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm. J-Endocr-Soc 2022; 6 A267.",62.0,YR,,M,Y,,,20231201,,MD,US,US,2023,Q4,Adult
232511571,23251157,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (then resumed),,,U,U,,,,,,Unknown,,2023,Q4,Labelled drug-drug interaction medication error,,2023,Q4,1,I,,20231123.0,20231201,20231201,EXP,,US-MYLANLABS-2023M1127121,MYLAN,"Maki MK, Manivannan N. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm. J-Endocr-Soc 2022; 6 A267.",62.0,YR,,M,Y,,,20231201,,MD,US,US,2023,Q4,Adult
232513351,23251335,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Acute generalised exanthematous pustulosis,,2023,Q4,1,I,20231104.0,20231127.0,20231201,20231201,EXP,FR-AFSSAPS-BX2023002033,FR-MYLANLABS-2023M1127451,MYLAN,,76.0,YR,,M,Y,,,20231201,,MD,FR,FR,2023,Q4,Elderly
232542361,23254236,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q4,Muscle tightness,,2023,Q4,1,I,,20231121.0,20231202,20231202,EXP,GB-MHRA-ADR 28328614,GB-Accord-392881,ACCORD,,59.0,YR,A,F,Y,104.0,KG,20231202,,MD,GB,GB,2023,Q4,Adult
232542361,23254236,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q4,Pain in extremity,,2023,Q4,1,I,,20231121.0,20231202,20231202,EXP,GB-MHRA-ADR 28328614,GB-Accord-392881,ACCORD,,59.0,YR,A,F,Y,104.0,KG,20231202,,MD,GB,GB,2023,Q4,Adult
232542361,23254236,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q4,Weight increased,,2023,Q4,1,I,,20231121.0,20231202,20231202,EXP,GB-MHRA-ADR 28328614,GB-Accord-392881,ACCORD,,59.0,YR,A,F,Y,104.0,KG,20231202,,MD,GB,GB,2023,Q4,Adult
232542361,23254236,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q4,Myalgia,,2023,Q4,1,I,,20231121.0,20231202,20231202,EXP,GB-MHRA-ADR 28328614,GB-Accord-392881,ACCORD,,59.0,YR,A,F,Y,104.0,KG,20231202,,MD,GB,GB,2023,Q4,Adult
232542361,23254236,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2023,Q4,Mobility decreased,,2023,Q4,1,I,,20231121.0,20231202,20231202,EXP,GB-MHRA-ADR 28328614,GB-Accord-392881,ACCORD,,59.0,YR,A,F,Y,104.0,KG,20231202,,MD,GB,GB,2023,Q4,Adult
232546791,23254679,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, Every Week",,,U,,,,,,,,/WK,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231122.0,20231203,20231203,EXP,,US-AUROBINDO-AUR-APL-2023-074641,AUROBINDO,"Chen Y, Wong BY, Shah S.. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. Journal of the Endocrine Society.. 2022;6(Supplement 1):A75-6",58.0,YR,,F,Y,,,20231203,,MD,US,US,2023,Q4,Adult
232546791,23254679,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, Every Week",,,U,,,,,,,,/WK,2023,Q4,Adrenal insufficiency,,2023,Q4,1,I,,20231122.0,20231203,20231203,EXP,,US-AUROBINDO-AUR-APL-2023-074641,AUROBINDO,"Chen Y, Wong BY, Shah S.. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. Journal of the Endocrine Society.. 2022;6(Supplement 1):A75-6",58.0,YR,,F,Y,,,20231203,,MD,US,US,2023,Q4,Adult
232546791,23254679,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, Every Week",,,U,,,,,,,,/WK,2023,Q4,Hyperglycaemia,,2023,Q4,1,I,,20231122.0,20231203,20231203,EXP,,US-AUROBINDO-AUR-APL-2023-074641,AUROBINDO,"Chen Y, Wong BY, Shah S.. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. Journal of the Endocrine Society.. 2022;6(Supplement 1):A75-6",58.0,YR,,F,Y,,,20231203,,MD,US,US,2023,Q4,Adult
232557781,23255778,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Diarrhoea,,2023,Q4,1,I,,20231122.0,20231204,20231204,EXP,,US-AUROBINDO-AUR-APL-2023-074623,AUROBINDO,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm.. Journal of the Endocrine Society. 2022;6(Supplement 1):A267",62.0,YR,,M,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232557781,23255778,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Drug level increased,,2023,Q4,1,I,,20231122.0,20231204,20231204,EXP,,US-AUROBINDO-AUR-APL-2023-074623,AUROBINDO,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm.. Journal of the Endocrine Society. 2022;6(Supplement 1):A267",62.0,YR,,M,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232557781,23255778,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Nausea,,2023,Q4,1,I,,20231122.0,20231204,20231204,EXP,,US-AUROBINDO-AUR-APL-2023-074623,AUROBINDO,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm.. Journal of the Endocrine Society. 2022;6(Supplement 1):A267",62.0,YR,,M,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232557781,23255778,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Drug clearance decreased,,2023,Q4,1,I,,20231122.0,20231204,20231204,EXP,,US-AUROBINDO-AUR-APL-2023-074623,AUROBINDO,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm.. Journal of the Endocrine Society. 2022;6(Supplement 1):A267",62.0,YR,,M,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232557781,23255778,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Renal injury,,2023,Q4,1,I,,20231122.0,20231204,20231204,EXP,,US-AUROBINDO-AUR-APL-2023-074623,AUROBINDO,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm.. Journal of the Endocrine Society. 2022;6(Supplement 1):A267",62.0,YR,,M,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232557781,23255778,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231122.0,20231204,20231204,EXP,,US-AUROBINDO-AUR-APL-2023-074623,AUROBINDO,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm.. Journal of the Endocrine Society. 2022;6(Supplement 1):A267",62.0,YR,,M,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232557781,23255778,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Lactic acidosis,,2023,Q4,1,I,,20231122.0,20231204,20231204,EXP,,US-AUROBINDO-AUR-APL-2023-074623,AUROBINDO,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm.. Journal of the Endocrine Society. 2022;6(Supplement 1):A267",62.0,YR,,M,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232557781,23255778,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,Y,,,,,,,,,2023,Q4,Dehydration,,2023,Q4,1,I,,20231122.0,20231204,20231204,EXP,,US-AUROBINDO-AUR-APL-2023-074623,AUROBINDO,"Maki MK, Manivannan N.. Metformin-Associated Severe Lactic Acidosis: A Case Study Of The Perfect Storm.. Journal of the Endocrine Society. 2022;6(Supplement 1):A267",62.0,YR,,M,Y,,,20231204,,MD,US,US,2023,Q4,Adult
232607251,23260725,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 mg,,,U,,,,,,,,,2023,Q4,Spinal compression fracture,,2023,Q4,1,I,,20231124.0,20231205,20231205,EXP,,JP-NOVOPROD-1145963,NOVO NORDISK,,79.0,YR,,M,Y,,,20231205,,MD,JP,JP,2023,Q4,Elderly
232607251,23260725,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 mg,,,U,,,,,,,,,2023,Q4,Abdominal discomfort,,2023,Q4,1,I,,20231124.0,20231205,20231205,EXP,,JP-NOVOPROD-1145963,NOVO NORDISK,,79.0,YR,,M,Y,,,20231205,,MD,JP,JP,2023,Q4,Elderly
232607251,23260725,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 mg,,,U,,,,,,,,,2023,Q4,Product prescribing error,,2023,Q4,1,I,,20231124.0,20231205,20231205,EXP,,JP-NOVOPROD-1145963,NOVO NORDISK,,79.0,YR,,M,Y,,,20231205,,MD,JP,JP,2023,Q4,Elderly
232607251,23260725,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 mg,,,U,,,,,,,,,2023,Q4,Decreased appetite,,2023,Q4,1,I,,20231124.0,20231205,20231205,EXP,,JP-NOVOPROD-1145963,NOVO NORDISK,,79.0,YR,,M,Y,,,20231205,,MD,JP,JP,2023,Q4,Elderly
232618403,23261840,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,QW,,,U,,,,,,,,/WK,2023,Q4,Hyperglycaemia,,2023,Q4,3,F,,20231207.0,20231205,20231218,EXP,,US-CHATTEMPRD-2023OHG017004,CHATTEM,"Chen Y, Wong BY, Shah S. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. Journal of the Endocrine Society. 2022;6(Supplement 1):A75-6. DOI: 10.1210/jendso/bvac150.157.",58.0,YR,A,F,Y,,,20231218,,MD,US,US,2023,Q4,Adult
232618403,23261840,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,QW,,,U,,,,,,,,/WK,2023,Q4,Drug interaction,,2023,Q4,3,F,,20231207.0,20231205,20231218,EXP,,US-CHATTEMPRD-2023OHG017004,CHATTEM,"Chen Y, Wong BY, Shah S. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. Journal of the Endocrine Society. 2022;6(Supplement 1):A75-6. DOI: 10.1210/jendso/bvac150.157.",58.0,YR,A,F,Y,,,20231218,,MD,US,US,2023,Q4,Adult
232618403,23261840,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,QW,,,U,,,,,,,,/WK,2023,Q4,Adrenal insufficiency,,2023,Q4,3,F,,20231207.0,20231205,20231218,EXP,,US-CHATTEMPRD-2023OHG017004,CHATTEM,"Chen Y, Wong BY, Shah S. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. Journal of the Endocrine Society. 2022;6(Supplement 1):A75-6. DOI: 10.1210/jendso/bvac150.157.",58.0,YR,A,F,Y,,,20231218,,MD,US,US,2023,Q4,Adult
232663361,23266336,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,N,,,,125469.0,1.5,MG,,,2023,Q4,Oedema,,2023,Q4,1,I,,20231123.0,20231206,20231206,EXP,GB-MHRA-MED-202311180929061040-TKPHM,GB-ELI_LILLY_AND_COMPANY-GB202311014071,ELI LILLY AND CO,,23.0,YR,,M,Y,160.0,KG,20231206,,CN,GB,GB,2023,Q4,Youth
232663361,23266336,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,N,,,,125469.0,1.5,MG,,,2023,Q4,Off label use,,2023,Q4,1,I,,20231123.0,20231206,20231206,EXP,GB-MHRA-MED-202311180929061040-TKPHM,GB-ELI_LILLY_AND_COMPANY-GB202311014071,ELI LILLY AND CO,,23.0,YR,,M,Y,160.0,KG,20231206,,CN,GB,GB,2023,Q4,Youth
232663361,23266336,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,N,,,,125469.0,3.0,MG,,,2023,Q4,Oedema,,2023,Q4,1,I,,20231123.0,20231206,20231206,EXP,GB-MHRA-MED-202311180929061040-TKPHM,GB-ELI_LILLY_AND_COMPANY-GB202311014071,ELI LILLY AND CO,,23.0,YR,,M,Y,160.0,KG,20231206,,CN,GB,GB,2023,Q4,Youth
232663361,23266336,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, unknown",,,N,,,,125469.0,3.0,MG,,,2023,Q4,Off label use,,2023,Q4,1,I,,20231123.0,20231206,20231206,EXP,GB-MHRA-MED-202311180929061040-TKPHM,GB-ELI_LILLY_AND_COMPANY-GB202311014071,ELI LILLY AND CO,,23.0,YR,,M,Y,160.0,KG,20231206,,CN,GB,GB,2023,Q4,Youth
232663361,23266336,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,N,,,,125469.0,,,,,2023,Q4,Oedema,,2023,Q4,1,I,,20231123.0,20231206,20231206,EXP,GB-MHRA-MED-202311180929061040-TKPHM,GB-ELI_LILLY_AND_COMPANY-GB202311014071,ELI LILLY AND CO,,23.0,YR,,M,Y,160.0,KG,20231206,,CN,GB,GB,2023,Q4,Youth
232663361,23266336,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,N,,,,125469.0,,,,,2023,Q4,Off label use,,2023,Q4,1,I,,20231123.0,20231206,20231206,EXP,GB-MHRA-MED-202311180929061040-TKPHM,GB-ELI_LILLY_AND_COMPANY-GB202311014071,ELI LILLY AND CO,,23.0,YR,,M,Y,160.0,KG,20231206,,CN,GB,GB,2023,Q4,Youth
232706472,23270647,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW (1.5)",,,U,,,,,,,,/WK,2023,Q4,Product administration interrupted,,2023,Q4,2,F,,20231130.0,20231207,20231214,EXP,,NVSC2023GR256935,NOVARTIS,,36.0,YR,,M,Y,,,20231214,,MD,GR,GR,2023,Q4,Adult
232706472,23270647,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW (1.5)",,,U,,,,,,,,/WK,2023,Q4,Transient ischaemic attack,,2023,Q4,2,F,,20231130.0,20231207,20231214,EXP,,NVSC2023GR256935,NOVARTIS,,36.0,YR,,M,Y,,,20231214,,MD,GR,GR,2023,Q4,Adult
232768691,23276869,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,Injection,,2023,Q4,Urinary bladder haemorrhage,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232768691,23276869,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,Injection,,2023,Q4,Haematuria,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232768691,23276869,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,Injection,,2023,Q4,Chest pain,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232768691,23276869,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,Injection,,2023,Q4,Cardiac failure,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232768691,23276869,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,Injection,,2023,Q4,Bladder cancer,,2023,Q4,1,I,20230625.0,20231204.0,20231208,20231208,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2023-176348,BRISTOL MYERS SQUIBB,,85.0,YR,E,M,Y,58.0,KG,20231208,,PH,JP,JP,2023,Q4,Elderly
232801302,23280130,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW (1.5)",,,U,,,,,,,,,2023,Q4,Transient ischaemic attack,,2023,Q4,2,F,,20231130.0,20231210,20231215,EXP,,GR-SANDOZ INC.-SDZ2023GR065871,SANDOZ,,36.0,YR,,M,Y,,,20231215,,MD,GR,GR,2023,Q4,Adult
232801302,23280130,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, QW (1.5)",,,U,,,,,,,,,2023,Q4,Product administration interrupted,,2023,Q4,2,F,,20231130.0,20231210,20231215,EXP,,GR-SANDOZ INC.-SDZ2023GR065871,SANDOZ,,36.0,YR,,M,Y,,,20231215,,MD,GR,GR,2023,Q4,Adult
232838931,23283893,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,LYWB08D,,125469.0,1.5,MG,,/WK,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20231102.0,20231128.0,20231211,20231211,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202311017352,ELI LILLY AND CO,,34.0,YR,,M,Y,97.0,KG,20231211,,CN,CN,CN,2023,Q4,Young Adult
232838931,23283893,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,LYWB08D,,125469.0,1.5,MG,,/WK,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,20231102.0,20231128.0,20231211,20231211,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202311017352,ELI LILLY AND CO,,34.0,YR,,M,Y,97.0,KG,20231211,,CN,CN,CN,2023,Q4,Young Adult
232838931,23283893,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,LYWB08D,,125469.0,1.5,MG,,/WK,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20231102.0,20231128.0,20231211,20231211,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202311017352,ELI LILLY AND CO,,34.0,YR,,M,Y,97.0,KG,20231211,,CN,CN,CN,2023,Q4,Young Adult
232838931,23283893,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,Y,,,,125469.0,,,,,2023,Q4,Diabetic ketoacidosis,,2023,Q4,1,I,20231102.0,20231128.0,20231211,20231211,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202311017352,ELI LILLY AND CO,,34.0,YR,,M,Y,97.0,KG,20231211,,CN,CN,CN,2023,Q4,Young Adult
232838931,23283893,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,Y,,,,125469.0,,,,,2023,Q4,Hyperkalaemia,,2023,Q4,1,I,20231102.0,20231128.0,20231211,20231211,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202311017352,ELI LILLY AND CO,,34.0,YR,,M,Y,97.0,KG,20231211,,CN,CN,CN,2023,Q4,Young Adult
232838931,23283893,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,1.5,MG,Y,,,,125469.0,,,,,2023,Q4,Acute kidney injury,,2023,Q4,1,I,20231102.0,20231128.0,20231211,20231211,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202311017352,ELI LILLY AND CO,,34.0,YR,,M,Y,97.0,KG,20231211,,CN,CN,CN,2023,Q4,Young Adult
232874231,23287423,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Intentional product use issue,,2023,Q4,1,I,,20231201.0,20231212,20231212,EXP,CA-MHPD-E2B_06633450,CA-Accord-394489,ACCORD,,77.0,YR,E,M,Y,,,20231212,,CN,CA,CA,2023,Q4,Elderly
232874231,23287423,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2023,Q4,Dementia,,2023,Q4,1,I,,20231201.0,20231212,20231212,EXP,CA-MHPD-E2B_06633450,CA-Accord-394489,ACCORD,,77.0,YR,E,M,Y,,,20231212,,CN,CA,CA,2023,Q4,Elderly
232898981,23289898,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5/W,,,U,,,,,,,,,2023,Q4,Transient ischaemic attack,,2023,Q4,1,I,,20231130.0,20231212,20231212,EXP,,GR-SANDOZ INC.-SDZ2023GR064817,SANDOZ,,36.0,YR,,M,Y,,,20231212,,MD,GR,GR,2023,Q4,Adult
232898981,23289898,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5/W,,,U,,,,,,,,,2023,Q4,Blood cholesterol increased,,2023,Q4,1,I,,20231130.0,20231212,20231212,EXP,,GR-SANDOZ INC.-SDZ2023GR064817,SANDOZ,,36.0,YR,,M,Y,,,20231212,,MD,GR,GR,2023,Q4,Adult
232933032,23293303,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5/W,,,U,,,,,,,,/WK,2023,Q4,Blood cholesterol increased,,2023,Q4,2,F,,20231218.0,20231213,20231222,EXP,,NVSC2023GR264561,NOVARTIS,,36.0,YR,,M,Y,,,20231222,,MD,GR,GR,2023,Q4,Adult
232933032,23293303,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5/W,,,U,,,,,,,,/WK,2023,Q4,Transient ischaemic attack,,2023,Q4,2,F,,20231218.0,20231213,20231222,EXP,,NVSC2023GR264561,NOVARTIS,,36.0,YR,,M,Y,,,20231222,,MD,GR,GR,2023,Q4,Adult
232945761,23294576,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,Y,,ASKU,,125469.0,1.5,MG,,/WK,2023,Q4,Intentional self-injury,,2023,Q4,1,I,20231001.0,20231207.0,20231213,20231213,EXP,GB-MHRA-MED-202312061312028420-NFVHP,GB-ELI_LILLY_AND_COMPANY-GB202312004140,ELI LILLY AND CO,,17.0,YR,,F,Y,110.0,KG,20231213,,CN,GB,GB,2023,Q4,Youth
232945761,23294576,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,Y,,ASKU,,125469.0,1.5,MG,,/WK,2023,Q4,Suicidal ideation,,2023,Q4,1,I,20231001.0,20231207.0,20231213,20231213,EXP,GB-MHRA-MED-202312061312028420-NFVHP,GB-ELI_LILLY_AND_COMPANY-GB202312004140,ELI LILLY AND CO,,17.0,YR,,F,Y,110.0,KG,20231213,,CN,GB,GB,2023,Q4,Youth
232947301,23294730,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,"UNK, QW (1.5)",,,U,,,,,,,,/WK,2023,Q4,Product administration interrupted,,2023,Q4,1,I,,20231210.0,20231213,20231213,EXP,,GR-BAUSCH-BL-2023-018280,BAUSCH AND LOMB,,36.0,YR,,M,Y,,,20231213,,MD,GR,GR,2023,Q4,Adult
232947301,23294730,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,"UNK, QW (1.5)",,,U,,,,,,,,/WK,2023,Q4,Transient ischaemic attack,,2023,Q4,1,I,,20231210.0,20231213,20231213,EXP,,GR-BAUSCH-BL-2023-018280,BAUSCH AND LOMB,,36.0,YR,,M,Y,,,20231213,,MD,GR,GR,2023,Q4,Adult
233059812,23305981,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, once a week 1.5 (Unit unspecifed)",,,U,,Unknown,,,,,,/WK,2023,Q4,Blood cholesterol increased,,2023,Q4,2,F,,20231214.0,20231218,20231222,EXP,,GR-EMD Serono-2023493656,EMD SERONO INC,,36.0,YR,A,M,Y,,,20231222,,MD,GR,GR,2023,Q4,Adult
233059812,23305981,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, once a week 1.5 (Unit unspecifed)",,,U,,Unknown,,,,,,/WK,2023,Q4,Transient ischaemic attack,,2023,Q4,2,F,,20231214.0,20231218,20231222,EXP,,GR-EMD Serono-2023493656,EMD SERONO INC,,36.0,YR,A,M,Y,,,20231222,,MD,GR,GR,2023,Q4,Adult
233119051,23311905,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,40.0,MG,,,2023,Q4,Adrenal insufficiency,,2023,Q4,1,I,,20231204.0,20231219,20231219,EXP,,US-TEVA-VS-3135873,TEVA,"Chen Y, Wong BY, Shah S. Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir. J-Endocr-Soc 2022; 6 (Suppl.) A75-A76.",58.0,YR,,,Y,,,20231219,,MD,US,US,2023,Q4,Adult
233139551,23313955,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,Unknown,,,,,,,2023,Q4,Confusional state,,2023,Q4,1,I,20230907.0,20231212.0,20231219,20231219,EXP,FR-AFSSAPS-ST2023001565,FR-PFIZER INC-202300443855,PFIZER,,66.0,YR,,M,Y,87.0,KG,20231219,,MD,FR,FR,2023,Q4,Elderly
233139551,23313955,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,Unknown,,,,,,,2023,Q4,Encephalitis,,2023,Q4,1,I,20230907.0,20231212.0,20231219,20231219,EXP,FR-AFSSAPS-ST2023001565,FR-PFIZER INC-202300443855,PFIZER,,66.0,YR,,M,Y,87.0,KG,20231219,,MD,FR,FR,2023,Q4,Elderly
233139551,23313955,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,Unknown,,,,,,,2023,Q4,Off label use,,2023,Q4,1,I,20230907.0,20231212.0,20231219,20231219,EXP,FR-AFSSAPS-ST2023001565,FR-PFIZER INC-202300443855,PFIZER,,66.0,YR,,M,Y,87.0,KG,20231219,,MD,FR,FR,2023,Q4,Elderly
233253521,23325352,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,Unknown,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231208.0,20231221,20231221,EXP,,US-QUAGEN-2023QUALIT00393,QUAGEN PHARMACEUTICALS,"Ying Chen.Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir.Journal of the Endocrine Society.DEC-2022;Volume 6, Issue Supplement 1:A75-A76",58.0,YR,A,F,Y,,,20231221,,MD,US,US,2023,Q4,Adult
233253521,23325352,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,Unknown,,,,,,,2023,Q4,Product use in unapproved indication,,2023,Q4,1,I,,20231208.0,20231221,20231221,EXP,,US-QUAGEN-2023QUALIT00393,QUAGEN PHARMACEUTICALS,"Ying Chen.Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir.Journal of the Endocrine Society.DEC-2022;Volume 6, Issue Supplement 1:A75-A76",58.0,YR,A,F,Y,,,20231221,,MD,US,US,2023,Q4,Adult
233253521,23325352,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,Unknown,,,,,,,2023,Q4,Adrenal insufficiency,,2023,Q4,1,I,,20231208.0,20231221,20231221,EXP,,US-QUAGEN-2023QUALIT00393,QUAGEN PHARMACEUTICALS,"Ying Chen.Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir.Journal of the Endocrine Society.DEC-2022;Volume 6, Issue Supplement 1:A75-A76",58.0,YR,A,F,Y,,,20231221,,MD,US,US,2023,Q4,Adult
233274411,23327441,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5/W,,,U,,,,,,,,,2023,Q4,Blood cholesterol increased,,2023,Q4,1,I,,20231216.0,20231221,20231221,EXP,,GR-BAUSCH-BL-2023-018862,BAUSCH AND LOMB,,36.0,YR,,M,Y,,,20231221,,MD,GR,GR,2023,Q4,Adult
233274411,23327441,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5/W,,,U,,,,,,,,,2023,Q4,Transient ischaemic attack,,2023,Q4,1,I,,20231216.0,20231221,20231221,EXP,,GR-BAUSCH-BL-2023-018862,BAUSCH AND LOMB,,36.0,YR,,M,Y,,,20231221,,MD,GR,GR,2023,Q4,Adult
233302991,23330299,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q4,Drug interaction,,2023,Q4,1,I,,20231211.0,20231222,20231222,EXP,,US-EPICPHARMA-US-2023EPCLIT01847,EPIC PHARM,Ying Chen.Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir.Journal of the Endocrine Society.DEC-2022; 6:A75-A76,58.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
233302991,23330299,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q4,Adrenal insufficiency,,2023,Q4,1,I,,20231211.0,20231222,20231222,EXP,,US-EPICPHARMA-US-2023EPCLIT01847,EPIC PHARM,Ying Chen.Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir.Journal of the Endocrine Society.DEC-2022; 6:A75-A76,58.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
233302991,23330299,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2023,Q4,Product use in unapproved indication,,2023,Q4,1,I,,20231211.0,20231222,20231222,EXP,,US-EPICPHARMA-US-2023EPCLIT01847,EPIC PHARM,Ying Chen.Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir.Journal of the Endocrine Society.DEC-2022; 6:A75-A76,58.0,YR,A,F,Y,,,20231222,,MD,US,US,2023,Q4,Adult
233416641,23341664,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,0.75,MG,,QW,2023,Q4,Cholelithiasis,,2023,Q4,1,I,20231115.0,20231221.0,20231226,20231226,DIR,FDA-CDER-CTU-2023-94531,,FDA-CTU,,74.0,YR,,M,N,91.0,KG,20231221,N,PH,US,,2023,Q4,Elderly
233416641,23341664,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,0.75,MG,,QW,2023,Q4,Pancreatitis,,2023,Q4,1,I,20231115.0,20231221.0,20231226,20231226,DIR,FDA-CDER-CTU-2023-94531,,FDA-CTU,,74.0,YR,,M,N,91.0,KG,20231221,N,PH,US,,2023,Q4,Elderly
233416641,23341664,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,0.75,MG,,QW,2023,Q4,Pancreatic carcinoma,,2023,Q4,1,I,20231115.0,20231221.0,20231226,20231226,DIR,FDA-CDER-CTU-2023-94531,,FDA-CTU,,74.0,YR,,M,N,91.0,KG,20231221,N,PH,US,,2023,Q4,Elderly
233450211,23345021,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,D,,,,,0.75,MG,,/WK,2023,Q4,Gastrointestinal disorder,,2023,Q4,1,I,,20230808.0,20231228,20231228,PER,,US-APOTEX-2023AP012171,APOTEX,"Goldman JD, Sangave N.. Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit. DIABETESJOURNALS. 2023;41(2):322-326",68.0,YR,,F,Y,77.098,KG,20231228,,PH,US,US,2023,Q4,Elderly
233450211,23345021,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,D,,,,,1.5,MG,,/WK,2023,Q4,Gastrointestinal disorder,,2023,Q4,1,I,,20230808.0,20231228,20231228,PER,,US-APOTEX-2023AP012171,APOTEX,"Goldman JD, Sangave N.. Misdiagnosis of Type 1 Diabetes Identified at a Primary Care Pharmacist Visit. DIABETESJOURNALS. 2023;41(2):322-326",68.0,YR,,F,Y,77.098,KG,20231228,,PH,US,US,2023,Q4,Elderly
233471781,23347178,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Encephalitis,,2023,Q4,1,I,20230907.0,20231221.0,20231228,20231228,EXP,FR-AFSSAPS-ST2023001565,FR-MYLANLABS-2023M1137335,MYLAN,,66.0,YR,,M,Y,87.0,KG,20231228,,MD,FR,FR,2023,Q4,Elderly
233471781,23347178,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,Unknown,,2023,Q4,Confusional state,,2023,Q4,1,I,20230907.0,20231221.0,20231228,20231228,EXP,FR-AFSSAPS-ST2023001565,FR-MYLANLABS-2023M1137335,MYLAN,,66.0,YR,,M,Y,87.0,KG,20231228,,MD,FR,FR,2023,Q4,Elderly
